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  7Summary 
Patients with hepatic glycogen storage diseases are at risk of hypoglycaemia after 
short fasts. They require an intensive dietary treatment regimen, including feeds as 
often as 2 hourly and overnight continuous glucose feeds. The use of uncooked corn-
starch helps children and adults to have longer fasting intervals and some to 
discontinue overnight pump feeds of glucose polymer via a gastric feeding tube.  
 
Unfortunately, some adults still remain dependent on nocturnal pump feeds and, for 
some, frequent doses of starch are still required during the daytime. Some have 
symptoms of flatulence, abdominal bloating and diarrhoea which may be caused by 
starch mal-digestion. This thesis studies the short- and longer-term effects of the 
introduction of a novel, physically-modified corn-starch into the dietary regimen of 
patients with two of the more severe forms of hepatic glycogen storage disease. 
Based on the findings of this thesis, updated dietary recommendations can be made 
to patients with hepatic glycogenoses and their families. 
 
  8CHAPTER 1 - INTRODUCTION 
1.1 Carbohydrates – properties and metabolism 
Glucose 
The metabolism of glucose is a fundamental requirement for many energy requiring 
processes in living organisms. Plants fixate energy from the sun by photosynthesis to 
create simple sugars such as glucose, polymers of which form the most exported 
form of energy.
 2 At physiological pH, the straight-chain form of glucose forms 
covalent bonds between the aldehyde group of carbon 1 and carbon 5 forming a 
glucopyranose ring (figure 1.1). The orientation of the hydrogen and hydroxyl group 
around carbon 1 determines whether D-glucose is an alpha or beta orientation. This 
stereochemistry of glucose gives it wide ranging properties, such that it can be stored 
in several different forms.  
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Figure 1.1 – Structure of straight chain glucose (Fisher projection - 1.1a), α-
glucopyranose (1.1b) and β-glucopyranose (1.1c) 
 
In animals, under aerobic conditions, the breakdown of each molecule of glucose 
culminates in the formation of 38 adenosine triphosphate molecules – this process is 
a fast and efficient means of releasing energy, allowing organisms to respond rapidly 
to changes in energy requirements.
3 Plants store glucose as glucose polymer in 
various forms of starch, providing a reservoir of energy to be used according to 
fluctuating demands.  
  9 
Starch  
Starch is a form of plant glucose polymer. It comprises linear chains of glucose 
molecules linked by α-1-4-glycosidic bonds, as well as alternative branched chains 
created by α-1-6 glycosidic bonds (figure 1.2). Amylose is almost exclusively linear 
1,4 bonds whereas amylopectin comprises of both linear chains and branched 1,6 
glycosidic bonds. 
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Figure 1.2 – Glucose polymerisation by the formation of linear α1-4 glycosidic 
bonds and branched α1-6 glycosidic bonds.  
 
Different species of plants have specific proportions of amylopectin and amylose as 
stored starch, resulting in species specific starch types. The significant effect 
stereochemistry has on glucose polymeric properties is typified by the structure of 
cellulose comprising glucose β-1-4-glycosidic bonds. In the β-orientation, the 
glycosidic bond is further strengthened by hydrogen bonds between adjacent 
  10hydroxyl groups.
2 Like amylose, cellulose is straight chained, but it is tough and 
fibrous and forms part of cellular architecture. It is also very resistant to digestion.  
 
Starch is organised as granules comprising both amylose and amylopectin chains. 
Amylopectin chains are often organised to form a crystalline structure with amylose 
chains filling intermediate space. Variation in granular organisation, determined by 
relative amounts and molecular interactions of amylose and amylopectin, gives each 
starch its own unique properties.
4 Starch is not soluble in cold water. However on 
heating to 55 – 70
 o C starch gelatinises allowing water into its structure – the 
crystalline amylopectin structure often remains intact but the interstitial amylose 
chains can leach out into the fluid. The granules swell with water entry forming a gel. 
At persistent higher heat, the entire gelatinous structure can dissociate to form a 
liquid. Conversely if allowed to cool, hydrogen bonds reform to create a more solid 
structure. This process is known as retrogradation. The retrograded starch has 
different physical properties to both the native, dissociated and the gelatinised 
starch.
5 The process of gelatinisation and retrogradation can be seen in daily cooking 
processes such as thickening sauces with cornstarch or making porridge. The 
physical properties of native starches can also be altered by treatment at high 
pressure, with chemicals or enzymes. When it comes to digestion of starches, an 
important determinant of bio-availability of glucose is not only the nature of the native 
starch, but how it has subsequently been processed. 
 
Release Of  Glucose from Dietary Starch 
Digestion of starch 
The physiology of an individual greatly determines to what extent glucose is liberated 
from available dietary starch. Starch digestion in humans begins with mastication and 
the release of salivary α-amylase in the mouth. Amylases cleave 1,4-glycosidic 
bonds in amylose releasing oligosaccharides and disaccharides such as maltose. 
  11The enzyme is rendered inactive by the low pH in the stomach. On release of a bolus 
of food from the stomach, salivary α-amylase is reactivated in the more alkaline small 
intestine and additional pancreatic α-amylase is released. Further digestive 
oligosaccharidases and disaccharidases are released from the intestinal brush 
border resulting in the formation of glucose.
6 Of relevance to patients with glycogen 
storage disease is the fact that pancreatic α-amylase is secreted in only small 
quantities in infants and hence they may have difficulty digesting complex 
carbohydrates such as uncooked cornstarch.
7 
 
Gastrointestinal Transit time 
Food enters the stomach and is emptied into the duodenum after a variable period of 
time. Gastric emptying is controlled locally by release of hormones from the 
duodenum, or centrally by sympathetic and parasympathetic innervation, and can be 
influenced by drugs such as metoclopromide. Dietary triacylglycerides delay gastric 
emptying by stimulating the release of cholecystokinin (CCK) and peptide YY (PYY.)
6 
Other hormones such as secretin, gastrin and gastric inhibitory peptide also delay 
gastric emptying.
8 It has also been shown that dietary constituents such as acetic 
acid and free fatty acids can specifically delay gastric emptying.
9;10 There is great 
variation between individuals, and with age, in both gastric emptying and 
gastrointestinal transit times. Transit times can also be altered by dietary composition 
with foods such as wheat bran passing through the bowel quicker than other foods 
such as refined carbohydrate and meat.
11 Hence the composition of the diet has a 
bearing both on gastric emptying and gastrointestinal transit time and the timing of 
nutrient absorption after a meal. 
 Absorption of glucose 
The classical model of glucose uptake across the intestinal mucosa is via a sodium 
dependent glucose / galactose transporter (SGLT1 – figure 1.3). Enterocyte 
cytoplasmic sodium concentrations are maintained at low levels by Na /K ATPase at 
  12the basolateral membrane. Sodium in the gastrointestinal lumen follows its 
concentration gradient into the cell via SGLT1.
12 The SGLT1 trans-membrane protein 
changes its configuration in the presence of sodium allowing the passage of glucose 
or galactose into the cell. The classical model proposes that glucose leaves the cell 
and enters the bloodstream via the GLUT2 glucose transporter. There are several 
studies demonstrating increased expression of GLUT 2 in enterocytes in response to 
elevations of environmental glucose in tissue cultures.
13-15 However, there is still 
controversy about the extent of the role of GLUT 2 in glucose transport. Some 
propose intracellular microsomal trafficking as an alternative means of glucose 
transport.
16(figure 1.3) 
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Figure 1.3  A) – the classical model of glucose uptake via SGLT1 at the brush 
border and GLUT 2 at the basolateral membrane. B) An alternative hypothesis 
of glucose uptake via microsomal trafficking using G6PT and G6Pase 
Figure adapted by kind permission of Elsevier Ltd from Santer et al:  Gastoenterology 2003
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Santer et al performed a study looking at glucose and galactose uptake in a patient 
with GLUT 2 deficiency and another with Glycogen Storage Disease type Ib (a known 
defect in microsomal glucose transport.) On the basis of significant elevations of 
  13breath hydrogen from baseline in the patient with GSD Ib after ingestion of glucose 
and galactose, compared to the patient with GLUT2 deficiency and a normal control, 
they suggested there was evidence of impaired glucose uptake in the patient with 
GSD Ib. They concluded that this was evidence that microsomal trafficking in 
enterocytes rather than facilitative diffusion by GLUT 2 was the predominant factor 
determining glucose transport into the blood-stream from enterocytes.
17 This 
determinant of glucose absorption clearly has particular relevance to the processing 
of dietary carbohydrate in patients with GSD I and has not yet been conclusively 
elucidated. The function of expressed glucose-6-phosphatase (G6Pase) and 
glucose-6-phosphate translocase (G6PT) in enterocytes is yet to be defined. 
 
There is a an increased incidence of inflammatory bowel disease in patients with 
GSD Ib, which may itself account for the breath hydrogen data in Santer’s study.
18;19 
In addition, many patients with GSD Ia are also known to have chronic or intermittent 
diarrhoea.
7;20 The digestion and absorption of starch and glucose respectively can be 
disrupted if there is evidence of bowel inflammation. This inflammation and disruption 
of mucosal integrity too could lead to sub-optimal absorption of glucose from dietary 
starch. 
 
Humoral response to glucose in the blood. 
The body maintains plasma glucose within a narrow margin. If the concentration is 
too low, end organ requirements for glucose as an energy source may not be met. If 
plasma glucose concentrations are too high, osmotic effects of hyperglycaemia, such 
as diuresis, may ensue. There are a complex range of regulatory mechanisms that 
keep the plasma glucose concentration relatively constant in healthy individuals. 
Insulin has a principal role in the regulation of the plasma glucose concentration. It is 
released in response to elevations in the plasma glucose and its actions involve the 
uptake of glucose by peripheral tissue. When plasma glucose concentrations are low, 
  14counter-regulatory hormones such as glucagon, growth hormone or catecholamines 
induce glucose release from stores such as glycogen.
3 Over the last 15 years, further 
layers of complexity have been discovered that overlay this simple model. (figure 1.4) 
Whilst insulin has a primary role in glucose uptake and decreased lipolysis, other 
humoral factors can also regulate, and are modified by, the action of insulin. 
Adipocytes release the hormone leptin with increased amounts in healthy individuals 
correlating with satiety. Mutations in the leptin gene resulting in leptin deficiency are 
associated with morbid obesity.
21;22 Rats and humans with either congenital or 
acquired lipodystrophy also have low plasma leptin concentrations resulting in 
secondary amenorrhoea, insulin resistance and diabetes.
23 Elevation of plasma 
insulin can also result in leptin release: insulin release can induce satiety.
24 
Conversely ghrelin is a hormone released by the stomach, pancreas, gastrointestinal 
mucosa as well as the hypothalamus and rises pre-prandially. Acylated ghrelin 
induces hunger, with the plasma concentrations decreasing post-prandially.
25 In 
mice, blocking ghrelin release during an oral glucose tolerance test results in 
lowering fasting glucose concentrations, attenuated glycaemic excursions and 
enhanced insulin responses with the converse occurring when ghrelin was infused.
8 
This suggests that ghrelin antagonises the action of insulin in the short-term. Several 
studies also suggest that ghrelin concentrations are lower in obese individuals with 
insulin resistance compared to those who are insulin sensitive.
24;26 Morbidly obese 
subjects that have bariatric surgery can have remission of type II diabetes mellitus, 
with those having a Roux-en-Y gastric bypass procedure reducing by upto 84% 
compared to 48% of those with gastric banding. The former procedure bypasses the 
stomach with food entering the small bowel distal to the duodenum. This procedure 
therefore, reduces gastric storage capacity but also bypasses some of the duodenal 
humoral feedback mechanisms related to feeding. The Roux-en-Y procedure is also 
associated with increased insulin sensitivity and reduction of leptin release long-term, 
but is not associated with increased ghrelin release either in the days post-
  15procedure, or long-term. Given that these subjects have significant demonstrable 
weight loss, the failure to induce appetite stimulation by ghrelin release appears an 
important mechanism of sustained insulin sensitivity and weight loss.  There is 
therefore, a complex interaction between humoral mechanisms of glucose control 
that changes with insulin sensitivity. Understanding of these relationships would also 
help in the understanding of blood glucose variations in disorders such as the 
glycogen storage diseases. 
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Figure 1.4  – The complexity of glucose homeostasis - inter-action with insulin 
The incretins are another group of peptides that have been extensively studied with 
relation to insulin release. They are gastrointestinal hormones including glucose-
dependent insulinotropic polypeptide (GIP) and glucagon-like-peptide-I (GLP I). GIP 
is secreted in response to eating, especially after fatty food in humans. Its principal 
action is to enhance glucose dependent insulin release by stimulating pancreatic β-
cell exocytosis.
27 It also increases insulin biosynthesis and β-cell proliferation. GLP 
increases the sensitivity of pancreatic β-cell to glucose by stabilising the β-cell 
potassium channel KIR6.2 and its expression at higher levels of glucose. As a 
consequence, it too enhances glucose-dependent insulin release.  
  16Of particular relevance to patients with GSD, a study performed by Wachters-
Hagedoom demonstrated sustained increases of GLP-1 and insulin when 7 healthy 
men ingested 53.5g of uncooked cornstarch compared to similar quantities of 
glucose and pasta. (figure 1.5)
28 
 
              
a  b 
Figure 1.5 - Glucose and insulin response (a) and Incretin response (b) of 7 
healthy volunteers after equivalent carbohydrate quantity meals of corn 
derived glucose, uncooked cornstarch and cooked corn-pasta 
 
Reproduced by kind permission of the American Society of Nutritional Sciences; Wachters- Hagedoorn 
et al, Journal of Nutrition 2006 
28 
 
This cross-over study of healthy volunteers attempted to study rate of appearance of 
glucose from an exogenous carbohydrate source by setting a background infusion of 
dideuteroglucose and subsequent ingestion of a naturally labelled 
13C starch. By 
examining the 
13CO2 content in the breath for the subsequent 6 hours after 
carbohydrate ingestion, rate of appearance of glucose from exogenous carbohydrate 
sources was calculated. The calculated rate of appearance of glucose from ingested 
carbohydrate closely matched the glucose and insulin profile of figure 1.5a; there was 
a rapid increase and fall when glucose was ingested with a slower rise in the pasta 
and uncooked cornstarch profile. However, the uncooked cornstarch profile 
  17continued to be higher than the pasta profile throughout the study. Figure 1.5 
demonstrates sustained elevation of insulin, GLP-1 and GIP with specific ingestion of 
cornstarch compared to the other carbohydrates. The sustained elevations were 
corroborated by calculations of area under curves (AUC), which were made between 
0 – 120 minutes and 120 - 240 minutes for each analyte for each study. As would be 
expected, the mean 0 - 120 minute AUC for plasma glucose (181.7 mmol/L – 2 hrs) 
and serum insulin (13450 pmol/L – 2hrs) after ingestion of glucose  was much higher 
than for UCCS (74.7 and 4964 respectively) and cooked pasta (65.3 and 4154 
respectively). Between 2 and 4 hours both parameters were very low after ingestion 
of glucose but remained higher with UCCS compared to cooked pasta; Glucose AUC 
was 20.2 mmol/L – 2hrs for UCCS compared to 10.6 for cooked pasta and insulin 
was 3726 pmol/L – 2 hours for UCCS and 976 for cooked pasta. The GIP AUC for 
UCCS from 2 – 4 hours was also elevated at over twice the value of cooked pasta 
whilst the GLP – 1 AUC for UCCS was elevated at 10 times the level for this time 
period. This demonstrates dietary factors have a dramatic role to play in humoral 
responses. Of the 3 carbohydrates tested, uncooked cornstarch specifically resulted 
in persistent elevation of incretins and insulin.
28 
 
 
 
 
 
 
 
 
 
  181.2  – Hepatic Glycogen Storages Disease 
Glycogen 
Animals are unable to synthesis starch but have a small amount of protein bound 
carbohydrate called glycogen, which comprises up to 60,000 glucose molecules. This 
enables organs to temporarily store glucose in an insoluble form contributing little to 
cytosolic osmolarity.
29 The highly branched structure of glycogen is a feature of 
mammalian cells that is absent in plant cells. (figure 1.6) 
The “densely” arranged glucose molecules also provide a readily available energy 
source for cellular respiration that is liberated in response to appropriate humoral 
triggers, such as the release of catecholamines. Defects preventing the normal flux of 
glucose molecules in the synthesis and degradation of glycogen can consequently 
lead to devastating consequences in cellular energy metabolism.  
 
Figure 1.6 Diagramatic representation of structure of glycogen comprising 
glucose straight chains formed by α 1-4 glycosidic bonds and branch points 
every 6-10 residues of α 1-6 glycosidic bonds. 
 
Metabolism of Glucose and Glycogen 
Post-prandial elevation of blood glucose causes release of insulin which induces 
uptake of glucose by peripheral tissues. Organs that have a high demand for glucose 
include the liver, brain and skeletal muscle. Many organs are able to store glucose 
temporarily as glycogen. In humans, glycogen forms only a small part of total energy 
  19reserves, with fats and proteins being much more abundant sources of energy.
30 
However, there is significant turnover of glycogen with relative flux between 
breakdown and synthesis determined by the concentration of glucose in the blood. If 
the concentration of glucose is low, glycogenolysis is favoured whereas when blood 
glucose is high glycogen synthesis is favoured. Glycogen stored in organs such as 
skeletal muscle is used for glucose production in that particular organ. Glycogen 
stored within the liver, however, is used to export glucose around the body at times of 
need.
31 As mentioned in the previous section, these processes are controlled by 
insulin and the counter-regulatory hormones such as glucagon. In the hepatic 
glycogen storage diseases, the process of glycogen breakdown is disrupted leading 
to fasting hypoglycaemia. 
Humoral control of glycogen metabolism is exerted through reciprocal action on 
glycogen synthase in the glycogen synthetic pathway and phosphorylase in the 
glycogen degradation pathway. An increase in cAMP mediated by counter-regulatory 
hormones such as glucagon, activates phosphorylase kinase resulting in increased 
phosphorylase action with corresponding increase in glucose release. Conversely, 
the enzyme responsible for dephosphorylation, namely phosphoprotein phosphatase 
is inhibited. Phosphoprotein phosphatase activity is increased by insulin via an 
inhibitory action of insulin on glycogen synthase kinase 3, leading to increased 
glycogen synthase activity and decreased phosphorylase activity. 
32;33  The reciprocal 
action of this regulatory cascade is indicated later in figure 1.10. 
 
 
 
 
 
 
 
  20The glycogen storage diseases (GSD) – Historical aspects 
The GSDs comprise a group of rare inherited disorders of glycogen metabolism. 
Identification of the causes of GSDs has been intertwined with the unravelling of 
essential biochemicaI processes of glucose metabolism and intracellular structure. 
Von Gierke described the pathological findings of glycogen storage within the liver 
and kidney in “Hepatonephromegalia glykogenica.” The American scientists, Carl and 
Gerti Cori spent most of their academic lives investigating the interaction of glucose 
and glycogen. They discovered what was known as the Cori ester – glucose-1-
phophate in 1936, later demonstrating that this was the first step of glycogen 
synthesis. They subsequently isolated glycogen phosphorylase and were also able to 
synthesise glycogen and starch in vitro. Their work on glycogen and glucose 
interactions led them to describe the process of re-cycling glucose via lactate and 
pyruvate (Cori cycle). It was for this work that they received the Nobel Prize for 
Physiology or Medicine in 1947.
34 This work led them to identify glucose-6-
phosphatase (G6Pase) as the enzyme responsible for glycogen storage disease type 
I.
35 This work was the first ever description of a disorder that was directly linked to an 
enzyme deficiency.  At the same time as they published this finding, they noted that 2 
of the 10 pathological samples they had examined, showed abnormal glycogen 
structure – one with “longer inner and outer chains than normal 
glycogen….resembled amylopectin,” and the other “had very short outer 
branches….resembling a phosphorylase limit dextrin.”
36 They were subsequently 
able to identify amylose 1,6 glucosidase (debrancher) as the enzyme deficient in a 12 
year old girl with limit dextrinosis, descrbing the enzymatic deficiency of glycogen 
storage disease type III.
37   
In the 1960’s a Belgian group, led by a student of the Coris’, Christian de Duve, 
attempted to characterize hepatic glucose-6-phosphatase. In the process of their 
research, they fortuitously discovered the lysosome,
38;39 and subsequently identified 
lysosomal acid maltase; the enzyme responsible for storage of glycogen within 
  21muscle causing Pompe’s disease or glycogen storage disease type II. The first 
author of this paper, Henri-Geri Hers correctly predicted in his first description that 
this enzyme deficiency would be the first of many lysosomal storage diseases.
40  
The descriptions of glycogen storage diseases types I, II, III and IV were all possible 
through meticulous and inspired thought about the biochemical processes of glucose 
metabolism. Over the subsequent years, several other diseases were identified 
based on this diligent early work. (figure 1.7) 
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Figure 1.7 – The Glycogen storage diseases 
Enzymes indicated in red and GSD disorder number in blue 
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  22Glycogen Storage disease Type I 
GSD I (McKuisick 232200) is caused by reduced activity of glucose-6-phosphatase: 
GSD Ia, by deficiency of the hydrolytic enzyme and GSD Ib, by deficiency of the 
endoplasmic reticulum trans-membrane glucose-6-phosphate transport protein, G-6-
P translocase (figure 1.8). The major metabolic consequence of ineffective function 
of G-6-P-ase is hypoglycaemia, provoked by relatively short fasts.
41  
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Figure 1.8 – Formation of glucose in the endoplasmic reticulum of cells 
 
The glucose-6-phosphatase enzyme complex comprises 357 amino acids. It is a 
trans-membrane enzyme with catalytic activity on the luminal surface of the 
endoplasmic reticulum.
42 It is expressed in the liver, kidney and gastrointestinal 
mucosa. Its role is the production of glucose from glucose-6-phosphate and is 
deficient in GSD type Ia. In the liver, glucose-6-phosphatase facilitates export of 
glucose, controlled by counter-regulatory hormones such as adrenaline or glucagon. 
The endoplasmic reticular trans-membrane protein, glucose-6-phosphate translocase 
is deficient in GSD type Ib. Glycogenolytic and gluconeogenetic processes create 
glucose-6-phosphate, but this cannot be exported in the form of glucose. 
Consequently the blood glucose cannot be raised and there is increased flux of 
  23glucose-6-phosphate through other pathways (figure 1.9).
41 There are several 
additional features of GSD Ib including neutropenia with recurrent infections and 
inflammatory bowel disease. The basis of these additional features of GSD Ib has not 
been fully elucidated. 
The secondary metabolic features of GSD type I arise in response to hypoglycaemia. 
(figure 1.9) This leads to glucose-6-phosphate production from glycogen breakdown 
or gluconeogenesis. Increased intra-hepatic catabolism of glucose-6-phosphate 
leads to greater flux along the glycolytic pathway resulting in increased  synthesis of  
pyruvate, lactate and acetyl co A. Accumulation of the latter leads to greater 
synthesis of triglycerides and cholesterol. In addition, catabolism of glucose-6-
phosphate through the pentose phosphate shunt leads to increased production of the 
5-carbon sugar ribose, which forms an essential component of nucleotides; the 
increased turnover of these results in elevations of uric acid. Poor metabolic control 
comprising high plasma concentrations of uric acid, cholesterol, lactate and 
triglycerides consequently occur when patients are frequently hypoglycaemic. 
Experiences gained over a series of studies demonstrate better secondary metabolic 
control when the tendency toward hypoglycaemic episodes is decreased.
43-45  The 
principal goal of treatment is therefore to maintain a steady “normal” blood glucose 
which leads to amelioration of secondary metabolic disturbance. 
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Figure 1.9 – Secondary metabolic effects of glucose-6-phosphatase deficiency 
 
Glycogen storage disease type III 
Aetiology.  GSD III (McKuisick 232400) is caused by glycogen debrancher deficiency.  
The AGL gene encoding the enzyme is large, containing 35 exons, spanning 85kb of 
DNA and translates a monomeric protein product of 1,532 amino acids.
41 This 
enzyme complex is unusual in that it has two distinct catalytic sites that perform 
different functions on the same glycogen polymer. Four glucose residues from a 
branch point, oligo-1,4-1,4-glucantransferase transfers three glucose molecules from 
the branch chain to an adjacent linear chain, thereby elongating the linear chain. The 
glucosidase site then cleaves the remaining glucose (1,6 linked.)
46 Deficiency of this 
enzyme consequently results in accumulation of a short chain form of glycogen – 
limit dextrin. Glycogen debrancher deficiency differs from GSD I in that some glucose 
can be released from glycogen by the continued action of glycogen phosphorylase 
and glucose-6-phosphatase. Despite this, the infantile presentation of this disease 
can be very similar to GSD I, and it is sometimes difficult to discriminate clinically the 
Uric Acid 
Glucose-6-
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Glycogen  5 Carbon 
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Acetyl co A 
Lactate 
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  25two conditions. Hyperlactataemia and hyperuricaemia are absent, because there is 
less flux of glucose-6-phosphate through glucose and pentose phosphate compared 
to GSD I. However, hyperlipidaemia is a feature. Gluconeogenesis is not prevented 
and consequently lipolysis is not inhibited. Therefore, ketosis is present in GSD III but 
absent in GSD I.  GSD I and III may also be distinguished by the expression of 
deficiency within skeletal muscle in most patients with GSD III. Those patients that 
have deficiency only in liver are labelled as GSD IIIb, whilst the majority (85%) that 
have more widespread deficiency in both skeletal and cardiac muscle are labelled as 
GSD IIIa.  
Clinical features Patients generally present in infancy with fasting hypoglycaemia, 
failure to thrive and hepatomegaly. Motor developmental delay is not uncommon. 
Typically, by adult life the hypoglycaemic tendency diminishes, but may become 
more apparent at times of stress such as pregnancy or peri-operatively. The 
myopathy of GSD IIIa is distal and slowly progressive in adulthood and some patients 
also develop a hypertrophic cardiomyopathy. Pathogenesis of these complications is 
unknown. Reduced bone density is seen in patients with both GSD IIIa and b. 
Polycystic ovarian disease and insulin resistance have been noted in glycogen 
storage disease type III.
47;48 There are a few reports of cirrhosis and subsequent 
hepatocellular carcinoma occurring in adult patients.
49;49;50 
 
Glycogen Storage Disease Type VI 
Hers described hepatic phosphorylase deficiency (McKuisick 232700) from liver 
biopsies of patients that had similar symptoms to patients with GSD Ia and III, but did 
not have these enzymatic deficiencies.
46 Hepatic phosphorylase deficiency is very 
rare and all cases so far reported have not had muscle, cardiac or brain involvement.  
Hepatomegaly, hypoglycaemia and growth delay are features of this disease. 
Typically patients present after the first year of life and hypoglycaemia is less 
pronounced in childhood than either GSD I or III and resolves by adult life.   
  26Hyperlactataemia and hyperuricaemia are not features of this disease but there may 
be mild hyperlipidaemia, with ketosis during hypoglycaemic episodes. 
Hypoglycaemia can be prevented with uncooked cornstarch if necessary, which can 
also stimulate catch-up growth.
51 
 
Glycogen Storage Disease type IX 
Defects of the phosphorylase system have been subject to some confusion in 
nomenclature. With the benefit of hindsight, it is now possible to describe the genetic 
and enzymatic basis of disease and hence clarify the numerical classification. In the 
past, some patients may have been thought to have had deficiency of hepatic 
phosphorylase and possible involvement of the brain, skeletal muscle or heart. It 
transpires that many of these patients have defects of the phosphorylase kinase 
system, which is currently classified as GSD IX.
29;41 The sex-linked variant of GSD IX 
(McKuisick 306000), had alternatively been classified as GSD VIII by some, whilst 
others had classified the neurological form of phosphorylase kinase deficiency as 
GSD VIII. 
 
Aetilogy Phosphorylase kinase is the final important step of the regulatory cascade 
controlling glycogen metabolism as indicated in figure 1.10. The active enzyme is a 
complex tetramer comprising four different monomers: α, β, γ, and δ. The α-subunit 
is encoded for by 2 different genes which confer expression in a particular organ: 
PHKA1 in muscle and PHKA2 in liver.
52 Similarly the γ-subunit is encoded by PHKG1 
for expression in the muscle and PHKG2 for the liver and testis. The β and δ 
subunits are coded for by single genes. The α and β-subunits are large enabling 
regulation of the enzyme. The γ-subunit contains the active site and δ-subunit is part 
of the calmodulin group of proteins that bind and respond to calcium activation. The 
calmodulin proteins have widespread regulatory functions and are not implicated in 
the pathogenesis of GSD IX.  There is considerable phenotypic variability in GSD IX, 
  27which is not surprising as the corresponding mutations could be in any one of a 
number of genes which may or may not be expressed in a particular tissue.
53-55 
 
Figure 1.10 – The activation cascade regulating the function of 
glycogen phosphrylase and glycogen synthase
 GSD IX is the most common of the glycogen storage diseases, but because of the 
phenotypic variability, difficulties with enzymatic and genotypic diagnosis as well as 
some relatively mild phenotypes, it is probably still under-diagnosed. The commonest 
clinical presentation is as “X-linked hepatic GSD IX “identified by Hug et al in 1966. 
Patients present in infancy or early childhood with similar manifestations to GSD type 
Ia, but the hypoglycaemic episodes may be less severe, and is not a feature of 
disease in some. There may be mild hyperlipidaemia and ketosis with fasting but 
hyperuricaemia is not a feature. Most symptoms resolve by adult life. Typical to an X-
linked pattern of inheritance, most affected individuals are boys, but there are also 
mildly affected females reported. 
 
 
 
 
  28Historical treatment of glycogen storage disease type I 
In the early 20
th century, glycogen storage disease type I was associated with 
significant mortality and morbidity. In response to some of the vital early work on 
glucose metabolism performed by Carl and Gerti Cori and Henry-Geri Hers, it was 
realised that patients’ symptoms improved with the use of frequent meals. Porto-
caval shunts in the 1960’s aimed to reduce hepatic first pass metabolism of dietary 
glucose.
56 The use of parenteral nutrition appeared a more effective strategy.
57 This 
was simplified further by the introduction of continuous nocturnal enteral feeds, in 
conjunction with frequent daytime meals.
43;44 The latter strategy demonstrated very 
clear improvement in growth and overall metabolic control. This treatment appears 
effective, but it is onerous and ongoing concerns with mechanical pump failure and 
tube dislodgement leading to dangerous hypoglycaemia remain.
58;59 Daytime meals 
may need to be frequent (<2 hours interval) and consequently several studies looked 
at dietary starches that release glucose slowly, to extend this period of 
euglycaemia.
4;7;60;61 Some of these studies are considered further in section 1.3. 
The introduction of uncooked cornstarch (UCCS) into the dietary regimen in the 
1980s improved daytime management and allowed some patients to replace 
nocturnal pump feeds of glucose polymer with a dose of cornstarch. An important 
consequence of the introduction of these dietary therapies was an improved quality 
of life and prognosis.  
 
Complications of glycogen storage disease related to diet 
Whilst many patients clearly benefit from UCCS, some patients do not have 
sustained normoglycaemia and many have symptoms of bloating, flatulence and 
gastrointestinal disturbance.
19 In some patients these symptoms may be related to 
incomplete digestion of starch.
62 Bodamer et al studied 8 patients with GSD Ia 
compared to 15 healthy controls examining 
13CO2 breath enrichment and H2 
excretion after a cornstarch load. The study aimed to quantitate glucose oxidation 
  29from ingested cornstarch. The authors’ data demonstrated that glucose oxidation was 
comparable to controls for the first 2.5 hours. Thereafter, glucose oxidation was 
significantly diminished in subjects with GSD Ia compared to control, (cumulative 
mean utilization 11.5% versus 18.4%.) Oxidation was significantly lower between 4.5 
hours and 6 hours. Based on previous studies, the authors comment that comparable 
oxidation for the first 2.5 hours indicates that gastrointestinal factors are similar 
between the 2 populations; ie gastric emptying, digestion and absorption of glucose. 
Differences in glucose oxidation observed after 4.5 hours is indicative of differences 
in post-absorptive metabolism. They comment that absorbed glucose is incorporated 
into glycogen with a slower turnover. This gives some explanation of the variable 
efficacy of cornstarch reported by Lee et al in 1996.
63 The baseline hydrogen 
excretion of the GSD Ia population was significantly greater than controls and 2 of 
the 8 GSD Ia subjects fulfilled the criteria for carbohydrate malabsorption 5 hours into 
the study. Breath hydrogen is a measure of colonic fermentation (as discussed later) 
and the results including the elevation at baseline are indicative of increased colonic 
fermentation of carbohydrate in the GSD Ia population compared to controls. This 
could lead to symptoms of abdominal bloating, flatulence and diarrhoea. Prior to the 
introduction of uncooked cornstarch, into the dietary regimen, diarrhoea was a well 
recognised feature of both GSD Ia and Ib. In 1978 a series of in-vitro and in vivo 
studies were performed by Milla et al.
64 They demonstrated impaired glucose 
absorption in patients with GSD Ia and Ib compared to controls and concluded that 
glucose malabsorption contributes to diarrhoea. However, the management of 
patients of GSD in the 1970’s does appear to have significantly improved since the 
introduction of nocturnal continuous glucose based feeds. 
44;65This improved 
outcome seems in contrast to a hypothesis that significant glucose malabsorption 
occurs.
17 However, several patients do complain of diarrhoea, and whether simple or 
complex carbohydrate malabsorption is causative, is yet to be determined. 
 
  30It is recommended that patients with GSD take 65% of their dietary intake as 
carbohydrate. This is greater than that taken by the general population.
66-68 
Carbohydrate ingestion inevitably leads to insulin release which has widespread 
metabolic consequences as discussed in section 1.1. Long-term effects of persistent 
elevations of insulin in the general population are subject to a huge volume of 
research world wide.
25;27;69-71 Hyperinsulinism is associated with the metabolic 
syndrome including hypertension and obesity, non-insulin dependent diabetes 
mellitus (NIDDM), increased cardiovascular mortality and polycystic ovarian disease. 
It is somewhat surprising that neither a significantly increased incidence of 
cardiovascular events nor NIDDM are reported in patients with GSD. There are case 
reports only of NIDDM in patients with GSD.
72;73 This may be because the majority of 
patients are young. Exaggerated insulin responses by some obese GSD I patients 
were reported by Mundy et al after oral glucose tolerance tests.
74 Lee et al reported a 
higher incidence of polycystic ovaries (PCOD) in adults and children with GSD Ia and 
III than controls. Adults with both GSD Ia and III showed evidence of insulin 
resistance after a glucose tolerance test but the children did not.
47 Insulin resistance 
is implicated in the patho-physiology of PCOD in the general population,
 and may 
cause this complication in the hepatic glycogen storage diseases.
75;76 
 
There are a number of long-term morbidities associated with the hepatic 
glycogenoses, including the development of hepatic adenoma and potentially 
hepatocellular carcinoma, renal tubular and glomerular disease and fractures related 
to osteopenia.
44;77-80;80-82 Whilst the pathophysiology of these morbidities is not 
known, it is clear that those with better metabolic control are less likely to develop 
significant complications. 
45;59;83There is evidence, therefore, of appropriate dietary 
treatment improving short-term glycaemic control, secondary metabolic features and 
long-term complications.
60 
 
  311.3 Carbohydrates – Dietary treatment in GSD and in healthy individuals 
Specific Dietary Treatment of GSD – As discussed, the principal problem of GSD I is 
impairment of endogenous hepatic glucose production. After the publication of 
endogenous glucose production rates by assessing incorporation of 6,6-
dideuteroglucose label into blood glucose in a wide range of children, it was possible 
to calculate predicted requirements
84. Since there is significant impairment of 
endogenous production in GSD I, glucose needs to be provided from exogenous 
sources. The study by Bier et al in 1977 calculated that requirements correlated 
linearly with estimated brain size implying that the endogenous glucose production 
was principally for the brain. The calculated requirement mean values were: 7.1 
mg/kg/min for children under the age of six, 5.4 mg/kg/min for older children and 2.3 
mg/kg/min for adults. Schwenk and Hammond specifically assessed six GSD I 
children aged between 1 and 7 years using similar methodology with incremental 
doses of labelled glucose.
1 It was noted that rates of 8-9 mg/kg/minute of glucose 
infusion completely suppressed lactate production and partially suppressed 
endogenous glucose production, without excessive insulin rise. Extrapolating from 
this basal requirement means that 65% of total dietary energy in young children with 
GSD needs to be from carbohydrate. Assuming the adult basal requirement is 
2.5mg/kg/hr, and the total calorie intake is 2500 calories, a 70 Kg adult would need 
40% of their energy requirement in the form of carbohydrate. The UK average 
contribution of carbohydrate to total energy requirements is 50%, with intakes of 40-
50 in other Western European populations.
85;86 The World Health Organisation has 
recommended carbohydrates from various sources provide 55% of energy intake in 
healthy adults.
87 
 
The aim of dietary treatment in children is to provide carbohydrate, sufficient protein 
to maintain adequate growth and to maintain satisfactory micronutrient intake. 
Uncooked cornstarch has little nutritional value compared to other carbohydrates 
  32such as rice and pasta and consequently there is potential for nutritional deficiencies 
if this forms the bulk of the 65% carbohydrate intake.
88 There are examples of low 
concentrations of essential fatty acids and Vitamin B12 deficiency being recorded in 
GSD I.
89;90 For adults, relative carbohydrate requirements are less and consequently 
nutritional management should be more straightforward. 
 
 
Lactose and Fructose restriction  In a series of informative studies, John Fernandes 
demonstrated the clear effect that fructose, sucrose and lactose had on blood 
glucose in a small number of patients with GSD I and III. Quite large doses (1 – 2 
g/kg/hr) of glucose and fructose were continuously infused for 3 hours and the effect 
on lactate and glucose was observed.
91 Plasma glucose concentrations increased 
further in the GSD I patients given glucose compared to fructose; lactate 
concentrations were higher in the fructose group. In control individuals and patients 
with GSD III, fructose is converted to glucose via glucose-6-phosphate as an 
intermediary. Fernandes hypothesised that gluconeogenesis is impaired in GSD I 
due to ineffective function of glucose-6-phosphatase. Fructose is obligatorily 
metabolised via the glycolytic pathway producing lactate as a consequence. He 
showed similar findings with the disaccharides sucrose (glucose-fructose,) and 
lactose (glucose-galactose) compared to maltose (glucose dimer.)
92 He proposed 
restriction of lactose, fructose and sucrose as they contribute to lactic acidosis and 
do not contribute effectively to gluconeogenesis. Theoretically this hypothesis has 
great credibility, but in practice such restriction could lead to multiple dietary 
deficiencies. The foods associated with lactose intake (milk) and fructose (fruits) and 
sucrose (table sugar), are in a wide range of processed foods and contribute 
significantly to overall dietary quality providing protein, calcium, essential fatty acids, 
vitamin C and fibre. This restriction coupled with a high carbohydrate intake could 
lead to significant dietary imbalances.  
  33There are therefore, divergent attitudes world-wide about the management of these 
patients with some opting to restrict these sugars and supplementing the diet, whilst 
others including the author’s group currently favouring no restriction. Long-term 
studies have tried to address complication rate between these two management 
strategies but to date have failed to find a difference.
59 Preliminary data presented on 
behalf of The International Study of Glycogen Storage Disease type I (ISGSD I) 
registry appeared to demonstrate comparable long-term outcome with severe 
restriction and no restriction, but less favourable outcome with moderate restriction 
(awaiting publication – oral presentation Hamburg SSIEM 2007.) 
 
Patients with hepatic GSDs can have an intensive dietary regimen with substantial 
carbohydrate intake. Some also have a fructose and lactose restricted diet that could 
compromise nutrition further. Such dietary management may have a significant 
impact on the completeness of the diet and itself lead to clinical problems such as 
obesity, diabetes, micronutrient deficiency and osteopenia.  
 
The role of the physical properties of a starch on metabolic control 
Uncooked cornstarch has been used in the dietary treatment of glycogen storage 
disease for over 20 years. It is a starch that is resistant to digestion and consequently 
releases glucose slowly as digestion progresses. In the cooked form, cornstarch 
gelatinises and the glucose polymer hydrolyses such that the starch becomes much 
less resistant to digestion.  
Our research group have undertaken the development of a new starch for glycogen 
storage disease in a number of ways. We have tried various synthetic starches with 
different ratios of amylose/amylopectin, but have not found the desired metabolic 
profile. High amylose content, for example in high amylose maize, is difficult to 
digest. The use of products with delayed gastrointestinal time and the use of 
pancreatic enzyme supplements have also not appeared effective. Much of the work 
  34of Mundy, Lee and Tester in the development of an appropriate starch is 
unpublished. However, of the several single case studies performed, the biochemical 
profile of one starch named WMHM20 appeared desirable. This starch is treated with 
heat under pressure with controlled moisture content and thus is a physically 
modified cornstarch. Englyst et al have described in-vitro studies of carbohydrate 
digestion that provide a quantitative classification of carbohydrate composition based 
on how resistant the starch is to digestion.
93 The method involves assay of simple 
sugars at various time points from a food and digestive enzyme incubation, reflecting 
in-vivo physiology.  The Englyst method demonstrated that physical modifications 
render uncooked WMHM20 more resistant to digestion than uncooked cornstarch ( 
67% and 60% respectively,) which could result in a better metabolic profile.
93 
 
Studies in the general population – glycaemic index and insulin sensitivity 
In 1981, the group of David Jenkins introduced a landmark concept into nutritional 
management using carbohydrates.
94 They coined the term “Glycemic Index” or GI to 
represent how substantial the rise of plasma glucose was after a standardized 
carbohydrate meal. Prior to this publication, the authors commented that instructions 
for diabetic patients were based on the carbohydrate content of food irrespective of 
the properties of the carbohydrate. Setting glucose as the control substance, the 
incremental area under the glucose curve for the first 120 minutes was compared 
using identical amounts of different carbohydrates in healthy individuals. The results 
were expressed as a ratio to the glucose curve. Their results indicated that 
substances such as Lucozade and honey had incremental areas similar to glucose 
but legumes such as kidney beans and lentils had incremental areas 30% that of 
glucose. Whilst not explicitly mentioned in this first publication, the implication was 
that plasma insulin concentrations would be positively correlated to the glycemic 
index. 
 
  35Regular consumption of high GI meals compared to isoenergetic low GI meals leads 
to higher 24 hour average glucose, insulin and glycosylated haemoglobin levels in 
both diabetic and non-diabetic individuals.
95 The greater relative release of insulin 
after a high GI meal as opposed to a low GI meal favours greater anabolic responses 
such as lipogenesis and glycogenesis. This is illustrated by significant elevations of 
the glucose, insulin and triacyglycerol responses in a test meal with rapidly available 
glucose (RAG) compared to slowly available glucose (SAG).
96 This study by Harbis 
et al examined insulin resistant individuals. They showed sustained elevation of the 
triacylglycerol for 6 hours when the RAG meal was taken with a concomitant rapid 
rise of apo B-100 and sustained elevation of apo B-48 for 6 hours when compared to 
a SAG meal. This association of elevations of glucose and insulin resulting in 
hyperlipidaemia is part of a “vicious cycle” whereby hyperlipidaemia also results in 
insulin resistance and hyperglycaemia. 
 
Hyperlipidaemia is associated with increased adiposity and the adipose tissue plays 
an important regulatory role in fatty acid metabolism. This is mediated through the 
hormone adiponectin that is highly expressed specifically in adipose tissue.
69;97 It has 
an insulin sensitising role. Adiponectin deficient mice are prone to insulin-resistance 
and diabetes. In humans, a certain T to G polymorphism in exon 2 of the adiponectin 
gene can result in increased circulating concentrations of adiponectin even though 
this polymorphism confers no change in the amino acid structure.
69 Family studies of 
the silent G polymorphism showed an increased incidence of diabetes and increased 
weight. 
 
These type of studies have important implications for patients with glycogen storage 
disease: 
- Because patients take large amounts of carbohydrate, they are prone to 
hyperglycaemia and hyperinsulism. 
  36- As discussed above, this may lead to hyperlipidaemia and increased adipose 
tissue. 
- Patient also have elevations of plasma lipids for independent reasons to the general 
population - metabolism of surplus glucose-6-phosphate via acetyl coA to 
tryglycerides. 
- Increased fat deposition may lead to insulin resistance independently of recurrent 
hyperglycaemia. 
- Insulin resistance leads to complications such as poly-cystic ovarian disease and 
may result in other morbidities including obesity, non-insulin-dependent diabetes 
mellitus and cardiovascular disease. 
 
 
  371.4 Outline of thesis 
The nutritional management of glycogen storage disease has often been called 
“the intensive regimen.”  The intensive regimen may not be without 
consequence. This thesis aims to characterise the intensive regimen and 
implement changes. Methods and participant characteristics are discussed in 
chapter 2.  The studies performed were as follows: 
Chapter 3 examines this nutritional management as a cross-sectional dietary 
survey of children and adults with GSD.  
Chapter 4 looks at the short-term effect a new carbohydrate therapy has on 
biochemical indices of metabolic control focusing on glucose, lactate and 
insulin profiles.  
Chapter 5 studies further short-term metabolic effects of starch by examining 
hydrogen breath test data and enrichment of 
13CO2 in breath.  
Chapter 6 examines the implementation of the new dietary starch into subjects’ 
long-term dietary regimen.  
Chapter 7 brings together these various studies drawing conclusions and 
suggestions for further study. 
   
Aim of Thesis 
The objective of this thesis is to improve the dietary macronutrient and micronutrient 
balance of patients with .the hepatic glycogen storage diseases.with the adjunct of a 
novel starch created specifically for their treatment  
Hypothesis – The blood glucose profile and secondary biochemical parameters 
are improved when modified cornstarch (WMHM20) is used compared to 
uncooked cornstarch. Dietary treatment also improves when WMHM20 is 
integrated into the dietary regimen of patients with the hepatic glycogen 
storage diseases.  
 
  38CHAPTER 2 – METHODS AND PATIENTS 
2.1 Background to methods used 
Cornstarch Loads 
The cornstarch load is widely used in the practice of metabolic medicine to determine 
the optimal dose and frequency of cornstarch. Whilst it has been widely used, it has 
never been validated as an investigative tool. This situation has arisen because it has 
been used as an intuitive profiling study, charting physiological responses to 
administered cornstarch. Biochemical profiles of patients with glycogen storage 
disease have been a feature since the enzyme defect was identified. In the 1960’s 
and 70’s, John Fernandes performed a series of informative studies, observing 
glucose and lactate responses to a variety of interventions
98;99 - his methods of 
investigation not only formed the foundation of subsequent starch load protocols, but 
influenced management of patients for decades to come.  
 
By the time that Sidbury, Chen and colleagues reported their findings in trials using 
cornstarch in 1984, the methods that they used were established practice.
7 It is not 
clear from this publication what specific profiling protocol was used, but the paper 
reported that glucose and lactate were measured pre-intervention and after various 
doses of uncooked cornstarch were given. Measurement of insulin was not part of 
the protocol. The paper did make some pertinent comments about starch loads that 
are useful in the design of such studies. Firstly, they comment that if the baseline 
glucose is low, duration of normoglycaemia is reduced compared to higher baseline 
glucose. They also noted that heating starch and adding lemonade led to a rapid rise 
100and fall of the glucose. Finally, they noted that the 8 month old infant that they 
studied showed little response to uncooked cornstarch. The optimum dosing regimen 
and precise effect on metabolic control cannot be gauged from this first paper, but 
this information becomes clearer from subsequent publications. Hourly glucose, 
lactate and insulin profiles were performed in the study by Fernades’ group in 1984 
  39101. They also measured hydrogen breath excretion. This study replicated the benefit 
of uncooked cornstarch in terms of adequate glucose and lactate profiles, also 
demonstrating that insulin response was not excessive and that there was no 
evidence of malabsorption from the hydrogen breath test. The same group performed 
carbohydrate profiles using several substrates including glucose, barley groats, 
couscous, macaroni and cornstarch, which they published in 1988.
4 Patient data and 
pre-test management were not indicated in this paper. Blood glucose was measured 
at 30 minute intervals after administration of carbohydrate and lactate, insulin and 
hydrogen were measured at hourly intervals. The test was terminated if the blood 
glucose fell to less than 2.0 mmol/L or there was evidence of symptomatic 
hypoglycaemia. Of the sources of carbohydrate tested, uncooked barley groats had 
the best profile including a similar duration of “normoglycaemia,” to uncooked 
cornstarch but better lactate suppression and less insulin rise. The authors justified a 
cut-off definition of hypoglycaemia of 2.0 mmol/L, by stating that subjects with GSD 
were less sensitive to hypoglycaemia if it occurred gradually. However, it would not 
now be considered ethically viable to have a definition of hypoglycaemia set well 
below higher evidence-based definitions of hypoglycaemia (2.6 mmol/L and 
above).
102-105 Subsequent studies also demonstrated satisfactory growth and 
metabolic control using uncooked cornstarch for several years.
20;45 
 
Cornstarch loads formed part of the protocol to determine the efficacy of cornstarch 
in a study published by Lee et al in 1996.
63 This study was a retrospective analysis of 
clinical practice. 14 patients’ data were presented and all were managed by frequent 
feeds and overnight pump feeds. In the four to six weeks prior to the starch load, 
cornstarch was gradually introduced into the diet so that participants would become 
accustomed to the treatment. Patients were admitted to hospital the night before the 
starch load and given their nocturnal nasogastric feed. The following morning an 
additional 10g of carbohydrate was given as a “bolus” prior to termination of the feed 
  40and uncooked cornstarch was administered within 1 hour of this. The dose of 
uncooked cornstarch was individualised. Blood glucose alone was reported as being 
measured hourly after the baseline samples were taken and the test ended when the 
blood glucose was below 3.0mmol/L. Using this protocol, the median duration of 
normoglycaemia was 4.25 hours. 
As a method, the uncooked cornstarch load has arisen from the history of metabolic 
profiling in glycogen storage disease. There has been no set protocol or consistency 
between protocols. It has often been applied using whatever local resources are 
available, with investigators taking certain steps, such as controlling baseline data, to 
avoid inconsistent results.  
 
Glucose – There has been much debate in the literature about the best means of 
measuring glucose. The first issue is which type of sample is being assessed – whole 
blood, plasma or intracellular. Plasma has relatively more water content with 
dissolved glucose than erythrocytes and consequently exhibits a higher glucose 
value than whole blood, depending upon the haematocrit. The World Health 
Organisation recommends a correction factor of 1.12 converting whole blood glucose 
to plasma values and assumes a haematocrit of 45%. This assumption is less 
appropriate if there is over-hydration or dehydration, anaemia or altered osmolarity of 
the blood. The intracellular compartment, rather than the plasma or whole blood is 
the physiological site where glucose action might appear most relevant. However this 
site is less accessible to measurement than blood or plasma. 
 
 There are 3 enzymatic methods of measuring glucose – glucose oxidase, glucose 
dehydrogenase and hexokinase.
106 The glucose oxidase method is the most 
common method to be used especially for point-of-care machines. However, it can 
be unreliable. The enzymatic reaction produces hydrogen peroxide and glucuronic 
acid – the measurement of hydrogen peroxide is often made by indirect means on 
  41point-of care machines and this is more susceptible to error. Hydrogen peroxide or its 
oxidizing potential cause ionic or colour changes that are measured indirectly by 
point-of-care machines. These machines also use test strips that separate blood from 
the enzymatic surface. As a consequence, such machines are less accurate 
especially at lower concentrations of blood glucose, when there is limited production 
of hydrogen peroxide. It should be noted that this point-of-care machines have been 
designed to detect high blood glucose concentrations in diabetic patients. The YSI 
2300 uses standard YSI direct glucose oxidase measurements. The main difference 
between it and other point-of-care glucose oxidase machines is that its membrane, 
impregnated with glucose oxidase is in contact with the sample.
107 The hydrogen 
peroxide is assayed directly by oxidation at the platinum sensing electrodes. This 
method has been validated against several others and is known to be reliable even at 
lower blood glucose concentrations. There are many advocates of the Haemocue
TM 
system that measures haemolysed blood glucose using glucose dehydrogenase as 
an enzyme. It therefore provides a measure of intracellular glucose and whole blood. 
Intuitively, one would expect this method to be reliable as it incorporates haematocrit 
into its measurement. There are several favourable reports of good correlations with 
measurements of plasma glucose concentrations when the appropriate correction is 
applied.
108 However, there are some reports of less reliable correlations especially for 
hypoglycaemia.
109 The hexokinase method is considered by many as the gold 
standard method and is used by many laboratories. However, equipment is 
expensive, requires regular maintenance and is not portable. 
For the protocols used in chapter 4.1 and 4.2, 2 mls of blood were collected into a 
sodium fluoride bottle with the sample subsequently being analysed by a hexokinase 
method (Vitros Fusion 5.1, Ortho-Clinical Diagnostic, High Wycombe, UK.). The 
fluoride in these bottles inhibits glycolysis thereby allowing stability of the sample for 
several hours.
110 A drop of blood from this sample was placed on a point-of-care 
machine (Advantage II, Roche diagnostics, Mannheim Germany)) as a screening tool 
  42for hypoglycaemia. This gave an estimate of blood glucose within 2 minutes of 
sampling and several hours before a reliable result was obtained. The protocol of 
chapter 4.3 used the YSI 2300 (Yellow Springs, Ohio, USA) at the bedside. A reliable 
plasma glucose result was therefore available within 10 minutes of sampling. 
 
Lactate Lactate is usually produced from pyruvate; it is a product of glycolysis in 
anaerobic conditions. When lactate is sampled from whole blood, glycolytic activity  
continues within erythrocytes , resulting in increased lactate production with time.. 
Consequently lactate either needs to be measured directly after sample collection, or 
intracellular anaerobic respiration needs to be arrested. Several laboratories 
therefore rapidly “deproteinise” samples to curtail respiration. The first study in this 
thesis used a lactate dehydrogenase enzymatic method. The sample was rapidly 
deproteinised using perchloric acid. The action of lactate dehydrogenase on the 
plasma formed NADH, which was quantified spectrophotometrically at 340 nm. 
Similarly to the measurement of glucose, there are discrepancies when whole blood 
lactate is compared to plasma – lactate is produced from peripheral tissues and 
diffuses with time into erythrocytes. Therefore, plasma lactate is often more elevated 
than haemolysed blood and is likewise dependent on haematocrit.  
The YSI 2300 uses similar methodology for lactate measurement as it does for 
glucose measurement. The immobilised enzyme, lactate (L-2-hydroxyacid) oxidase 
produces hydrogen peroxide, which is measured directly by the sensor. This method 
has been validated against standard de-proteinising techniques and was used in the 
protocol of chapter 4.3 of this thesis.
111  
 
Stable isotopes - Natural enrichment of 
13CO2 in the breath – Many elements exist 
partly as “stable isotopes” which have extra mass due to additional neutron or 
neutrons within the nucleus of the atom. Carbon is present in 3 forms 
12C, 
13C and 
14C with 6, 7 and 8 neutrons within each atom respectively. By far the most abundant 
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12C, which forms almost 99% of atmospheric carbon dioxide. 1.1% of atmospheric 
carbon dioxide has 
13C and there is only a trace amount of the radioactive 
14C. Some 
plants such as potatoes preferentially incorporate 
12C into their carbon skeleton. 
These plants fix CO2 using ribulose-bisphosphate carboxylase forming a 3-carbon 
compound product via the Calvin pathway.
112 In warmer climates, plants such as 
maize have evolved a more energy efficient process of CO2 fixation in which a 4-
carbon product results from the C4 or Hatch-Slack pathway.
112 These plants are more 
able to utilise 
13C within atmospheric CO2 and hence incorporate more 
13C within 
their carbon structure.
113 The variation in the proportion of 
13C and 
12C within plants 
lends itself to research applications studying the fate of such ingested substances. In 
this context the substance ingested acts as a natural tracer.
114;115 
 
The appearance of 
13CO2 in the breath following the ingestion of a particular 
substrate labelled with 
13C depends upon the production of labelled CO2  as a 
metabolic end-product. The ratio of 
13CO2:
12CO2 in breath can be measured by 
isotope ratio mass spectrometry (IRMS) and, assuming constant or complete 
oxidation of the products of digestion and constant production of CO2, the rate and 
extent of substrate digestion and absorption can be quantified. 
 
The methodology of Isotope ratio mass spectrometry (IRMS) introduces cleaned and 
dried CO2 into a vacuum system. It is then ionised, accelerated and deflected in an 
arc which is proportional to the ionic mass. The two commonest masses of CO2 
reflect the incorporation of stable isotopes, 
12C
16O2 with a mass of 44 and 
13C
16O2 
with a mass of 45. The ions of different mass are separated and collected 
individually. They are converted into electrical currents and measured. The ratio of 
13C:
12C can then be calculated. The technique is suitable for detecting small 
differences in enrichment, but requires a relatively large sample (of the order of 
micromoles of CO2).
115 
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Continuous-flow isotope ratio mass spectrometry (CF-IRMS) was developed around 
20 years ago for 
13CO2 analysis in expired air. It provides rapid automatic sample gas 
preparation using a smaller sample size than conventional IRMS but with better 
precision than gas chromatography / mass spectrometry (GC/MS) and precision 
comparable to IRMS. 
 
13C enrichment is commonly measured by reference to an international standard. 
That chosen is PeeDee Belemnite (PDB), a limestone of well-defined isotopic 
abundance. The relative difference is then expressed as delta per mil (‰). The 
13C:
12C ratio for PDB is 0.0112372. The natural abundance of 
13C relative to PDB 
within uncooked cornstarch, WMHM20 and Maxijul (SHS Ltd, Liverpool, UK) was 
quantified by elemental analyser isotope ratio mass spectrometry after complete 
combustion (Isoanalytical, Sandbach, UK). These were  δ-‰  -11.13, -10.75 and -
11.32 respectively. In a breath test experiment baseline 
13C is quantified in the breath 
and subsequent results are expressed as enrichment or delta over baseline 
(DOB).
115 
 
Most healthy individuals in Western Europe consume a diet low in C4 derived carbon 
which is therefore low in 
13C, with a δ-‰ of approximately -24. As cornstarch has a δ-
‰ of -11, oxidation of cornstarch can usually reliably be detected against a normal 
Western European diet, because CF-IRMS can detect differences as small as 0.1 – 
0.2 ‰. This does not necessarily hold true for all individuals, some of whom may 
have different baseline 
13C enrichments. 
 
The oxidation or utilisation of glucose derived from treatment starch is calculated 
from the 
13C enrichment in expired CO2 using the formula on the following page: 
 
  45 
Starch utilisation (mg/kg/min)
62 = 
[δ ‰CO2(t)- δ ‰CO2(t0) / δ ‰ starch- δ ‰CO2(t0)]  X [VCO2(t)X 180/(22.4X6XWt)]  
 
δ ‰CO2(t) – delta value of expired CO2 at given time-point 
δ ‰CO2(t0) – delta value of expired CO2 at baseline 
δ ‰ starch – delta value of starch after complete combustion 
VCO2 (t)- Mean rate of exhaled CO2 (ml/min) 
Molecular weight of glucose = 180g 
1/22.4 – conversion to moles of CO2
1/6 – conversion to moles of glucose 
Wt– weight 
It was not the aim of this study to accurately determine starch utilisation, but rather to 
measure the difference in utilisation between the two starches in the same individual. 
Therefore, a number of additional assumptions were made compared to previous 
studies. VCO2  was not measured but derived from a previous publication at 227 
ml/kg/min.
62 Actual body mass was used as opposed to lean body mass. In both 
instances, these were constants that applied to the calculation of utilisation for each 
of the starches used. Therefore, these assumed values did not influence the trend of 
utilisation in any direction. 
The study described in chapter 4.4 used naturally enriched cornstarch and WMHM20 
as a substrate with 
13CO2  / 
12CO2 enrichment being assessed by CF-IRMS. 
 
Hydrogen Breath Test Hydrogen is a product of bacterial fermentation and cannot be 
produced or utilised by mammalian cells. It is absorbed into the bloodstream and 
excreted in the breath. Administration of a non-absorbable carbohydrate produces a 
rise in hydrogen production after a period of time and this is detectable in end tidal 
breath measurements. This is the basis of the hydrogen breath test and it has been 
  46used as a measure of both small intestinal carbohydrate malabsorption and oro-
caecal transit time.
116;117 It was first described for carbohydrate malabsorption 35 
years ago and has been used to estimate the degree of malabsorption by the amount 
of substrate being fermented. It has also been used in young infants to measure the 
fermentation of lactose.  
Breath hydrogen was assessed using a portable hydrogen device (micro-H2 , 
Medisense, Rochester, UK) in the studies described in chapter 4.3 and 4.4. The 
sensor comprises a heated palladium silicon dioxide interface that dissociates 
hydrogen on contact leading to a decrease in potential which is registered by the 
monitor. The relative change in potential is compared to a known calibrated 
standard.
100 This method appears to be a reliable method of analysis of hydrogen 
compared to other methods with sensitivity of 1 ppm of hydrogen in the range 0 – 
500 ppm. 
 
Dietary Assessment The impact of diet on disease has been of substantial interest 
over the last 30 years with associations being made, for example, between high 
glycaemic index diets and diabetes and high fat diets with ischaemic heart disease 
and cancer susceptibility.
118-120 Despite these assertions, the valid quantification of 
dietary intake is difficult to ascertain. There are numerous methods of dietary 
assessment but each has inherent errors as a tool.
121;122 Methods that can be used 
include: direct observation of intake by a researcher, 24 hour retrospective recall, 
prospective diaries completed by research subjects for between 1 and 7 days, 
weighed records of intake and food frequency questionnaires. Errors can be divided 
into 3 categories – the assessment is not representative of the overall diet, 
inaccurate quantification of actual intake or assessment leads to change in eating 
behaviour.  
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dietician. With appropriate time and examples of food portion measures, this can be 
an accurate assessment of what the subject took for 24 hours, but 24 hours may not 
represent what a person normally takes. Diet diaries can be variable, dependent on 
the intellectual ability of the subject completing the form. They may not be accurate if 
the subject forgets to enter data into the diary and are regarded as semi-quantitative 
if the subject uses household measures as an estimate. The longer a subject can 
accurately record what they take, the more representative the record is of the long-
term diet, but compliance decreases with longer assessments. For this reason, many 
opt for a 3 or 5 day record as opposed to a 7 day record. A 3 day record should 
include a weekend day and 2 working days for those working full-time in order to 
represent what is normally taken in the week. There is potential for a diary to alter 
eating behaviour if for example a subject opts for an easy to record “ready meal” in 
preference to recording an intricate recipe. Direct observation may seem the most 
reliable method, but is labour intensive and prone to subjects altering behaviour to 
what the subject feels the observer expects. A food frequency questionnaire has a 
list of foods (sometimes greater than 100,) and asks subjects to complete how often 
and how much of each food subjects have. This method can be more representative 
of long-term diet because it considers longitudinal intake over months.
123 However at 
best, it is semi-quantitative. It has a use for large epidemiological studies where large 
amounts of data can be assessed at relatively low cost, but is less appropriate for 
smaller studies, especially from an ethnically diverse population such as London, 
where the questionnaire may not represent the dietary intake from different cultures. 
 
The methods used in this study are written diet diaries for 3 days in adults and 5 days 
for children, which were examined immediately on receipt by a state registered 
dietitian. After review, inconsistencies or clarification was made either with the patient 
or carer by face-to-face questions or by telephone. In this manner, data collected 
  48were a composite of prospective diet diaries and recall. Data were entered onto 
specialist software (Dietplan 6, Forestfield Software, Ltd. Horsham, UK. – referenced 
to McCance and Widdowson's The Composition of Foods.)
88 Output from diet diaries 
were collated and comparisons made with both UK dietary reference values and UK 
national dietary surveys.
66;67;124  
 
Dietary Reference Values 
In the United Kingdom, the panel on dietary reference values was set up in 1987 by 
the Committee on Medical Aspects of Food Policy (COMA) to review 
recommendations for food energy and nutrient intake. The panel created four 
working groups examining requirements for energy and protein, fat and 
carbohydrate, vitamins and minerals. The working groups reported back to the panel 
culminating in the publication in July 1991 of the COMA report on Health and social 
subjects 41.
124 The panel departed from previous reviews that instructed 
“recommended daily amounts” (RDA) which was a specific quantity of recommended 
intake, to a range of dietary values that people should take in order to avoid 
problems. COMA suggested that dietary reference values (DRV) would comprise 
“reference nutrient intakes” (RNI) which has been set as 2 standard deviations above 
the estimated average requirement (EAR) and is deemed sufficient to prevent 
problems in most people. Using a Gaussian curve, COMA also suggested that there 
should be a lower reference intake (LRNI.) The panel felt that if intake is habitually 
below this value then untoward problems were likely to ensue in the majority of 
people. The problems that could occur are specific to the nutrient concerned but 
categories of requirement include:  
a) the nutrient intake required to maintain a circulating level or degree of enzyme 
saturation or tissue concentration; 
b) the intakes of a nutrient which are associated with the absence of deficiency 
diseases; 
  49c) the intake of nutrient associated with an appropriate biological marker of nutritional 
adequacy. 
The basis of the DRV for different nutrients consequently varies depending on the 
nutrient; this thesis compares values obtained in patients with published DRVs. In 
most instances either the RNI or EAR are published and used. In some instances, 
the LRNI is quoted too. Age and gender related EAR for energy intakes are given in 
appendix 1. 
 
National Diet and Nutrition Surveys 
The DRVs are values that an expert panel recommend subjects take. These expert 
considered guidelines are not necessarily based on rigorously derived evidence.  The 
national diet and nutrition surveys are assessments made to see what nutrition 
people actually take. The first surveys commissioned by the UK Department of 
Health and Ministry of Agriculture, Fisheries and Food were carried out in 1986 /7 
and were performed on adults. This was published in 1990 and due to its success; a 
complete programme of surveys was instituted as part of the UK Office for National 
Statistics. The first of these was performed in children aged 1½  to 4½ performed in 
1991 and published in 1995. After feasibility studies, the next survey, on children 
aged 4 to 18 years, was carried out in 1997 and published in 2000.  A further survey 
was performed on adults in 2001 and published in 2004. 
 
The programme is a well resourced national survey. The methods of these surveys 
are very rigorous with great attention paid to detail. Each survey had greater than 
2000 participants and subjects were stratified in sub-analyses by age, gender, social 
class and region. Selection processes of participants were diversified across regions 
and once a target region was identified, selection of individual participants was 
random. Dietary assessments were made by specialised teams of field workers and 
a weighed intake for 7 days was performed. Each family was issued with 
  50standardised calibrated weighing scales and educated in the use of completing 
diaries with weighed foods. Field workers visited households 24 hrs after the diary 
commenced offering support and advice. They visited several other times in the 7 
day period if further support was required. If a subject ate out, portion sizes and 
ingredients were ascertained directly from the retailer. 
The dietary survey indicates normal eating behaviour in the UK. For the purposes of 
this thesis, this is a control population against which patients with GSD have been 
compared. The 2 surveys used are the children survey of 1997 published in 2000 
and the adult survey performed in 2001 and published in 2004.
66;67 Details of data 
used are indicated in appendix 1. 
 
2.2 Patients 
A number of studies are described in this thesis. All patients were recruited from the 
3 tertiary metabolic units in London: children were from Great Ormond Street 
Hospital and The Evelina Children’s Hospital and adults from the National Hospital 
for Neurology and Neurosurgery, Queen Square. All adults recruited gave voluntary 
informed written consent to the studies after being issued with participant information 
sheets. The carers of children under the age of 16 gave written informed consent, 
having first been issued with a carer’s information sheet. Children between the age of 
10 and 16 were issued with an age appropriate participant information sheet and 
were asked to give consent if deemed to be competent enough to do so by the 
researcher. This written consent was taken in addition to parental consent. Children 
under the age of 10 had a full verbal explanation of the study by the researcher and 
gave verbal consent to the studies.All patients that took part in these studies had 
evidence of fasting hypoglycaemia, with either enzymatic demonstration of glycogen 
storage disease from liver or from leucocytes (GSD III,) or recognised mutations in 
the appropriate genes. All patients took uncooked cornstarch in their dietary 
treatment regimen. Characteristics of patients are described on table 2.  
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ID Age 
yrs 
SEX 
(M/F)
GSD 
Type 
Diagnosis 
(Gene / Biopsy) 
Presentation & age of 
diagnosis 
Normal 
Carbohydrate use 
Medications     Complications 
A 3  F  IA  c.79delC/N 
G188S/N 
Hypoglycaemic fits age 3 
days, hyperlipidaemia 
D - 30g UCCS TDS 
N - 100g polymer 
Allopurinol Nephrocalcinosis 
Died post studies 
B 
 
4  
 
F IA  Homozygous 
C150-151delGT 
At birth – sibling of C  D –25g UCCS QDS 
N – 90g polymer 
Multivitamins  
C  5 M IA  Homozygous 
C150-151delGT 
FTT, large abdomen, 
recurrent infections 
D - 35g UCCS TDS 
N 105g polymer 
Multivitamins  
D  5 M IA  R83C 
C347X 
Haematuria, FTT, lactic 
acidosis 
D – 40g UCCS TDS 
N – 105g polymer 
Allopurinol  
Multivitamins 
 
E  7 M IA  Biopsy  Sweaty,  FTT,  large 
abdomen age 2.5 yrs 
D – 50g UCCS TDS 
N – 150g polymer 
Allopurinol  
Multivitamins 
Obese 
F  12  M  IA  Biopsy  Large abdomen 3 weeks 
Resp. distress 7 months 
D – 60g UCCS TDS 
N – 125g polymer 
none Behavioural   
problems 
G 21  M  IA  Homozygous 
C150-151delGT 
Diarrhoea and FTT at 6 
months.  
Seizure disorder 
D – UCCS 60g BD 
N – 125g polymer 
Allopurinol,Ramipril
, 
Clonazepam 
Carbamazepine
Intellectual 
impairment, 
Seizures 
H 22  F  IA  Homozygous 
C150-151delGT 
Irritability at  8 months  D – 30g UCCS BD 
N – 55g UCCS 
Allopurinol 
Ramipril. Vit B12 
PCOD 
Renal impairment
I 22 M  IA  Homozygous 
R83C 
Hypoglycaemia – 6 
months 
FTT 
D – UCCS – 65g BD 
N – 160g polymer 
Allopurinol 
Salazopyrin 
Inflammatory 
bowel disease 
J 23  F  IA  Homozygous 
C150-151delGT 
FTT, hypoglycaemic fits, 
large abdomen at  7  
months. 
D – UCCS 40g QDS 
N – UCCS 80g 
Allopurinol 300mg 
Multivitamins 
Short stature 
Chronic fatigue 
Renal calculi 
V 25  F  IA  Homozygous   
R83C 
Hypoglycaemic seizures 
– 2 months 
 
D – UCCS 40g QDS 
N - 120g Polymer 
Allopurinol 300g 
Multivitamins 
PCOD 
Table 2.1  – Patient characteristics
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yrs 
SEX 
(M/F)
GSD 
Type 
Diagnosis 
(Gene / Biopsy) 
Presentation & age of 
diagnosis 
Normal 
Carbohydrate use 
Medications     Complications 
K  33  M  IA  Biopsy  18 months – irritability 
and hepatomegaly 
D –UCCS 50g QDS 
N – UCCS 50g X2 
Allopurinol 300mg, 
simvastatin, 
codeine, 
lansoprazole
Hepatic adenoma 
(resected) 
Chronic scar pain 
Heartburn
W  41  F IA  Biopsy  Hepatomegaly 
Short Stature age 1 
 
N – UCCS 30g 
 
None 
 
X  42  M IA  Biopsy   
Hepatomegaly 
FTT – 18 months 
 
N – UCCS 40g 
 
None 
 
Short Stature 
 
L  34  M  IA  Biopsy  Enlarged liver, FTT at  6 
months 
 
N – UCCS 60g 
 
None 
 
M   47  M  IA  Biopsy  FTT age 6 months   
N – UCCS 60g 
Allopurinol 300 mg 
Enalapril, 
Ezetimibe 
Atorvastatin, 
Hepatic adenoma 
Renal impairment 
TIA - ? cause 
Hyperlipidaemia
N  13  M  IB  Biopsy  Age 3 yrs - Lethargy,   
Developmental delay 
D – 80g UCCS BD 
N – 175g polymer 
Allopurinol 50mg   
O 14  F  IB  1042delCT 
480delA 
Large abdomen, listless 
Resp infection from birth - 
3 months  (biopsy)  
D – 60g UCCS TDS 
N – 60g UCCS X2 
Allopurinol 150 mg 
Septrin, GCSF 
Thalidomide 
Crohns Disease 
Bronchiectasis 
 
P 15  F  IB  496G>A 
1393G>A 
Hepatomegaly 
18 months 
D – 25g UCCS BD 
N – 45 g UCCS X2 
Allopurinol 150mg 
GCSF 
 
Y 17  M  IB  Homozygous 
IVS7+2delAAGT 
Hepatomegaly 
Family history (Z & Z1) 
D – 40g UCCS TDS 
N – 140g polymer 
Allopurinol Obese 
 
Z 19  F  IB  Homozygous 
IVS7+2delAAGT 
Hepatomegaly 
(Family History (Z) 
D – 30g UCCS TDS 
N – 120g Polymer 
Allopurinol 
GCSF 
Anaemia 
Recurrent 
infections 
Table 2.1 continued 
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yrs 
SEX 
(M/F)
GSD 
Type 
Diagnosis 
(Gene / Biopsy) 
Presentation & age of 
diagnosis 
Normal 
Carbohydrate use 
Medications     Complications 
Z1 25  M  IB  Homozygous 
IVS7+2delAAGT 
Hepatomegaly 6 months 
Recurrent infections 
 
D – Poor compliance 
N -60g UCCS 
Allopurinol 
GCSF 
Anaemia, fatigue 
Crohns Disease 
Transplant list 
Q 27  M  IB  Homozygous 
IVS7+2delAAGT 
Age 3 years  D – 40g UCCS QDS 
N – 40g UCCS BD 
Allopurinol 200 mg 
GCSF 
Short stature 
Diarrhoea 
R 35  M  IB  R415X 
2
nd unknown 
Large abdomen at 2.5 yrs 
Sibling of S 
D- 
N- 30g 
Allopurinol – 
300mg 
Fl h t
Hepatic adenoma 
Chronic anaemia 
S 38  F  IB  R415X 
2
nd unknown 
5 yrs - Large abdomen, 
sweating, irritability  
D – 20g UCCS BD 
N – 40g 
Ferrous sulphate  Chronic anaemia 
T  3   F  IIIa  Liver biopsy  Recurrent Hypoglycaemia 
– 2 months 
D – 30g UCCS TDS 
N – 75g polymer 
Multivitamins 
Protein supplement 
Myopathy 
U  12  M  IIIa  Liver Biopsy  Lethargy, sweatiness at 5 
months. 
D – 45g UCCS BD 
N – 70g polymer & 
milk
Multivitamins Overweight 
 
Table 2.1 Recruited subjects age, disorder and treatment characteristics at time of participation at first study.  
ID – identity- referred to in subsequent chapters  
D = Day; N = night;  
UCCS – Uncooked cornstarch;  
FTT – failure to thrive; PCOD – Poly-cystic ovarian disease.  
GCSF – Granulocyte Colony Stimulating Factor  
* Details in chapter 3.1 
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Introduction 
This chapter assesses the dietary management of patients with glycogen storage 
disease. There are specific targets of carbohydrate intake for patients with GSD 
which originated in studies performed in the 1960s and were confirmed by 
calculations from endogenous glucose production studies performed predominantly 
in children. It is recommended that 65% of dietary calories should be in the form of 
carbohydrate. This quantity of carbohydrate intake is greater than that recommended 
or taken by the general population. In our clinical experience, adults have a limited 
pattern of eating learnt from childhood, that may not necessarily be appropriate in 
adult life. Excessive carbohydrate intake, especially of low glycaemic index foods are 
well recognised to have adverse health outcomes and it is therefore important to 
characterise the GSD diet in order to see whether improvements can be made. 
71;95;119 Children in particular can often require 2 hourly feeds of glucose polymer, 
which has a short duration of action. Adults may take uncooked corn-flour regularly. 
Both glucose polymer and uncooked corn-flour have little additional nutritional value 
apart from providing carbohydrate. Therefore, the potential for dietary insufficiencies 
exist if the remainder of the diet is not complete.  
 
There are several dietary targets of management that have been established for 
individuals from the general population as a whole as well as specific targets for 
patients with GSD. In the UK, population targets are referred to as dietary reference 
values comprising the estimated average requirement (EAR) and “reference nutrient 
intakes” or RNI which has been set as 2 standard deviations above the EAR and is 
deemed sufficient to prevent problems. (chapter 2.1)
124 
 
The basis of the RNI for different nutrients varies depending upon the nutrient; it is a 
nutritional target that it is projected will prevent nutritional diseases due to 
  55insufficiency. However, the converse of nutritional disease due to excess is not 
addressed by RNI. Because these recommendations developed in 1991, do not 
address surplus intake, this chapter also examines patients’ nutritional intake 
compared to what is taken on average within the UK by comparison with national 
dietary surveys.
66;67;124 Further details on dietary reference values and the national 
dietary surveys are in chapter 2.1. Biochemical and clinical indices of nutrition are 
also presented. 
 
This chapter is divided into four sections. Chapter 3.1 describes several short case 
histories demonstrating how patients integrate dietary treatment into their  lifestyle. 
Several different cases are selected, demonstrating how people can be affected very 
differently with GSD. They show that death can still occur, that morbidities such as 
end-stage renal failure or poor metabolic control leading to hepatic transplantation 
may still occur. Even with good compliance, if a fixed insult occurred early in life, 
neurological complications can ensue and that compliance means intensive therapy 
even in adult life. The first case demonstrates the therapy before implementation of 
currently accepted treatments of naso-gastric feeds and uncooked cornstarch 
Chapter 3.2 describes a cross-sectional survey of the diets of children and adults 
with GSD I and III. Chapter 3.3 discusses the results. Chapter 3.4 summarises the 
findings and conclusions. 
 
3.1 – Dietary Case Studies 
Subject K – Subject K is a 40 year old factory worker with GSD Ia, born in 1969 He 
is single and lives at home with his parents. He was the fifth of six children with no 
other child being affected. Birth was uneventful. At the time of weaning his mother 
noted that he had sweaty episodes with periods of eyes rolling. A protuberant 
abdomen was also noted. After several admissions to a local hospital, the diagnosis 
of GSD Ia was made by liver biopsy performed at a tertiary hepatology unit at the age 
  56of 18 months. In the early 1970’s he was placed on sucrose and fructose restricted 
diet in early childhood, but was never treated with overnight continuous pump feeds. 
His parents recall waking him up for glucose feeds overnight when he was at school; 
he only started taking uncooked cornstarch when he started work at the age of 18. 
He recalls always needing to eat carbohydrates regularly as part of treatment. At the 
age of 34 years, several adenomata were seen within the liver and these were 
surgically removed during a partial hepatectomy. Since this time, he has had chronic 
pain at the site of the scar requiring treatment with low dose opiates. He also has 
symptoms of heartburn and intermittent diarrhoea and constipation. He is treated with 
lansoprazole and periodically takes laxatives. He was referred to the tertiary 
metabolic unit at the age of 34, after the adenomata had been resected. He now 
takes UCCS five times a day. An example of a daily dietary record, taken from an 
actual diet diary is given below:    
•  05:00 – 50g starch 
•  6:15 – 1 weetabix with milk & tea 
•  09:00 – 50g starch – Fish-paste sandwich 
•  13:00 – 50g starch 
•  16:30 – 2 slices of toast and 1 egg 
•  17:00 – 50g starch 
•  20:00 – Chicken and chips 50g starch 
•  23:00 - 100g starch and half bottle of lucozade. 
Subject Z 
Subject Z is a 27 year old male, born in 1982, being the second of four children. Both 
he and a younger sister have GSD Ib, reported in a previous publication.
125 He is 
single and lives at home with his parents. He developed hepatomegaly and irritability 
at the age of 9 months and had recurrent episodes of infection. He was treated 
initially with nocturnal nasogastric pump feeds of glucose polymer and frequent 
daytime carbohydrate. As a child he was very reluctant to insert nasogastric tubes 
  57and as a teenager completely refused to do so. Due to recurrent infections, 
recombinant GCSF therapy was commenced at the age of 10. At the age of 12, he 
had frequent loose stools – colonoscopy revealed inflammatory bowel disease and 
sulphasalazine was commenced. By the age of 14, both daytime and nocturnal 
uncooked cornstarch were prescribed, but adherence to dietary and medical therapy 
was sub-optimal. Z preferred taking commercially available high glucose drinks rather 
than prescribed therapy. Despite frequent hospitalisations for recurrent infections, Z 
was academically competent and commenced a degree in Computer Science at 
University at the age of 19 years. However, complications became increasingly more 
prominent as a young adult as he became chronically fatigued, under-weight with 
frequent episodes of infection and severe diarrhoea. Assessments demonstrated 
chronic anaemia (haemoglobin 7g/dl – range 13 – 15). At the age of 22 he took a 
temporary break from his studies in order to regain health but after 2 years, he 
continued not to be able to return back to university. Due to his chronic ill health, he 
was placed on the liver transplant programme at the age of 24 and subsequently 
received an orthotopic liver at the age of 25. An example from his dietary record, 
before his liver transplant, is given below: 
•  04:00 – 200mls lucozade (– 18% sugar) 
•  08:00 – 90g cornstarch with 10mls ribena (13% sugar) and water 
•  10:30 – Full plate of grilled chicken and plain rice & 200 mls lucozade 
•  16:00 – Milkshake 220 mls (14% sugar)  - small portion rice and chicken 
•  19:30 – 1 banana & 220mls of milkshake 
•  22:00 – Full plate of rice and chicken. 200mls mixed fruit juice (8% sugar) 
•  24:00 - 90g cornstarch with 10mls ribena (13% sugar) and water 
Subject V –Subject V is a 28 year old woman, born in 1981 with GSD type Ia. She is 
single and lives at home with her parents. She presented at 6 months of age with 
irritability and hypoglycaemic seizures. She was treated from this age with nocturnal 
glucose pump feeds and frequent daytime meals. She was very compliant with 
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tube. In childhood, she had frequent episodes of symptomatic hypoglycaemia if 
therapy was discontinued or during inter-current illness. Such episodes still occur 
periodically in adult life. By the age of 7, she commenced regular therapy with 
uncooked cornstarch but has never discontinued nocturnal pump feeds. She was 
academically gifted at school and completed her degree and masters and is 
completing a doctorate in her chosen field. Her medical complications include poly-
cystic ovarian disease. An example of her dietary record is given. 
•  08:30 – discontinue nocturnal feed 20mls of 25% glucose polymer. 
•  08:45 –  20g rolled oats with 150 mls semi skimmed milk 
•  09:00 – 50g cornstarch and 200 mls semi skimmed milk 
•  11:00 – 40g fruit yoghurt 
•  13:00– 4 slices roast pork, 75g cooked pasta with ½ teaspoon of tomato 
sauce. 50g cornstarch with 200mls semi-skimmed milk  
•  16:30 – banana 
•  17:00 - 50g cornstarch and 200 mls semi skimmed milk 
•  18:30 – 2 lamb chops, mashed potato and ½  boiled carrot. 
•  21:00 - 50g cornstarch and 200 mls semi skimmed milk 
•  23:30 – 25 g cornstarch and 200 mls semi skimmed milk 
•  00:30 – 40mls/hr of 25% glucose polymer via nasogastric tube until 08:30 
with sachet of multi-vitamin preparation. 
Subject H  Subject H is a 26 year old woman, born in 1983 with GSD Ia. She is 
married and lives with her husband and an extended family. She presented at 9 
months of age with a protruberant abdomen and failure to thrive. She was treated 
with nocturnal glucose pump feeds and frequent daytime meals. Uncooked 
cornstarch was used in the dietary regimen from the age of 10 years. As a child and 
young teenager H was very compliant with therapy. In the peri-pubertal years, she 
tried to limit her calorie intake, being conscious of the effect large amounts of 
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took some cornstarch, but therapy was inconsistent. Despite poor adherence to 
therapy, she attended university, qualifying with a degree in Genetics. After 
qualification, she commenced full-time employment and recently married. Over her 
adult life, weight has fluctuated considerably. She has had proteinuria and 
hypertension for several years and over the course of the last year, there has been a 
dramatic decline in the glomerular filtration rate to 24 mls/min/1.73 m
2. This has been 
accompanied by consistent elevation of the plasma creatinine. She takes maximal 
reno-protective medications. An example of her dietary record is given. She is a 
vegetarian. 
•  06:30 – 25g cornstarch with 100 mls water 
•  07:15 – ½ bowl of fruit and fibre cereal with 100mls semi-skimmed milk 
•  11:15 – 1 chocolate glazed, custard filled doughnut ; 250 mls water 
•  13:45 – 4 strawberries; 3 slices of French bread – 2 with hummus and 1 with 
cheese dip. 5 potato crisps. 
•  14:45 – 25g of cornstarch with 100mls water. 
•  16:30 –  50g of pasta, 3 spoons of pesto sauce, small portion of mixed salad, 
1 banana and 1 tangerine. 
•  20:30 – 20g of potato crisps 
•  21:00 – 1 Indian style fried dumpling made from mixed milled grains, (millet, 
rice, wheat and barley) and chick peas (12g). Small bowl of boiled rice and 
20mls of low fat natural yoghurt 
•  21:45 – 7 chocolate finger biscuits. No nocturnal cornstarch 
Subject G Patient G is a 24 year old man with GSD 1a. He is single and lives at 
home with his parents. He was diagnosed at the age of 6 months having had a 
history of irritability and seizures. In early childhood he had several life threatening 
problems with hypoglycemia and seizures. He had a tendency to severe diarrhoea 
and vomiting resulting in admissions with hypernatremic dehydration. At the age of 
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related to protracted hypoglycaemia. On this occasion, persistent elevation of 
intracranial pressure was measured by invasive intra-cranial monitoring.  Residual 
learning difficulties and seizures ensued. He continued to have refractory epilepsy 
throughout much of childhood and adult life. He has moderate learning difficulties. As 
an adult he has supervised training for work within restaurants organized by a 
learning disability team, but has not developed skills sufficient to live independently. 
He has limited understanding of his underlying condition and periodically fails to 
adhere to prescribed therapy. He continues to take a nocturnal pump feeds and daily 
doses of uncooked cornstarch. An example of his dietary record is given. 
•  07:00 – Off nocturnal feed50g cornstarch & 250mls of milkshake (10 % sugar) 
•  11:50 – 2 wheat wholemeal chapatis with butter. 1 dessert spoon of black 
bean curry with 1 tablespoon of mango and carrot sweet chutney. 
•  13:15 – 50g cornstarch with 250 mls of milkshake 
•  13:30 Indian condensed milk ice cream (Kulfi) – 80g and 200mls whloemilk 
with 8 fresh strawberry milkshake. 
•  19:30 – Vegetable quarter pounder – (from packet) 
•  23:30– Vegetable burger (from packet) and 500 mls lucozade sport (3.5% 
sugar; 6.4% carbohydrate.) 
•  23:45- 80g Kulfi 
•  24:00 35% glucose polymer solution at 40ms/hr until 07:00 
Subject A  Patient A was a three year old girl at the time of this study. She presented 
at the age of 3 days with hypoglycaemic seizures and hyperlipidaemia. Diagnosis 
was made on the basis of the identification of pathogenic mutations in G6PC gene. 
She remained in hospital for the first 4 months of life in order to establish a safe 
enteral feedng regimen without episodes of hypoglycaemia. She remained on two 
hourly feeds with overnight continuous feeds of glucose polymer until the age of 2 
years. Prior to this, uncooked cornstarch was introduced but was poorly tolerated due 
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the age of 3 years when she participated in these studies. 6 months later at the age 
of 4 years she became comatose overnight at home. This episode was presumed to 
be related to hypoglycaemia, possibly due to failure of the overnight pump feed. She 
was urgently admitted to hospital but unfortunately died shortly thereafter. An 
example of the dietary record provided for this study is shown below: 
 
•  08:00 –  Off Nocturnal pump – 10g bolus of glucose polymer 
•  0815 – Three table spoons of tinned custard. 5g of crisps, 100 mls of 
blackcurrant and apple juice. 
•  09:00 – 30g of uncooked cornstarch mixed in 100mls of semi-skimmed milk 
•  10:30 – 1 hash brown, 1 tablespoon of baked beans, 50 mls of diluted 
blackcurrant cordial. 
•  13:00 – 120g of full cream fruit yoghurt. 10 grapes. 50 mls of orange and 
mango smoothie. 
•  14:00  – 30g of uncooked cornstarch mixed in 100mls of semi-skimmed milk 
•  17:30 – “Take away” Fish and chips – 10 chips, 1/3 small battered cod. 
•  18:00 – 30g of uncooked cornstarch mixed in 100mls of semi-skimmed milk 
•  20:00  - 100g glucose polymer in 500mls water at 40 mls/hr for 12 hrs. 
 
The dietary management of glycogen storage disease as indicated by these dietary 
diaries is intensive. In childhood, parents are concerned about the real risk of 
hypoglycaemia related morbidity and mortality, which persists to some extent in adult 
life. Chapter 3.2 attempts to collate the analyses of these data for the population of 
patients with GSD that were recruited to the cross-sectional survey for this thesis. 
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hepatic glycogen storage disease 
Aim  To document current nutritional intake of patients with GSD and make 
recommendations to improve the macronutrient and micronutrient balance of the diet 
in line with peers and current guidelines.  
Methods 
This study was part of other studies investigating nutritional management of the 
hepatic glycogen storage diseases and  was performed in 2-stages – the assessment 
of diet in children aged 3- 15 years old with hepatic GSDs and the assessment of diet 
in adults with GSD type 1. All patients took uncooked cornstarch as part of their 
dietary regimen. There was ethical approval for these studies from the joint ethics 
committee of Institute of Child Health & Great Ormond Street Hospital and the joint 
ethics committee of The National Hospital for Neurology & Neurosurgery & Institute 
of Neurology. Written informed consent was taken prior to collection of data.  Carers 
of children were instructed on how to complete a diet diary by a specialist nutritional 
nurse when they attended the hospital and were issued with a 5-day diet diary. 
Participants were encouraged to document all recipes of home prepared foods with 
estimates of quantity ingested, and retain, for inspection, nutritional information on 
packaging from processed foods.  Diaries were performed on 2 weekend days and 3 
week days. Blood was drawn at this visit for the following tests:  
- Full blood count 
- Iron 
  - Vitamin B12 
  - Red cell Folate 
- Thiamin 
  - Vitamin D 
 -  Zinc    
 -  Copper 
  63 -Manganese 
 -  Selenium 
 -  Calcium 
 -  Albumin 
 -  Phosphorus 
             -Liver Function Tests  
Patients and carers re-attended the hospital between 7 and 28 days after issue of the 
diet diary in which time the diary was completed. At the second visit, the diary was 
discussed between the nurse and carer to ensure data were complete. All diary data 
were anonymised and entered onto specialist software (Dietplan 6,  Forestfield 
Software, Ltd. Horsham, UK. – referenced to McCance and Widdowson's The 
Composition of Foods.  )
88, by an experienced state-registered dietician. Data were 
expressed as an output giving mean daily intake for the five days. 
 
Adults were asked to complete a 3-day diet diary incorporating one weekend day and 
2 week days. They attended the hospital in a similar manner to the children and 
blood was taken for the same tests, as described above. Participants were instructed 
on diary completion by a state-registered dietician who also examined diaries 
returned by post. If any clarification was needed on written information, participants 
were contacted by telephone and queries were discussed. Data were analysed using 
Dietplan 6 and expressed as mean daily intake.  
Results - Patients 
Demographic data are presented in table 3.1. The identity of the patient is referred to 
in subsequent tables. 
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Identity  AGE 
(yrs) 
Weight 
(kg) 
Height 
z-score 
BMI 
z - score 
Gender  GSD 
Type  
A 3 16.3  0.1  -1.6  F  1a 
B 4 20  2.1  0.79  F  1a 
C  5  21.3 0.44 1.23 M  1a 
D  5  31.3 0.35 >  3.0  M  1a 
E 7 37  -0.60  >  3.0  M 1a 
G  24 58 -0.12  -0.05  M  1a 
I  25 87 1.88  0.92  M  1a 
H  25  63.2 -1.28  0.57 F  1a 
V  25  76.4 0.88 0.68 F  1a 
K  38 55 -3.00  -1.00  M  1a 
W 41 72 0.05  0.44  F  1a 
X 42  74.2  -  0.27  -0.43  M 1a 
M  13  60.9 -1.29  1.64 M  1b 
O  14 56 -1.77  0.34  F  1b 
P  15  52.2 -0.56  0.20 F  1b 
Y  17  86.3 -2.85  2.69 M  1b 
Z  19  61.7 -1.12  0.60 F  1b 
Z1 25 49.1  -3.0  -1.48  M  1b 
Q  27  50.4  -2.55 -1.59 M  1b 
R  35  55.3  -2.85 -1.04 M  1b 
T  3  18  0.03 0.15 F  3 
 
The following tables indicate both absolute amounts quantified per day from diet 
diaries as well as relative contributions. Data are also presented relative to dietary 
reference values from data prepared by the Committee on Medical Aspects of Food 
Policy (within the UK), as well as relative to UK national diet and nutrition 
Surveys.
66;67 None of the patients participated in occupations or recreational activities 
that classified them as being physically active. Hence, no correction for increased 
  65energy expenditure was necessary. Data from the national diet and Nutrition surveys 
are age and sex matched – data taken from these surveys and used in comparisons 
in the following tables are presented in appendix 1. The data presented in the 
following tables therefore reflects what nutritional deficiencies are possible in these 
patients and the extent to which the diet differs from the rest of the population. 
 
Results of Dietary Analyses 
Table 3.2 Energy Intake estimated from diet diaries compared to estimated 
average requirements and stratified into contributions of macronutrients. 
Percentage contribution 
to total energy by: 
  
  
  
  
ID 
  
  
  
Age 
  
  
Total 
Energy 
Intake 
  
Estimated
Average 
Require- 
ment 
Percent
Intake 
relative 
 to EAR 
CHO  Protein  Fat 
A  3 1597  1165 137 74  6 19.9 
B  4  1398  1165  120  74.6  8.5  16.9 
C  5 1695  1715  99 73.9  7.4  18.8 
D  5  2574  1715  150  64.3  10.8  24.6 
E  7 2075  1715 121  70.4  8.7  20.9 
G  24  3032  2914  104  59.5  9.5  31 
I  25  3000  3020  99  75.7 14.1 10.2 
H  25  1570  2079  76  59.2  8.2  32.5 
V  25 2946 2294  128 69.2  17.8 13 
K  38  2415  2599  93  77.4  7.6  15 
W  41  1861  2079  90  68.7 12.6 18.7 
X  42  2551  2914  88  66.1  12.9  21 
M  13  2940  2220  132 68.2 12.8 18.9 
O  14  2186  1845  118  64.7  9.8  25.5 
P  15 2944 2110  140 66.8  12. 2 21.2 
Y  17  3502  2755  127  58.8  11.4  29.7 
Z  19 2147 2217  97  70  8.7 21.4 
Z1  25  2942  2561  115  71.1  18.1  11.3 
Q  27 3044 2561  119  59 14.2  26.8 
R  35  1870  2599  72  55.9  14.9  29.2 
T  3 1075  1165  92 76.6  8.6  14.8 
Mean  110.3 67.8 11.1  21.0    
   St Dev  21.5 6.5 3.4  6.4 
 
Table 3.2 Indicates increased energy intake compared to estimated average 
requirements, with carbohydrates providing most of total energy intake. 
  66 Figure 3.1 – Relative contribution to total energy intake of macronutrients 
assessed by this study of GSD patients and the wider population. 
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Table 3.3 Carbohydrate intake relative to national diet and nutrition survey and 
estimated average requirements 
ID  Age  CHO 
Intake (g) 
Mean survey
Intake (g) 
Percent 
Relative 
To survey 
CHO 
EAR 
 (g) 
Percent 
Relative 
To EAR 
A  3  298  191  156  187  159 
B  4  275  191  144 187 147 
C  5  321  209  154  276  116 
D  5  425  209  203 276 154 
E  7  388  248  156  276  141 
G  24  481  273  176 446 108 
I  25  598  273  219  464  129 
H  25 250  196  128  312  80 
V  25  537  196  274  350  153 
K  38  500  279  179 391 128 
W  41  340  206  165  312  109 
X  42  450  279  161 446 101 
M  13  529  271  195  340  156 
O  14  377  228  165 276 137 
P  15  524  214  245  317  165 
Y  17  545  301  181 419 130 
Z  19  393  206  191  336  117 
Z1  25  542  277  196 385 141 
Q  27  478  277  173  385  124 
R  35 278  279  100  391  71 
T  3  214  191  112  187  114 
Mean  174.9     127.6 
  Std Dev  40.6     25.2 
 
Table 3.3 Indicates dramatically increased carbohydrate intake compared to the 
general population and estimated average requirements. 
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Table 3.4 Protein intake relative to national diet and nutrition survey and 
estimated average requirements. 
 
ID  Age  Protein 
Intake  
(G) 
Mean 
Survey 
Intake 
Percent 
Relative 
To Survey 
Protein
RNI 
(g) 
Percent 
Relative 
To RNI 
A  3  22.7  44.5  51  14.5  157 
B  4 28.9  49  59  14.5  199 
C  5  30.7  49  63  19.7  156 
D  5 68.1  49  139 19.7  346 
E  7  44.2  54.8  81  19.7  224 
G  24 71.9  77.8  92  55.5  130 
I  25  104  77.8  134  55.5  187 
H  25 32.6  58.7  56  45  72 
V  25  129.3  58.7  220  45  287 
K  38 46.1  90.1  51  55.5 83 
W  41  58.2  65.1  89  45  129 
X  42 82.6  90.1  92  55.5  149 
M  13  93.4  64  146  42.1  222 
O  14 53.7  52.9  102  41.2  130 
P  15  89.7  54.8  164  45.4  198 
Y  17 99.4  76.5  130  55.5  179 
Z  19  45.6  59.9  76  45  101 
Z1  25 130  90.6  143  55.5  234 
Q  27  108  90.6  119  55.5  195 
R  35 69.3  90.1  77  55.5  125 
T  3  22.4  44.5  50  14.5  154 
Mean  101.6     174.1 
  Std Dev 44.9     65.8 
 
 
Table 3.4 Indicates that patients broadly take similar quantities of protein to the 
general population, which is much greater than estimated average requirements. 
However there are 2 individuals (H and K) that fail to meet these requirements (see 
discussion). 
 
 
 
 
 
 
 
  68 
 
 
 
 
 
Table 3.5 Fat intake relative to national diet and nutrition survey and estimated 
average requirements.  
 
 
ID  Age   Fat 
Intake 
(g) 
Mean  
Survey 
Intake 
Percent 
Relative 
To Survey 
 Fat 
RNI 
(g) 
Percent  
Relative 
To RNI 
A  3  33.3  56  60  45.3  74 
B  4 25.3 56  45 45.3  56 
C  5  34.9  60  58  66.7  52 
D  5 68.7 60  114 66.7  103 
E  7  47.2  70  68  66.7  71 
G  24 104  86  121  113 92 
I  25  33.7  86  39  117.4 29 
H  25 57.3  60  96  80.8 71 
V  25  42.1  60  70  89.2  47 
K  38 40.2  87  46  101 40 
W  41  38.5  61  63  80.8  48 
X  42 59.5  88  67  113 53 
M  13  61.2  77  79  86.3  71 
O  14 62  67  92 71.8  86 
P  15  68.8  51  136  82.1  84 
Y  17 114.8  89  129  101.1 114 
Z  19  50  64  78  86.2  58 
Z1  25 36.2  87  42  99.6 36 
Q  27  90.6  87  104  101  90 
R  35 60.6  88  69  101 60 
T  3  17.3  56  31  45.3  38 
Mean  76.5     65.4 
  Std Dev  30.6     23.2 
 
 
Table 3.5 Indicates that patients take much less fat than the general population. They 
also take much less fat than the estimated average requirement. At low levels of fat 
intake (such as patient I,) the quality and type of fat taken, may be important (see 
discussion).  
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I 
D 
AGE  BMI  Type  % Rx CHO 
Energy 
Relative to 
Total Energy 
%CHO energy 
relative to  
Total  
Energy 
Rx glucose 
Delivery 
mg/kg/min 
CHO 
glucose 
delivery  
mg/kg/min 
Target 
Glucose 
delivery 
% glucose 
delivery  
relative to 
target 
A  3  13.5  1a  45  74  7.8  12.7  7- 9  141 
B  4 16.5 1a  43 74  5.4  8.5  7-  9  94 
C  5  17  1a  45  74  6.2  10.6  7- 9  118 
D  5 25.9 1a  38 64  5.6  8.6  7-  9  96 
E  7  30.6  1a  55  70  5.4  7.3  7- 9  81 
G  24 21.8  1a  31 59  2.8  5.9  3  197 
I  25  28.4  1a  37  76  2.2  4.6  3  153 
H  25 26  1a  19 59  0.8  3.6  3  120 
V  25  26.7  1a  49  69  3.4  5.0  3  167 
K  38 22.3  1a  54 77  4.3  6.1  3  203 
W  41  26.8  1a  40  68  1.9  3.1  3  103 
X  42 24.2  1a  35 66  2.2  4.2  3  140 
M  13  27.1  1b  46  68  4.0  6.0  3  200 
O  14 21.2  1b  23 65  1.7  5.0  3  167 
P  15  24.9  1b  35  67  3.4  6.4  3  213 
Y  17 34.6  1b  34 59  2.4  4.4  3  147 
Z  19  25  1b  36  70  2.1  4.1  3  137 
Z1 25 19.9  1b  24 71  1.9  6.3  3  210 
Q  26  19.7  1b  35  59  3.8  6.6  3  220 
R  35 22.2  1b  9 56  1.7  3.0  3  100 
T  3  14.9  3  61  77  6.1  7.0  7 - 9  78 
    37.8  67.7  3.6  6.1    146.9 
   
Mean 
Std Dev  12.5  6.5  1.9  2.4    46.6 
Table 3.6  Absolute carbohydrate intake of patients with GSD indicating proportions from treatment (Rx) relative 
to total energy intake and compared to target delivery with reference to Schwenk & Hammond
1 Final column 
assumes highest glucose delivery rate ie 9mg/kg/min for children aged 7 years and below. 
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Table 3.6 shows the proportion of total energy derived from treatment carbohydrates (uncooked cornstarch and glucose polymer) as well as that from 
the diet. The absolute carbohydrate intakes are expressed as glucose delivery rates. In most cases, delivery exceeds target. Table 3.7 Mineral intake and RNI by dietary assessment 
 (* patient taking complete micronutrient supplement – supplement composition not included in analysis) 
Blue indicates intake above dietary reference ranges and red indicates intake below the range. 
  Calcium
 
RNI  Magnesium  RNI Phosphorus RNI Iron RNI Copper  RNI Zinc RNI Manganese Selenium RNI 
A*  243  350  88  85  420  270 3.6  6.9  0.41  0.4  2.2  5  0.74  9  15 
B*  340  350  148  85  531  270 7.6  6.9 0.66 0.4  3.9   2.15  15.9  15 
C*  558  450  141  120 640  350 6.9  6.1  0.66  0.6  4.4  6.5  2.58  15.8  20 
D*  335 450  163  120 845  350 7.1  6.1 1.21 0.6 9.1 6.5  1.92  60.9  20 
E*  548  450  114  120 729  350 6.3  6.1  1.31  0.6  6  6.5  0.79  31.7  20 
G  1783 700  300 300 1772 550 8.9  8.7  0.85 1.2  8.6 9.5  2.22  24.7 75 
I*  1054  700  359  300 1545  550 18  8.7  1.66  1.2  12  9.5  3.04  109.6  75 
H  589 700 216 270 728 550 9.4 15  1.39 1.2  4.8 7   2.11  25 60 
V*  1658  700  302  270 2004  550 7.5  15  0.67  1.2  12  7  1.17  72.4  60 
K  618 700  183 300 810 550 15  8.7  1.2  1.2  6.2 9.5  1.73  19 75 
W  672  700  267  270 1074  550 23  15  1.58  1.2  15  7  5.83  113  60 
X  665  700  306  300 1330  550 13  8.7 1.25 1.2  10  9.5  2.92  54.5  75 
M*  976  1000 312  280 1614  775 14  11  1.24  0.8  14  9  3.92  51  45 
O*  556 800  219 280 906 625 11  15  1.11  0.8  5.5 9   2.31  33.2  45 
P  1479  800  333  300 1600  625 16  15  1.89  1  10  7  2.63  84.3  60 
Y*  704 1000 304  300 1474  775 13  11 1.35  1 10  9.5  3.5  62.8  70 
Z  353  700  164  270 727  550 4.9  15  1.09  1.2  4.9  7  1.59  49.4  60 
Z1  1232 700  370  300 1666  550 14  8.7 2.53 1.2  14  9.5  2.65  119  75 
Q  446  700  251  300 1673  550 22  8.7  1.74  1.2  13  9.5  2.56  44  75 
R  434 700  153 300 779  550 7.7  8.7 0.62 1.2  5.2  9.5  1.43  33.2 75 
T*  308  350  60  85  322  270 4.6  6.9  0.5  0.4  3.5  5  0.61  8.7  15 
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(* patient taking complete micronutrient supplement – not included in analysis) (Underlined values below reference range) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Thiamin 
 
RNI  Ribo-
flavin 
RNI  Niacin  RNI  B12  RNI  Folate  RNI  Panto-
thenate
Vit C  RNI 
A*  0.5 0.5  0.5 0.6 6.9 7.7 1.7 0.5  73 70 1.6 58 30
B*  1.4 0.5  0.4 0.6 5.04 7.7 0.3 0.5 117 70 1.1 18 30
C*  0.7 0.7  0.7 0.8 5.33 11 1 0.8  76 100 1.6 21 30
D*  1.2 0.7 1.1 0.8 18.25 11 2.6 0.8  227 100 2.5 35 30
E*  0.7 0.7  0.7 0.8 10.1 11 3.5 0.8  81 100 2.1 23 30
G  1.4 1.2 3.4 1.3 9.16 19 11 1.5 202 200 7.5 63 40
I*  2.4 1.2  2.2 1.3 37.7 20 6.2 1.5  529 200 5.8 500 40
H  1.1 0.8  0.8 1.1 10 14 0.7 1.5  194 200 3 197 40
V*  2 0.9  3.2 1.1 31.9 15 12 1.5  226 200 11 37 40
K  1.1 1  1 1.3 15.77 17 1.8 1.5 1243 200 7.6 109 40
W  5 0.8  5.7 1.1 52.3 14 21 1.5  556 200 12 157 40
X  1.9 1.2 1.4 1.3 19.4 19 4.2 1.5  319 200 5.3 130 40
M*  1.5 0.9  z2.3 1.2 25.3 15 5.9 1.2  212 200 5.5 84 35
O*  1.2 0.7  0.7 1.1 15.9 12 1.4 1.2  170 200 3.1 137 35
P  1.4 0.8  2.4 1.1 21 14 5.8 1.5  261 200 5.1 101 40
Y*  1.6 1.1  1.1 1.3 26.54 18 4.2 1.5 256 200 6.2 133 40
Z  0.9 0.8  0.5 1.1 11.9 14 2.4 1.5  180 200 2.7 271 40
Z1  4 1.3 4.2 1.3 85.2 17 7.3 1.5  630 200 11 40  
Q  1 1  1.3 1.3 21.5 17 9.7 1.5  154 200 3.5 48 40
R  1.2 1  1 1.3 15.87 17 2.3 1.5  166 200 3.7 77 40
T*  0.4 0.5  0.5 0.6 2.84 7.7 0.6 0.5  67 70 0.8 34 30
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(Underlined values below reference range) 
ID  Folate  B12  B1  Ferritin  Copper  Zinc  Selenium  Vitamin D  Phosphate  Calcium  Alk phos 
A*  6.6  679  129    22.2  12.1  1.04  50  1.33  2.31   
B* 20.6  731  253  19 20  13.8  0.84  46 1.46  2.34  
C*  24  871  210  24  21.4  16.2  0.92  47  1.27  2.41   
D* 15.4  962  171  44 20  15.1  0.94  51  1.43  2.44   
E*  7.2  451  256  22  17.7  11.9  0.96  64  1.61  2.22   
G 226  180  184  40  20.8  14.6  0.88  28 1.38  2.55  231 
H  5.8  163  112  48  17.7  13.9  1.16  20    2.18  85 
V* 937  387  149  103  15.9  17.4  1.28  67  1.14  2.39  72 
K  368  163  153  36  11.3  14.7  0.9  74    2.37   
M*     221    21.3 13.7  1.0  61  0.77  2.34   
O*  7.2  >1200  328  21  13.6  14  0.77  41  1.57  2.36   
P 3.9  793  145  41  16.4  12.9  0.9  40 1.23  2.27  
Y*  147  1345  110  38  25  15.7  0.71  28  1.51  2.45  104 
Z 280  911                   
Q  6.7  500  63    24.4  15.5  0.84  23  0.9  2.41  175 
R 388  240  52  67 24.4  10.4  1.04 32  1.36 2.32  395 
T*  10  786  272  22  23.5  10.7  1.15  40  1.69  2.4   
Normal 
Range 
3.0 – 
20.0 
ug/L 
170 – 
900 
ng/L 
66 – 200 
nmol/L 
7 – 150 
ug/L 
11– 22 
umol/L 
11 –24 
umol/L 
0.9– 1.7 
umol/L 
15 – 100 
nmol/L 
0.81- 1.80 
mmol/L 
2.22 – 2.51 
mmol//L 
30 - 126    
U/L 
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The diet diaries form a record of dietary intake of this group of patients from the age of 
3 to 38. This is a very broad age range but several patterns of intake of nutrients are 
observed. This discussion first looks at the macronutrient intake concentrating on total 
energy and carbohydrate. The derivation of carbohydrate target intake is then 
discussed. Following this the intake of fat is examined, followed by micronutrient intake 
and then the social impact of the diet. Finally, methods used are appraised. 
 
Total Energy and carbohydrate 
The mean energy intake of this population from table 3.2 is 110 % of EAR. The age 
matched control means from national surveys vary between 77% and 93% of EAR 
(appendix 1,) with girls aged 15 to 18 taking the lowest amount of total energy relative 
to EAR. The fact that GSD patients take more energy than estimated requirements, as 
opposed to the general population that takes less, means that energy intake for this 
group differs from their peers. The mean proportion of macronutrients contributing to 
total energy intake are shown graphically on figure 3.1. Whilst mean carbohydrate 
intake of 67.8% of total energy is slightly above the target of 65% for patients with 
GSD, the quality of diets that have carbohydrate intake between 70 and 78% of total 
energy could well be poor; it is unlikely that the remainder of the diet could be 
sufficiently broad in range to be nutritionally complete. It is also of concern that some 
individuals with GSD have energy intake of the order of 150 % of EAR. The mean 
contribution (+/- SD) of the macronutrients, carbohydrates, protein and fat are 67.8% 
(+/- 6.5), 11.2 % (+/- 3.6) and 21.0 (+/- 6.4%) respectively. The percentage contribution 
to dietary energy are misleading if the absolute intake is either very high or very low. 
For instance, subject H has an energy contribution from protein of 8.2%, which is not 
out of keeping with the rest of the GSD population (mean 11.1% +/- 3.6), but has 
reduced energy intake. The absolute protein intake of H is 56 % of what the average 
from age and sex matched controls take and 72% of the estimated average 
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as well as estimated from food diary,) in keeping with a low protein diet of this scale. 
Typical of the general population, most other subjects have protein intakes greater 
than the EAR.   
The target contribution to energy requirements by carbohydrates is 65%. Some 
subjects clearly take more than this. In some instances this proportion of carbohydrate 
is within a diet that itself has far greater energy content than average. For instance 
subject V has an energy intake of 128% greater than EAR, of which 69.2% is from 
carbohydrates. This proportion results in a carbohydrate intake of 274% compared to 
controls and 153% compared to EAR. 
 
The significant amount of carbohydrate taken and the requirement to ensure adequate 
protein intake inevitably results in decreased intake of dietary fat in most cases. As 
long as essential fatty acid intakes are adequate, a low fat diet itself does not result in 
harm and may provide some health benefits. 
The data presented clearly demonstrate the differences in the GSD population from 
age and sex matched controls. The hepatic glycogen storage diseases are life-
threatening diseases associated with mortality and serious morbidity if the acute and 
repetitive tendency towards hypoglycaemia is not addressed. It is not surprising, 
therefore that patients, and clinicians alike, take extra care to prevent these episodes 
and in some instances this could result in carbohydrate intake greater than necessary. 
However, these data also suggest that some individuals meet the carbohydrate intake 
requirements at the expense of protein, essential fat, vitamin and mineral intakes, 
which themselves can lead to clinical sequelae. 
 
 
 
 
  75There is evidence from these data of different approaches taken by patients to 
accommodate the dietary regimen of GSD: 
1 To maintain total energy intake similar to the general population and incorporate 
treatment starch and dietary starch within the 65% target, thereby limiting fat or protein 
intake. (eg subjects G and O) 
2 To take a similar diet to peers but with treatment starch as extra leading to greater 
energy intake and risk of obesity. (eg subjects D, Y and V) 
3  To take less energy than is required – some patients lose their appetite with larger 
starch intakes or have concerns about obesity – starch is a much less efficient energy 
source than fat. These subjects are at particular risk of micronutrient deficiencies. (eg 
subjects H and K) 
4 Patients with GSD Ib – several have inflammatory bowel disease and diarrhoea, 
consequently taking greater amounts of food but due to mal-absorption do not gain 
weight. (eg subject Z1 and Q). 
 
 
Endogenous glucose production studies 
The premise of 65% carbohydrate intake as a requirement is based on rates of 
endogenous glucose production studies in both control “normal” individuals and 
patients with glycogen storage disease specifically. The studies in GSD have 
predominantly been performed in children and may not be applicable to adult 
treatment. 
In 1977, Bier et al published endogenous glucose production rates in children.
68 These 
were calculated from studies on 54 children in the form of an isotope dilution study. 
This physiological assessment has been used since the 1950’s and there have been 
refinements to protocols since the early studies. 
98 The method involved the infusion of 
dideuteroglucose followed by subsequent quantification of the proportion of labelled 
and unlabelled glucose. By making serial measurements of this proportion after 
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calculated.  Bier calculated that endogenous production was 7.1 mg/kg/min for children 
under the age of six, 5.4 mg/kg/min for older children and 2.3 mg/kg/min for adults. An 
absolute requirement of this study methodology is to ensure that research subjects are 
in a steady state of equilibrium between infusion and production – a subsequent report 
suggested that unless the priming infusion was for 5 hours, steady state was not 
attained and errors were likely with over-estimation of endogenous production.
99 In this 
study, endogenous production in adults was 2.16 mg/kg/min with a 2.5 hour priming 
infusion and 1.76 mg/kg/min using a 5 hour priming infusion in the same adults, which 
replicated magnetic resonance imaging studies of glycogen turnover in fasted 
subjects
100 - the Bier Study priming infusion was between 3 and 4 hours. 
In the hepatic glycogen storage diseases, the primary aim is to prevent episodes of 
hypoglycaemia and to minimise the secondary biochemical disturbances of lactate, 
triglycerides and uric acid. It has been postulated that suppressing endogenous 
glucose production by providing sufficient exogenous glucose can also prevent these 
biochemical disturbances.
2 Hypoglycaemia provides the stimulus for both endogenous 
glucose production and secondary metabolic disturbance, whilst elevated blood 
glucose concentrations can potentially suppress both processes. The study of 6 
children aged 1 to 7 years, by Schwenk and Hammond demonstrated that an infusion 
rate of nasogastric glucose of 8.6 mg/kg/minute reduced blood lactate levels but that 
endogenous glucose production was completely suppressed at a higher infusion rate 
of 10.5 mg/kg/minute. As described earlier, this methodology may be prone to the 
same over-estimation of endogenous glucose production that applied to the study of 
Bier et al that used short priming infusions.  
There are several reports and some data in these studies, presented later, showing 
that fasting intervals in patients with glycogen storage disease increase as patients 
grow older.
48;103;104 This should mean that treatment carbohydrate can be taken less 
often. Collins et al studied endogenous glucose production rates in adults and children 
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5 that were studied, endogenous glucose production rates were about 50% of that 
predicted from the normal population (normal population defined as those from the 
study by Bier et al.)
68 Of the 6 patients who were aged 15 and older, 2 similarly had 
production rates at about 50% of that expected from the normal population. The 
remaining 4 adults not only had endogenous production between 60 and 100% of 
predicted levels but also showed up to 100% variation between identically managed 
studies. This suggests that adults with GSD can have more between individual 
variation and intra-subject variation in endogenous glucose production rates than 
children. 
 
It has traditionally been assumed that knowledge of endogenous glucose production 
rates is important to derive theoretical glucose requirements of individuals with GSD.  It 
has been these studies that have been used to derive the target figure of 60 – 70% of 
total food energy from carbohydrates.
101 Fernandes and Pikaar suggested a broader 
intake of carbohydrate between 50 – 70% before either nasogastric feeds or 
cornstarch became established therapies.
102 Clearly if endogenous glucose production 
is normal, as has been demonstrated in some adults, then the total daily carbohydrate 
intake need be no higher than normal. Children and adults differ in terms of the insulin 
response to a glucose load but, in addition, adults are usually less sensitive to insulin 
than children. On the bases of endogenous production and insulin resistance, the 
tendency towards hypoglycaemia is decreased in adults, yet most still have intake from 
carbohydrates greater than 65%. A target of glucose delivery may seem appropriate in 
childhood, when data from endogenous glucose production studies and insulin 
sensitivity appear consistent, but in adults with GSD, these factors vary more and 
indeed have not been studied to the same extent. The level of variability between 
patients means that management should be individualised rather than generalised 
from published data. It is of more practical relevance to gauge how much carbohydrate 
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estimate glucose production. To some extent this does happen, but over and above a 
physician’s desired target for the patient, is the patient’s expectation of their disease 
and this can guide their treatment too. From the long-term studies discussed in chapter 
6, we describe significant reduction in overall glucose delivery in some adults, without 
deterioration of metabolic control; part of this can be attributed to features of the new 
starch but part of this is undoubtedly patients’ willingness to accept changes to 
preconceived ideas on treatment with a new therapy. 
It may be for some patients with GSD that treatment has become a way of life, that has 
preserved their life, and it has become difficult for them to alter their routine. 
 
Intake of Fat 
The intake of protein by the general population is substantially greater than the 
estimated average requirement. For most individuals with glycogen storage disease, 
therefore some reduction in protein intake will not cause substantial problems. 
However, the most efficient method of accommodating extra carbohydrate is by 
reducing fat intake. Each gram of triacylglycerol releases more than twice the energy 
than a gram of carbohydrate upon complete oxidation.
105 Consequently every gram 
reduction of fat intake permits more than 2g intake of carbohydrate with the same total 
energy intake. It is for this reason that dietary recommendations suggest restriction of 
fat in preference to protein. The dietary reference values of fat by the COMA report in 
the UK are predominantly derived from population data and social eating habits in the 
UK rather than actual deficiencies of fat.
1 The only known absolute requirements for 
fats are those for the essential fatty acids, linoleic and α-linolenic acid, which 
collectively are recommended to contribute a minimum of 1.2% to total energy intake.  
It is also acknowledged that if this requirement is not met the main functional 
derivatives of these two fatty acids, 20:4 cis n-6 Eicosatetraenoic (arachidonic) acid 
and 22:6 cis n-3 Docosahexaenoic acid (DHA) respectively, become essential. DHA is 
  79an important component of neural and retinal tissue and dietary sources include fish 
products. It is often regarded as a desirable, if not essential nutrient within the diet. The 
n-3 and n-6 long chain fatty acid biosynthetic pathways use the same enzymes for 
elongation and desaturation within the endoplasmic reticulum as well as partial 
oxidation within peroxisomes.  Because of this, the 2 pathways compete with each 
other for substrate and the ratio of intake of the two polyunsaturated fats is 
important.
106 (figure 3.2) The ratio of intake of α-linolenic acid to linoleic acid that is 
recommended,  is 1 to 5.  
 
 
Figure 3.2 – Metabolism of linoleic, C18:2 ω6 (left)  and α-linolenic acid, C18:3 ω 
3 (right).
126 
 
The diet diaries demonstrated low intakes of all fats especially of mono-and poly-
unsaturated fats. The software used was not able to generate reliable outcome data for 
the poly-unsaturated fat species. The database used and its references have not been 
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sufficient data to allow determination of each essential fatty acid. Calculations of 
essential fat from these references were made but the author was confident that they 
were unreliable for the reasons mentioned and the data has not been included in this 
thesis. Therefore, no definitive comment can be made from these assessments. 
Neither were the essential fatty acids measured, so no deficiencies were noted.  The 
low fat intake does provide a risk of deficiency of essential fatty acids but this has not 
been quantified. In children and pregnant women, such deficiencies may lead to sub-
optimal maturation of growing neonatal and infantile brains. The further potential health 
benefits of these fatty acids for adults may also  be compromised.
127;128 
 
From published literature, there is no uniform consensus about the level of intake of 
essential fatty acids that are necessary. COMA report 41 gave a very low estimate of 
requirements compared to other studies. There have also been several studies 
published subsequent to the COMA report from 1991, that have recommended much 
higher dietary intakes. The COMA report stated that its recommendations were based 
on requirements sufficient to prevent diseases of EFA deficiency. However, there is a 
difference between what is essential to prevent disease and what is desirable to 
enhance health. There have been several studies looking at the beneficial effects of 
mono and poly-unsaturated fats on heart disease, intellectual ability and neoplastic 
diseases but deficiency states of these fats are rarely reported.
1;107-110 As far as heart 
disease and neoplastic diseases are concerned, evidence based on epidemiological 
studies and some animal models that has so far failed to prove conclusive benefit in 
humans. Intellectual ability of children at the age of 4 was improved in one double-blind 
study of mothers taking supplements of α-linolenic acid during pregnancy.
110 Essential 
fatty acids have received considerable public attention as desirable food supplements. 
It is still difficult to define how much of each is required for optimal health. The COMA 
DRV for the essential fatty acids linoleic acid (18:2 cis n-6 Octadecadienoic acid) and 
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and 0.2% to total energy intake respectively. Dietary intake of fat in patients with GSD 
is meant to be lower than the general population so it is more likely that patients will 
not meet these requirements. Part of the problem, is that these patients have a 
deliberate skewed increase in energy intake of carbohydrate so proportionate 
contribution to total energy intake may not be entirely representative. However, despite 
this, the absolute intake is still lower than other populations quoted in national dietary 
surveys and other published literature. In summary, essential fatty acid intake is 
projected to be low from diet diaries. 
 
Plasma triglyceride concentrations and to a lesser extent cholesterol are well known to 
be elevated in GSD I. These can also be mildly elevated in GSD III, VI and IX.
41;102 
Hyperlipidaemia in the general population is associated with the formation of atheroma, 
ischaemic heart and cerebrovascular disease. Over the last 40 years, several 
investigators have considered whether hyperlipidaemia may specifically cause clinical 
problems in GSD and whether lipid lowering treatment is indicated. The vascular 
complications of hyperlipidaemia do not appear prevalent in patients with GSD 
although there are relatively few patients who are over the age of 50 years, the age  
when these hyperlipidaemic diseases become more common. Hyperlipidaemia is, 
however, associated with other complications in GSD such as pancreatitis. There have 
been several studies trying to characterise and intervene with the hyperlipidaemia. 
Levy et al described essential fatty acid deficiency in patients with GSD I and  went on 
to supplement patients with fish oil and demonstrate reduction of the total plasma 
tryglycerides as well as plasma total cholesterol and LDL, with a concomitant increase 
in HDL.
72 If atherogenesis is a serious risk, this form of therapy would be of benefit. 
Another recent Japanese study used MCT milk as a treatment and this led to a 
reduction of total plasma triglycerides in 3 patients.
111 They postulated that the shorter 
chain fatty acids are metabolised to acetyl co-A in contrast to long-chain fatty acids 
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A generated inhibits glycolysis as well as enhancing ketone body production. These 
data are in stark contrast to Fernandes and Pikaar’s published nearly 40 years 
earlier
102. This detailed study demonstrated that MCT resulted in elevation of 
triglycerides – they postulated that acetyl CoA was used to synthesize palmitate as 
opposed to ketone bodies and glucose. It is likely that the patients studied have 
different types of disease – the Japanese group indicate that the common GSD Ia 
mutation in Japan, G747T causes a milder phenotype than classically observed 
elsewhere.  
Hyperlipidaemia in the hepatic glycogenoses is likely to be due to increased de novo 
synthesis of lipid due to increased substrate. There is some evidence of decreased 
turnover.
129 Biochemical elevations may respond in selected populations to therapy 
with MCT or essential fatty acid supplements. However, it remains to be seen whether 
such interventions have any relevant long-term clinical benefit. There does not appear 
to be any increase in morbidity or mortality in this group related to cardiovascular 
events; indeed vascular endothelial studies show that these patients should be 
relatively protected against such episodes.
130-132There are, however, insufficient 
longitudinal outcome data to dismiss the potential risk of long-term hyperlipidaemia in 
this group of patients and further studies and clinical follow up are required.  
 
Micronutrient intake 
The intake of carbohydrate is substantial in patients with GSD. There is consequently 
potential for micronutrient deficiencies if there is insufficient attention to the 
completeness of the diet. Surprisingly there are few reports of micronutrient 
deficiencies in the literature. Kishnani et al report the case of one individual with long-
term incomplete adherence to nutritional therapy
73. At the age of 16 ½, he presented 
with weight loss, depression, vomiting and malaise. He had no evidence of 
inflammatory bowel disease. At presentation he was pancytopenic with a haemoglobin 
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folate, iron and vitamin B12. Symptoms and biochemistry resolved after therapy. This 
case highlighted how individuals can focus on carbohydrate therapy to the exclusion of 
the remainder of the diet and makes the case for micronutrient supplementation. 
 
Most of the patients from the cohort studied in this thesis that take overnight pump 
feeds take a multivitamin preparation as part of their overnight recipe. This includes 7 
of 8 children and 2 of 3 adults on pump feeds. Conversely most adults that take 
uncooked cornstarch as part of their normal dietary regimen at night-time do not take a 
complete nutritional supplement. Dietary insufficiency from diet diary was noted in 4 of 
the 21 subjects for calcium and 8 for magnesium. Of the four patients with projected 
calcium deficiency, 3 were on a multivitamin preparation that corrected the deficiency 
but only 3 of the 8 with projected magnesium deficiency had this corrected with a 
multivitamin. Biochemical measurements of magnesium were only performed in 
children and in all cases were normal. Similarly the plasma calcium was normal in all 
17 patients that had this measured as part of this study. However, plasma calcium 
concentrations do not accurately reflect total body calcium deficiency. In order to 
assess calcium balance effectively, factors such as bone mineral deposition, enzymes 
of calcium turnover (eg alkaline phosphatase), humoral regulation (eg parathyroid 
hormone) and renal function need to be considered.
133 In glycogen storage disease all 
these factors may be affected, resulting in a greater effect on calcium balance than diet 
alone.
78;80 
Several subjects had other projected mineral deficiencies. Because most of the 
children were on dietary supplements, there were no instances of deficiencies being 
measured biochemically. However, for adults plasma zinc concentrations were just   
below the reference range in 2 individuals and selenium was low in 5 individuals.  In all 
these cases of selenium deficiency, the diet assessment indicated that intake was well 
below the RNI. A further 7 patients had projected intake less than RNI for selenium. 
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2 subjects had serum vitamin B12 concentrations below the reference range, with only 
one of these being estimated to be below the RNI from the dietary diary. This subject 
(H) is a vegetarian and is known to have had vitamin B12 deficiency in the past. 
Functional assessments of B12 deficiency namely measurements of methylmalonic 
acid and total homocystine were not made. Several subjects were assessed not to 
achieve RNI for niacin, riboflavin and folate. Of these, only folate was measured (some 
from serum and some from red blood cells,) but deficiency was not noted. 
  
Social impact of the diet 
The case histories show that a number of adults continue to have an intensive, 
repetitive pattern of eating, with a limited range of foods taken. It is striking that several 
have the same meal several times a day; the 3-day diet diaries show that this pattern 
can continue for several days. Several also use high glucose drinks as an alternative to 
treatment carbohydrate. This may appear to some as a more socially acceptable 
alternative to mixing and drinking cornstarch. However, high glycaemic index drinks 
are a less desirable method of treatment as they promote greater insulin release than 
lower glycaemic index alternatives; in the long-term insulin resistance would also be 
more likely if this strategy of treatment is applied.  
 
From a broader social perspective, it is notable that a significant proportion of adults 
with GSD continue to live with their parents. This pattern is present in the wider group 
with only 5 of the 12 adults aged 17-42 living independently and only 2 of the 12 being 
with long-term partners. Parents have an immense burden of social and medical care 
placed on them, when they learn how to look after a child with GSD. Similar to several 
other chronic illnesses, parents have to adjust their lives to accommodate the illness. 
This modification to life plans can persist for many years, even when the children have 
become adults. Unlike several other diseases, the management of these children does 
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consequences if this is relaxed inappropriately. It can therefore,  be difficult for parents 
to step back from this intense level of care and likewise it can be difficult for the 
children to adjust to become independent, both in their own medical management and 
forming relationships with others. The psychosocial needs of children and parents 
living with chronic diseases have been addressed for several diseases such as cystic 
fibrosis and diabetes mellitus.
134-136 This has only recently been systematically studied 
in GSD.
137 The study from Storch et al surveyed a cohort of patients managed in 
Florida. This study showed that parents perceived great difficulties for their children 
over a range of activities, whereas the children themselves felt more similar to their 
peers. The authors comment that this is probably because the children try to adapt to 
or deny the differences that are present, such that they feel they are similar to peers. 
 
The potential of patients with the hepatic glycogen storage diseases to have diets 
similar to their peers seems very limited. The dietary treatment is intensive, especially 
in childhood, but the disrupted pattern of eating is maintained in adult life. Quite apart 
from what is medically justified, patients have patterns of eating that can lead to 
problems. The difference from peers can lead to both physical and psychological 
disturbance. Our data does not reveal the torment that some individuals report in a 
clinical setting about obesity, low self esteem related to large body shape or slight 
frames in GSD Ib. 
 
Appraisal of Methods 
This study attempts to assess the quantity and quality of foods taken by patients with 
glycogen storage disease. If the survey were published in peer review literature, it 
would be the largest detailed survey of dietary records to have taken place. 21 patients 
were analysed of which 17 had biochemical investigations relating to nutrition. The 
survey relies on diet diary records. These can often be difficult for patients to complete 
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Our research team anticipated problems and direct face-to-face teaching about 
completion of such records were performed directly to individual participants by either 
a nutrition nurse or state registered dietician. The same person received the form from 
the research subject and entered data onto the database. If there were issues that 
needed clarification, the researcher contacted the person completing the form directly 
and on occasions visited the home to clarify recipes and measures used. Within the 
resources available, this was the best possible ascertainment of dietary intake 
possible. However, it may still not have been accurate enough. This method cannot 
legislate for items such as snacks and drinks that may have been forgotten on the 
dietary record. These are quite often forgotten even upon direct questioning.
122;138;139 
 
The dietary records were then summarised into total quantities of each food taken and 
entered onto a software programme. The programme then provided an output of food 
group constituents from the dietary record, which was then entered onto database 
software (Microsoft Excel, Illinois, USA) and group descriptive data were generated. At 
several points in this process there is potential for manual error and mis-entering of 
data. Each output and input was checked several times by different personnel but 
errors were still possible. The diet analysis software programme is referenced to 
standard texts including “McCance and Widdowson's The Composition of Foods.” 
However the output is generated without detailed knowledge of the internal workings of 
the software programme. Recipes of cooked foods in particular could be 
misrepresented – details of exact ingredients and methods of processing food can be 
assessed incorrectly by the programme. Sample outputs were re-assessed manually to 
see if they appeared plausible. Some differences were noted, notably a discrepancy 
between “McCance and Widdowson's The Composition of Foods” and the 
manufacturer’s data of an individual cereal the reference book claimed to cite. Also 
significant discrepancies were noted in the calculation of essential fatty acid 
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been used in this thesis. It was not the object of this thesis to validate the software 
being used – it is currently extensively used in clinical practice. Errors were, however,  
detected in some results obtained from the programme and these need further 
investigation. 
 
Data from research participants were compared with both nationally recommended 
dietary reference values and data from National Diet and Nutrition Surveys. Dietary 
reference values are recommendations made by government appointed expert panels. 
The expert panel have reviewed literature in order to derive recommendations. This 
does not, however mean that there is validated evidence for their use. Firstly, the 
principal aim of the reference values is to address insufficiency and intake may be 
adjusted disproportionately high in order to guarantee that insufficiency does not occur. 
The report on health and social subjects 41 in which DRVs are defined states the 
following: “Current surveys in the UK indicate energy by the population below the 
prevailing RDA (recommended daily amount.)… As in most developed countries, 
problems relating to insufficient energy intakes are uncommon in the UK. In contrast, 
however, many of the diseases which are characteristic of developed countries are 
related to overweight and obesity in the population which result from a chronic excess 
of dietary energy intake over expenditure.” Therefore, the recommendations are set 
higher than survey values of energy intake, yet it is known that the general population 
is becoming more obese.  
 
For this reason, a comparison was also made with dietary surveys. These surveys 
provide a comprehensive summary of UK diets with approximately 2000 individuals 
studied for each survey. They are regionally representative and great care has been 
taken to maintain the quality of the data. Our sample of patients is presumed to be 
representative of this wider population. However, the genetic basis of glycogen storage 
  88disease means that certain populations are at greater risk of developing disease than 
others. In particular the research participants in this study had 4 patients with GSD Ia 
from a Gujarati Indian background, each of whom were homozygous for the C150-
151delGT frame-shift mutation.
140 Similarly, there were 4 Pakistani patients  with GSD 
Ib who were homozygous for a splice site mutation at the exon 8 and intron 8 junction 
and 2 Jamaican siblings who unusually have had only one mutation identified (R415X), 
despite complete sequencing of the gene as part of a research study.
141 
125 The 
recruitment of 4 Gujarati and 4 Pakistani from a total of 21 subjects in particular skews 
the research population from the “normal population.” Culturally, Gujarati Indians are 
vegetarian and all 4 subjects recruited have a vegetarian diet. Culturally, Pakistani 
individuals eat only halal meat, so their choices for meat products can be altered if 
halal preparations are unavailable. From the Gujarati and Pakistani patients studied, 
there may be an over-representation of a vegetarian Asian diet compared to the 
reference population. The reference data has been stratified for age and sex and 
further regional and social stratification could have been used; however, the greatest 
influence on intake in our recruits is ethnicity, and associated cultural eating patterns, 
rather than social or regional background.  
2 subjects aged 3 yrs and 5 months and 3yrs and 11 months had their data compared 
to the reference data of subjects aged 4 to 6 years old in the the national dietary 
surveys. They could have been compared to age matched populations from the survey 
carried out on subjects aged 1 ½ to 4. However this survey, conducted in 1992, was 
one of the earlier surveys by this group. The presentations of results are less detailed 
in this survey compared to later ones and it is probable that available foods may have 
changed in the intervening years between this national survey and our study. The later 
studies in older children conducted in 1997 and in adults in 2001 have been used for 
our comparisons.  
Further comparisons of patients were made compared to biochemical reference 
values. In general the reference ranges are derived from a standard population and 
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could represent deficiency. However, in this study, no functional assessments of 
deficiency were made, either in terms of corroborative biochemistry such as 
methylmalonic acid and homocysteine in B12 deficiency or in terms of clinical 
assessments such as an echocardiogram for selenium deficiency or bone mineral 
density for calcium deficiency. For some minerals or vitamins such as vitamin B12, the 
diet diary and serum measurement is a useful tool in screening for functional 
deficiency. However for others such as calcium, the functional test of bone mineral 
density is more representative of total body calcium homeostasis.  
 
Chapter 3.4 - Conclusion 
There are undoubtedly regional, social and cultural differences in dietary intake. The 
cross-sectional survey performed in this thesis cannot legislate for these differences. 
However, the nature of the intensive dietary treatment of glycogen storage disease 
does mean that there are patterns of nutrient intake and eating behaviour that 
differentiate this group of individuals from the general population, irrespective of their 
background. This difference may not necessarily cause physical harm, but certain 
characteristics could pre-dispose to disease states or result in social differences 
leading to physical or mental health problems. 
The dietary analyses have found that patients with GSD have substantial intake of 
carbohydrate. For some adults in particular, it seems difficult to justify the amount and 
quality of carbohydrate being taken. The large amounts of this macronutrient in the diet 
does compromise intake of essential fats, minerals and vitamins in some individuals. In 
most cases micronutrients and essential fatty acid supplements are required. In others, 
excess overall nutritional intake may also lead to obesity. Further study and 
modification of these patients’ diets are indicated in order to optimise their health and 
long-term outcome. 
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waxy maize starch on patients with hepatic glycogenosis. 
Introduction 
Uncooked cornstarch forms the basis of treatment for many patients with the hepatic 
glycogen storage diseases. As discussed in chapter 1.3, there are many problems with 
its use and some adults remain on treatment with nocturnal overnight pump feeds of 
glucose polymer and some still need to administer corn-starch at 4 hourly intervals. 
The quest for an efficacious starch has pre-occupied many research groups, including 
our own, for over 30 years. After a series of studies, the metabolic profile of a heat 
modified waxy maize starch appeared favourable. This chapter describes accumulated 
experience of the use of this starch in GSD from a pilot study (chapter 4.1) in one 
individual to a larger study involving children and adults (chapter 4.2) and a further 
study in adults only (chapter 4.3). This chapter will focus on the effect the starch has 
on short-term biochemical markers: glucose, lactate and insulin with chapters 5 and 6 
concentrating on different aspects of these trials. The hypothesis for each study is the 
same, but the investigations are different. 
 
Hypothesis Heat modified waxy maize starch (WMHM20) has a longer duration of 
normoglycaemia compared to equivalent amounts of uncooked cornstarch in patients 
with hepatic glycogen storage disease. 
 
4.1 Pilot Study 
Aim To compare duration of normoglycaemia using equivalent amounts of WMHM20 
and uncooked cornstarch in 1 patient with glycogen storage disease type 1. 
Method  
A 22 year old female subject with glycogen storage disease type Ia (further details on 
this subject – subject V in chapter 2.2) attended the ward on 2 separate occasions, 2 
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the starch being administered. The subject’s normal treatment comprised of 40g 
uncooked cornstarch taken four times a day with an overnight pump feed of 25% 
glucose polymer infused at 40mls/hr  between midnight and 07:30. At 07:30 the subject 
had a bolus of 20g of glucose polymer drink. The night before each occasion the 
subject had a starch-load, she stayed locally to the hospital. The following morning, the 
20g bolus of glucose was given was given and the subject attended the ward to take 
the 60g of the nominated starch, mixed in cold water, within 60 minutes. Prior to 
ingestion of the starch, clinical observations and enquiry were made to ensure that the 
patient was well, an intravenous cannula was placed and baseline glucose and lactate 
were taken. Blood was collected into sodium fluoride bottles. The samples were 
deproteinised with potassium perchlorate within 30 minutes of collection and 
separated. Plasma glucose and lactate were measured by glucose oxidase and lactate 
dehydrogenase methods respectively as described in chapter 2. Glucose was also 
measured at the bedside using 1 drop of whole blood on a point-of-care glucometer 
(Advantage II, Roche diagnostics, Mannheim Germany) to guide time of test 
termination. The test was terminated when the blood glucose was less than 2.6 
mmol/L. After the test, 200mls of 25% glucose polymer was administered followed by 
40g of uncooked cornstarch, The plasma glucose and lactate measured in the 
laboratory are presented in the results. 
 
The results from the paired starch loads in the pilot subject are shown below in table 
and figure 4.1.  
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  Glucocse (mmols /L)  Lactate (mmols/L) 
Time  (  Hrs)  UCCS 
 
WMHM20   
 
UCCS WMHM20 
0 5.3  5.7  2.66  2.20 
1 6.5  7.2 
 
3.16  3.43 
2 6.0  5.7 
 
2.53  2.43 
3 6.1  5.4  2.50  2.10 
4 4.5  4.8 
 
2.54  2.63 
5 2.9  3.9 
 
3.94  3.63 
6 1.7  3.2  6.28  6.34 
7  2.4   7.63 
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Table and figure 4.1 – glucose and lactate profile after 60g of starch ingested in 
pilot subject. 
 
The patient starts with equivalent glucose and lactate concentrations, has a higher 
peak glucose with WMHM20 at 1 hour which decreases below the UCCS plasma 
glucose at 2 hours. From this point the glucose decreases at a rate of 0.66 mmols/hr 
for the WMHM20 curve whereas the UCCS curve decreases at a rate of 1.1 
mmols/L/hr. For the last 3 hours of the UCCS test, the rate of decline is 1.5 mmols/L / 
hour wheras the WMHM20 decline remains steady between 0.6 – 0.8 mmols/l/hr. At 4 
hours the glucose concentrations are comparable but thereafter, the glucose 
concentration is higher for WMHM20 compared to UCCS. The lactate curves are 
  93closely matched, but because the WMHM20 test lasted longer, the lactate at the end of 
the test is higher. 
The pilot study in one individual appeared to show that WMHM20 resulted in a longer 
duration of normoglycaemia with a slower rate of decline of glucose compared to 
UCCS; on this basis further studies were performed. 
 
4.2 – Short –term biochemical outcome comparing 2g/kg (maximum 120g) of 
WMHM20 with UCCS. 
Introduction Having shown that WMHM20 appeared favourable in one patient, this 
protocol was designed to assess the effect in a wide range of patients with GSD. The 
largest recommended dose of UCCS was used in this study to try and maximise any 
potential differences, with an equivalent amount of WMHM20 being used as 
comparison. 
Aim  To evaluate duration of normoglycaemia using an equivalent large amount of 
WMHM20 compared to uncooked cornstarch in patients with glycogen storage disease 
type I and III. 
Method  This study formed part of a broader study – data from breath samples 
collected are presented in chapter 5. The study protocol was approved by the Joint 
Ethics Committee of The National Hospital for Neurology & Neurosurgery and Institute 
of Neurology, London U.K., and the Institute of Child Health / Great Ormond Street 
Hospital Ethics committee, London, U.K. GSD I and III patients were recruited from 
adult and paediatric tertiary referral metabolic units in London.  Written informed 
consent was taken from all adults above 16 years and a legal guardian of children 
under 16 years. The diagnosis of GSD I and III was based on a liver biopsy showing 
reduced activity of the appropriate enzyme, a mutation in the appropriate gene or white 
blood cell glycogen debrancher enzyme activity indicative of GSD III. All had evidence 
from their medical history of fasting hypoglycaemia and were taking UCCS.  
 
  94The study had a randomised double-blind cross over design. Patients anonymised by 
reference number were randomly allocated to receive either UCCS or WMHM20. Each 
starch was manufactured using food-grade techniques and packaged in identical 
containers bearing a reference number. The patient reference numbers and container 
reference numbers were paired by Glycologic Ltd, (Glasgow, Scotland) and the 
supervising physician was blinded to this pairing. Research participants were asked to 
re-attend for the second starch load, using the alternative starch 3 days to 28 days 
afterwards. The supervising physician devised a safe pre-test personalised fasting period 
for each patient based on previous cornstarch loads and medical history. Instructions 
were given to the research subject, or their carer, for the participant to have the same 
diet the day before, and fast interval immediately before, each starch load. 
Starch Load Test Initially, an intravenous cannula was placed in the patient’s arm and 
baseline blood and breath samples were collected. Then, 2g of the nominated starch per 
kg body weight (maximum 120g) was mixed in cold water and ingested. Breath and 
blood samples were performed hourly after the starch administration. No further intake, 
apart from drinking water, was allowed. The starch load test ended when the patient had 
fasted for 10 hours, the blood glucose was ≤3.0 mmol/L on the bedside glucose monitor 
or the patient wished to end the test. When the blood glucose was ≤4.0 mmol/L in 
children aged 3 to 16 years, blood tests were performed at 30 minutes intervals, until the 
test end.  
Biochemical data The blood samples were analysed: bedside whole blood glucose 
(Advantage II, Roche diagnostics, Mannheim Germany), laboratory plasma glucose and 
lactate (Vitros Fusion 5.1, Ortho-Clinical Diagnostic, High Wycombe, UK) and serum 
insulin was performed by a solid-phase, two-site chemiluminescent immunometric assay 
(Immulite 2000, Diagnostic Products Corporation, Los Angeles, USA). The laboratory 
glucose and lactate sample were collected into lithium fluoride, transported on ice and 
separated within 30 minutes of sampling. The insulin samples were collected as a clotted 
sample and also separated within 30 minutes. The bedside glucose monitor was used as 
  95a screening tool to identify hypoglycaemia (blood glucose of ≤3.0 mmol/L) and 
consequently determine when to end the test. Statistical analyses were performed on 
laboratory plasma glucose data and not the bedside test results. Further details about 
glucose and lactate measurements used are presented in chapter 2.2 
 
 
Results - Patients Patient demographics are shown in Table 4.2 
 
Biochemical Outcomes If the patient ended the test with a laboratory glucose ≤3.0 
mmol/L, the duration of normoglycemia is indicated by the last glucose > 3.0 mmol/L – 
usually 1 hour (occasionally 30 minutes) previous to the low value. Median test 
duration for WMHM20 was 9 hours (IQ range 6.0 – 10.0) and for UCCS was 7 hours 
(IQ range 5.0 – 9.0)(p = 0.0935.) . Comparative test duration is indicated in table 4.3 
and illustrated as a Kaplan – Meier survival plot on figure 4.1. The patients ended the 
tests for various reasons: for WMHM20, 6 had genuine hypoglycaemia, 2 patients 
ended their trial because the bedside glucose monitor under-read the laboratory 
glucose, 6 for personal reasons unrelated to hypoglycaemia and 7 lasted the full test 
duration of 10 hours. For UCCS, 9 patients ended the test with genuine 
hypoglycaemia, 4 because the bedside glucose monitor under-read the laboratory 
glucose, 3 for personal reasons unrelated to hypoglycaemia and 5 patients lasted for 
the full test duration of 10 hours. Patients as a whole had a longer period of 
euglycemia using WMHM20, but 8/21 from the WMHM20 group and 7/21 from the 
UCCS group terminated the study prematurely. With time-to-event analyses, censoring 
data that did not finish with a genuine hypoglycaemia, there was no statistical 
difference between the 2 treatments (figure 4.2). 
 
 
  96Age 
(Yrs) 
ID SEX 
(M/F)
GSD 
Type
Normal Carbohydrate use  Medications     Complications 
3  A  F  IA  D - 30g UCCS TDS    N - 100g polymer  Allopurinol  Nephrocalcinosis 
4  B  F  IA  D –25g UCCS QDS    N – 90g polymer  Multivitamins   
5   C  M  IA  D - 35g UCCS TDS    N 105g polymer  Multivitamins   
5  D  M  IA  D – 40g UCCS TDS    N – 105g polymer  Allopurinol; Multivitamins   
7  E  M  IA  D – 50g UCCS TDS    N – 150g polymer  Allopurinol; Multivitamins   
12  F  M  IA  D – 60g UCCS TDS    N – 125g polymer  none   
21  G  M  IA  D – UCCS 60g BD      N – 125g polymer  Allopurinol,Ramipril, 
Clonazepam, Carbamazepine
Intellectual 
impairment,
22   H  F  IA  D – 30g UCCS BD      N – 55g UCCS  Allopurinol, Ramipril. Vit B12  PCOD 
Renal impairment 
22  I  M  IA  D – UCCS – 65g B      N – 160g polymer  Allopurinol,  Salazopyrin  Inflammatory bowel 
disease
23  J  F  IA  D – UCCS 40g QDS    N – UCCS 80g  Allopurinol, Multivitamins  Short stature 
Chronic fatigue 
33  K  M  IA  D –UCCS 50g QDS     N – UCCS 50g X2  Allopurinol. simvastatin, codeine, 
lansoprazole
Hepatic adenoma 
Chronic scar pain 
34  L  M  IA  D –                               N – UCCS 60g  None   
47  M  M  IA  D –                               N – UCCS 60g  Allopurinol Enalapril, Ezetimibe 
Atorvastatin, Aspirin, Amlodipine
Hepatic adenoma 
Renal impairment 
13  N  M  IB  D – 80g UCCS BD       N – 175g polymer  Allopurinol 50mg   
14  O  F  IB  D – 60g UCCS TDS     N – 60g UCCS X2  Allopurinol 150 mg Septrin, GCSF 
Thalidomide
Crohns Disease 
Bronchiectasis
15  P  F  IB  D – 25g UCCS BD       N – 45 g UCCS X2  Allopurinol   GCSF   
24  Q  M  IB  D – 40g UCCS QDS    N – 40g UCCS BD  Allopurinol    GCSF  Short stature 
35  R  M  IB  D-                                 N- 30g  Allopurinol, Ferrous sulphate  Hepatic adenoma 
Chronic anaemia 
38  S  F  IB  D – 20g UCCS BD       N – 40g  Ferrous sulphate  Chronic anaemia 
3  T  F  IIIa  D – 30g UCCS TDS    N – 75g polymer Multivitamins  Protein supplement  Myopathy 
12  U  M  IIIa  D – 45g UCCS BD    N – 70g polymer & milk  Multivitamins   
  97  Table 4.2 – Patients recruited to study – For further diagnostic details, please refer to chapter 2.2 using ID from this table  
D = day; N=Night Table 4.3 – Pre-test management, trial duration and conditions for trial 
termination for both WMHM20  and Cornstarch 
ID  Pre-load 
fast (hrs) 
Nocturnal 
regimen 
WMHM20 
(hrs) 
T*  UCCS 
(hrs) 
T* 
A  <0.5  CNPF  3  h  3  h 
B <0.5  CNPF  4  h  4  h 
C  <0.5  CNPF  3  h  4  h 
D <0.5  CNPF  7  u  4  u 
E  <0.5  CNPF  9  p  6  u 
F 1  CNPF  9  p  7  p
*
G  2  CNPF  10  m  10  m 
H 4  UCCS  10  m  9  h 
I  1  CNPF  6  h  5  u 
J 2  UCCS  6  h  8  h 
K  2  UCCS  10  m  6  h 
L  10 UCCS  10 m  10  m 
M  12  UCCS  7  p  10  m 
N 1  CNPF  9  p  9  p
 
O  5.5  UCCS  10  m  8  h 
P 3  UCCS  9  p  10  m 
Q  4  UCCS  10  m  7  u 
R 2  UCCS  8  h
  10 m 
S  12  UCCS  10  m  5  h
 
T <0.5  CNPF  5.5  u  2  h 
U  0.5  CNPF  7  p  8  p 
   Median 9   7   
T* Conditions for test end:  
h = hypoglycaemia (glucose < 3.0 mmolL
-1,) confirmed on laboratory glucose. 
u = under-reading: bedside glucose (< 3.0 mmolL
-1), resulting in test end; lab glucose > 
3.0 mmolL
-1. 
p = personal reasons unrelated to hypoglycaemia at test end. 
m= maximum test duration = 10 hours. 
CNPF – Continuous nocturnal pump feed. UCCS – Uncooked cornstarch 
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Figure 4.2  Kaplan-Meier survival plot of test duration – time to event analysis 
censoring patients that failed to finish with glucose <3.0: p = 0.30 
Figure 4.3 shows the mean glucose profile. There was no statistical difference between 
the 2 profiles but the baseline glucose concentrations are not comparable.  
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Figure 4.3  Mean Glucose profile (+/- 95% confidence interval for 21 patients) 
 
There was no significant difference in the mean area under the curve for the glucose 
(p=0.47) profiles. However, the area under the curve does not necessarily represent 
the primary outcome of duration of normoglycemia as discussed later. Consequently 
the gradients for each glucose and lactate profile from baseline to peak values and 
  99from peak to trough were taken as described in methods. There was no statistical 
difference for the gradient of increase in glucose but WMHM20 had a slower glucose 
decline than cornstarch (p=0.05,) in the whole cohort. There were no statistical 
differences in the lactate profile but the mean lactate decreased faster in all GSD I 
patients (p=0.17) for WMHM20 compared to UCCS. The mean gradients for each 
sector are demonstrated in Figure 4.4 to illustrate how the difference applies to the 
glucose and lactate profiles.  
 
WMHM20 
UCCS 
Figure 4.4 – Extrapolated profile based on mean gradients of rise and fall of 
glucose (4.4a) and lactate (4.4b). 
 
  100Lactate  Similar to the glucose profiles, there were no significant differences in the 
lactate profiles. The same parameters of assessing gradients from baseline to trough 
and from trough to peak lactate were performed for patients with GSD I as indicated in 
figure 4.4b. GSD III is not associated with hyperlactataemia and these patients lactate 
profiles are consequently not included.  
 
 
Insulin  The mean insulin profile is shown on figure 4.5.  Comparison of paired mean 
values throughout  the profile by t-test shows that the WMHM20 curve is lower than the 
UCCS curve (p = 0.0007). However, similar to the glucose profile, the baselines are 
different.  
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Figure 4.5 – Mean Insulin profile (+/- 95% confidence interval) for 21 patients that 
took equivalent amounts of UCCS compared to WMHM20. p < 0.0007 for mean 
profile. 
The area under the insulin curves were compared for each individual by non-
parametric analyses. The areas were not normally distributed with the range of areas 
between 2 IU/L hrs and 295 IU/L hrs. The median areas and inter-quartile ranges were 
40.4 IU/L hrs (12.1 - 79.7) for WMHM20 and 54.1 IU/L hrs (18.1 – 86.1) for UCCS. 
Comparison by Wilcoxon paired rank test showed that there was a trend towards the 
  101WMHM20 areas being less (p=0.073.) This changed slightly when 5 subjects with non 
comparable baseline insulin concentrations were excluded (p=0.088.) 
      
Conclusion 
This study demonstrated that WMHM20 could be better than UCCS.. There was a 
trend for median duration of normoglycaemia to be longer although this finding was not 
statistically significant. The rate of decline of glucose extrapolated from gradients of 
decline from individual profiles was less (p=0.05.) The mean insulin profile was lower 
(p < 0.001) although baseline values differed and there was a trend towards a lower 
area under the insulin curve. On the basis of these findings, which were all compatible 
with one another, it was concluded that further studies were indicated and that the 
product should be developed. 
 
Chapter 4.3 – The short-term effect of 50g of Vitastarch
tm on the metabolic profile 
of patients with Glycogen storage disease type I. 
 
Introduction Having demonstrated that large doses of WMHM20 appeared to show a 
benefit greater than UCCS, the WMHM20 product was developed by a nutrition company 
(Vitaflo Ltd, Liverpool, UK.) The addition of a small amount of emulsifying fats made the 
starch more miscible in water and potentially more palatable as a consequence. 
This study protocol formed part of a larger study examining the long-term use of 
Vitastarch in patients with GSD. The effect starch treatment has on breath tests is 
discussed in chapter 5 and on long-term management goals in chapter 6. The lower 
dose of 50g was used in this study of adults as this is a common amount used in 
everyday management. This means that this dose could be used in a long-term clinical 
study and should translate readily into clinical practice if proven to be efficacious.  
Aim  To evaluate duration of normoglycaemia when 50g Vitastarch compared to 50g 
uncooked cornstarch is ingested in adults with GSD I. 
  102Method The study protocol was approved by the Joint Ethics Committee of The National 
Hospital for Neurology & Neurosurgery and Institute of Neurology, London U.K. The 
study had a randomised double-blind cross over design. Patients anonymised by 
reference number were randomly allocated to receive either UCCS or Vitastarch. Each 
starch was manufactured using food-grade techniques and packaged in identical sachets 
bearing a reference number. The patient reference numbers and sachet reference 
numbers were paired by Vitaflo Ltd and the supervising physician was blinded to this 
pairing. The supervising physician devised a safe personalised fasting period for each 
patient based on previous cornstarch loads and medical history. 
 
Starch Load Test Initially, an intravenous cannula was placed in the patient’s arm and 
baseline blood and breath samples were collected. When the participant’s blood glucose 
was under 4.5 mmol/L, they mixed 50g of the nominated starch in cold water and drank 
the fluid. Breath and blood samples were performed at 30 minute intervals for the next 2 
hours and hourly thereafter. No further intake, apart from drinking water, was allowed. 
The starch load test ended when the patient had fasted for 10 hours, the plasma glucose 
was ≤3.0 mmol/L on the bedside glucose analyser (YSI 2300) or the patient wished to 
end the test. When the blood glucose was ≤ 3.5 mmol/L, blood tests were performed at 
30 minutes intervals, until the test end.  
Biochemical data Plasma was extracted from whole blood samples immediately at the 
bedside. Plasma glucose and lactate were analysed immediately (YSI 2300 - Yellow 
Springs, Ohio, USA). Serum insulin was frozen within 30 minutes of collection and 
subsequently thawed and analysed by a solid-phase, two-site chemiluminescent 
immunometric assay (Immulite 2000, Diagnostic Products Corporation, Los Angeles, 
USA).   
Repeat Starch Load  Data from the first starch load was used to guide management 
using the particular starch for the subsequent 16 weeks. After a further washout period of 
  1032 – 4 weeks on normal treatment, participants re-attended for a further starch load with 
the alternative starch. 
Results -  Patients 
10 patients aged 16 – 38 were recruited to the study. A total of 4 patients withdrew 
from the trial protocol. One patient completed 14 weeks of trial protocol on Vitastarch 
but failed to attend the end of phase outpatient assessment or any other clinical follow 
up. This participant felt the trial protocol was too onerous. Two participants completed 
the first phase – one having taken Vitastarch and the other UCCS, but did not attend 
for the second phase because they too felt the protocol was too onerous. The fourth 
patient completed the first phase on uncooked cornstarch but withdrew early in the 
second phase taking Vitastarch as they found the taste unacceptable. Six patients 
completed the entire study and seven patients had paired biochemical data for starch 
loads on UCCS and Vitastarch.  
Starch Loads  
The duration of these starch loads are indicated on table 4.4 and figure 4.6 
 
 
 
 
 
 
 
 
 
 
Table 4.4 – test duration for patients taking 50g of Vitastarch compared to UCCS. 
Age 
(Yrs) 
Sex 
(M/F) 
GSD 
Type 
UCCS 
(Hrs) 
Vitastarch 
(Hrs) 
23  M  GSD IA  7  7.5 
24  F  GSD IA  4.5  6 
25  F  GSD IA  6  6.5 
38  M  GSD IA  5  10 
16  M  GSD IB  7  7.5 
18  F  GSD IB  5  7.5 
24  M  GSD IB  4  5.5 
  104The median duration of action of UCCS was 5 hrs (range 4- 7) and Vitastarch 7.5 hrs 
(5.5 – 10.) On a Kaplan-Meier style survival curve, time-to-event analysis was performed 
using the log-rank test. The one patient that failed to become hypoglycaemic after fasting 
10 hours was right-censored at 10 hours. Using this analysis, median test duration was 
significantly greater for Vitastarch compared to UCCS (p = 0.023.) 
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Figure 4.6 - Kaplan-Meier survival plot of 7 patients completing paired starch 
loads. P = 0.023  by time-to-event analysis. 
 
The mean glucose profiles for the 7 paired starch loads are shown on figure 4.7. The 
baseline glucose concentrations are very similar for UCCS 3.82 and one SD (+/- 1.07) 
versus 3.81 (+/- 0.89) for Vitastarch. The graph indicates that for the first four hours of 
the starch load the plasma glucose is always higher with UCCS. At four hours the mean 
glucose is the same value – 3.98 mmol/L and subsequently the mean glucose for UCCS 
is always lower than Vitastarch. The higher peak glucose is reflected with 6 from 7 
patients having higher peak glucose with UCCS compared to Vitastarch (p = 0.043 using 
Wilcoxon signed rank test.)  
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Figure 4.7 - Mean glucose profile (+ / - 95% confidence interval) for 7 patients 
starch loads 
 
Similar to the previous study (Bhattacharya et al, 2007)
142, the glucose rises more slowly 
to it’s peak with Vitastarch compared to UCCS with a mean rise of 0.63 mmol/hr 
compared to 1.61 mmol/L, although this finding is not statistically significant. The 
gradient of decline is also less, decreasing at a mean of 0.357 mmol/hr with Vitastarch 
compared to 0.632 mmol/hr with UCCS (p = 0.028 using non parametric analysis).  
 
In all cases, peak glucose concentrations occur in the first four hours of the starch load 
with the mean and median profile for UCCS being greater than Vitastarch. After four 
hours the profiles are reversed with Vitastarch being higher than UCCS. Simple analyses 
of areas under the curve and median curves for the entire profile are consequently 
unrepresentative of the data.  This coupled with the fact that some subjects withdraw 
from the study after 4 hours due to hypoglycaemia, mean that there is incomplete data 
after 4 hours for comparisons. For this reason, a series of analyses have been 
performed examining the profiles in the first 4 hours, when there is complete data from 7 
pairs of starch loads (figure 4.8). Firstly the median glucose profile of UCCS was 
significantly greater for the first four hours (p<0.02.) There was a trend towards the 
  106Vitastarch area under the glucose curve (above the cut-off of 3.0 mmol/L), being less 
than the UCCS area under the curve (p=0.11 – figure 4.9) 
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Figure 4.8 – Median glucose profile for first 4 hours (+/- interquartile range) for 7 
patients that took 50g of UCCS and Vitastarch . p < 0.02 (Wilcoxon signed rank). 
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Figure 4.9 Area under the glucose curve for 7 patients for the first 4 hours of 
each starch load p = 0.11 
Lactate 
The mean lactate profiles were very closely matched throughout the starch loads. 
There was no statistical difference between the mean profiles. Also comparison of 
paired area under curves for the first four hours were similar (p = 0.47; figure 4.10) 
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Figue 4.10 – Mean lactate profile (+/- 95% confidence interval) 
 
Insulin Similarly to the glucose data, there was a rise in the insulin profile in the first 2 
hours after the starch load. The mean and median insulin concentrations are similar at 
baseline and at 7 hours when insulin measurements were discontinued. At all other 
times throughout the profile, both the median and mean insulin profile is greater for 
UCCS than for Vitastarch. Comparison of the mean profile was statistically significant 
by a two tailed paired t-test (p =0.0098.)  Comparison of the paired area under the 
insulin curve for the first 4 hours of the starch loads, for which there is complete data 
also demonstrates that the Vitastarch median area of 8.48 IU/ml hrs is less than the 
UCCS median area of 47.6 IU/ml hrs as indicated in figure 4.12 (p = 0.03). 
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Figure 4.11 – Mean Insulin profile (+/- 95% confidence interval) for 7 patients that 
took 50g of UCCS and Vitastarch.  p = 0.0098 (paired t-test). 
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Figure 4.12 Area under the Insulin curve for 7 patients for the first 4 hours of 
each starch load p = 0.03 (Wilcoxon signed rank test). Column shows median 
and interquartile range. 
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Data from these studies demonstrate that Vitastarch comprising emulsified WMHM20 
has a beneficial effect on the metabolic profile compared to UCCS. At equivalent doses 
there is a longer duration of action, lower glucose peak, slower glucose decline and 
lesser insulin release compared to uncooked cornstarch.  
 
Many of these differences are seen more clearly in the second clinical trial, which 
ironically had fewer subjects participating. The pilot study recruited a compliant subject 
whose management is meticulous such that baseline criteria were reproducible. This 
pilot study demonstrated a longer duration of action that warranted further 
investigation.  
 
Control of Baseline Characteristics - The first study (chapter 4.2) recruited a wide 
range of patients aged between 3 an 47 years of age, with 3 different diseases, namely 
GSD Ia, GSD Ib and GSD III. The age ranges and disease differences alone had an 
effect on the variability of data. However, over and above this, there was evidence of 
variability within individuals; some of which could be accounted for difference in pre-
test preparation for the two tests; other individuals prepared in the same way for the 2 
starch loads but still had widely varied baseline biochemistry. In GSD type I, a patient 
that has fasted would have a low glucose, high lactate and low insulin. The pre starch-
load preparation was individualised, but advised the same evening meal the night 
before each starch load, and a safe fasting period prior to starch administration. This 
was determined by the last cornstarch load and their normal dietary routine. For 
patients that were not on overnight continuous pump feeds of glucose polymer, 
cornstarch was administered between 2 and 12 hours before the starch load. Pre –test 
instruction for these individuals was relatively straightforward as it was usually close to 
normal treatment. Most patients on an overnight continuous feed knew that within 1 
hour of discontinuing the feed, they would become hypoglycaemic. These patients 
  110would often have a “bolus” of glucose polymer just before they stopped the pump. The 
effect of this bolus of glucose polymer would be to cause an initial rise in glucose and 
insulin and suppression of lactate. However, the insulin rise would lead rapidly to 
hypoglycaemia, low insulin and raised lactate. This shift was seen in some of the 
subjects, most notably young children, on pump feeds. For example 1 patient at 
baseline had a plasma glucose of 2.5 mmol/L, lactate of 5.8 mmol/L and insulin of <2 
IU/L prior to one starch load. Prior to the other starch load, baseline biochemistry was 
glucose 5.4 mmol/L, lactate  5.4 mmol/L and insulin 9.9 IU/L, yet there was only 10 
minutes difference in timing of these samples. The rapid changes of glucose in these 
types of circumstances are indicative of greater insulin sensitivity in younger children 
compared to adults. 
Ideally, starch would be administered for a corn-starch load when the glucose 
concentration is normal, lactate is suppressed and when insulin release is minimal. It 
has been reported that cornstarch efficacy is sub-optimal if these conditions are not 
met
7;61;143. In practice, controlling all 3 inter-dependent variables is very difficult. To fulfil 
this ideal, the first requirement would be real-time glucose, insulin and lactate 
measurements. The next requirement would be for the researchers to be able to 
control the subjects’ energy intake in order to achieve the desired baseline 
characteristics. The best way to do this would be by administration of intravenous 
glucose titrated to endogenous requirements as shown in the protocol by Schwenk and 
Hammond. 
1 Such ideal pre-test management has resource implications and still may 
not be perfect. From a resource perspective, patients would need to be admitted the 
night before the starch load in order to adjust doses accordingly –  the cost of overnight 
admission alone was double the entire cost of the first study. The disadvantage of 
controlling study variables to such a degree is that the findings could translate poorly 
into clinical practice; in reality, patients eat a variety of meals, not just corn-starch, and 
have fluctuating biochemistry and activity levels that are ignored in tightly controlled 
studies. 
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The second study (chapter 4.3) benefited from reliable glucose and lactate 
measurement at the bedside; whole blood glucose and lactate were measured within 2 
minutes and plasma glucose and lactate within 10 minutes of sample collection. 
Bearing in mind the example of the child above, even this has a “Heisenburg” type 
uncertainty about it – by the time the glucose and lactate at a given time-point is 
defined, the metabolic circumstances have changed and has to be re-defined. 
Definition of test-end. – The first study, chapter 4.2, used a bed-side glucometer to 
screen for hypoglycaemia and guide test management. These are known to be 
unreliable but are readily available, quick and relatively cheap. Analyses of results of 
glucose and lactate data were performed from plasma samples measured by accurate 
laboratory glucose dehydrogenase and lactate dehydrogenase methods respectively. 
However, complete results of these were often not available until the day after the 
starch load and could not guide management during the studies. Six of the 42 (14%) 
starch loads terminated prematurely because the bed-side glucometer under-read the 
“true” glucose.  A further nine of the 42 (21%) starch loads finished prematurely when 
the patient was not hypoglycaemic. Eight of these were children aged between 7 and 
13 years. In four out of five of these cases, the children had fasted for 9 hours using 
the new starch WMHM20 and one had fasted for 9 hours using UCCS. Patients with 
GSD, particularly children cannot fast for protracted periods – the artificial 
circumstance of a starch load testing maximum possible fast is contrary to their daily 
treatment routine. The perception of hypoglycaemia is a subjective feeling and can 
manifest as tiredness, irritability and sweating in the early stages with perception 
varying between individuals. Many patients avoid this perception by eating regularly; 
some consequently are not used to perceiving either hypoglycaemia or hunger. It is 
possible that some associate hunger with hypoglycaemia and consequently finished 
the test feeling hungry rather than hypoglycaemic. The plasma glucose concentration 
at the end for the six patients finishing prematurely taking WMHM20 ranged between 
  1123.2 – 5.7 mmol/L, and for UCCS between 3.2 - 4.6 mmol/L. It is conceivable that 
subjects perceived hypoglycaemia when the plasma glucose was nearer 3.0 mmol/L 
but it seems unlikely when the blood glucose is greater than 4.0 mmol/L that genuine 
hypoglycaemia was imminent or perceived correctly. However, because the bed-side 
glucometer was the only device available to guide management and is known to be 
inaccurate,
106 for safety reasons, tests ended when the patient perceived 
hypoglycaemia irrespective of the bed-side reading. 
 
Improvements made to Vitastarch study (chapter 4.3) - Several modifications to the 
protocol were made to the second study, in attempts to overcome some of the 
difficulties of the first study. Additional resources were available but there was still not 
enough to arrange overnight admissions for patients. A reliable point-of care glucose 
machine that measured both whole blood glucose and lactate within 2 minutes of 
sample collection and plasma concentrations within 10 minutes was used (YSI 2300.) 
It was possible to be confident about the measurement of glucose and lactate and 
relay this information to the patient. For this reason, most tests ended appropriately. 
Only adults were recruited meaning that the rapid changes in glucose seen in the first 
study were less evident. The second study also used a lower dose (50g versus 120g) 
so fasting times were in general shorter and patients were less likely to end the test 
because they were hungry. An attempt was made to control baseline characteristics 
more effectively by trying to administer the starch when the glucose concentration was 
between 4 and 4.5 mmols/L. After an intravenous cannula was placed, the blood 
glucose was taken and if it was greater than 4.5, no starch was given and the blood 
glucose was repeated 30 minutes later. Starch was administered when the glucose fell 
into the desired range. However of the 14 starch loads assessed, there were still 5 
exceptions to this management (35%). In four cases, the plasma glucose was below 
the level of 4.0 mmol/L at baseline. The researcher has 3 choices in this scenario: a) to 
continue to administer the starch, b) to administer glucose or glucose polymer to 
  113elevate plasma glucose to target baseline or c) terminate the test and repeat on 
another day when the glucose is at baseline. The last option was not considered as 
this was a major inconvenience for the patient and had not been assessed by an ethics 
committee. Elevation of the glucose to the target glucose baseline may have seemed a 
reasonable solution but it does not address the potential problem of lactate and insulin 
variation. It is inevitable that infusion of glucose or glucose polymer to correct 
hypoglycaemia will cause insulin release and this in itself will prejudice starch-load 
duration. Despite the flaws, starch was still administered when the plasma glucose was 
below 4.0 mmol/L. In one case, starch was administered when the baseline glucose 
was 4.85 mmols/L. This subject had a baseline lactate of 7.29 mmol/L, which is likely 
to have risen as the glucose fell. In this case too, starch was administered despite not 
being in the target range. As mentioned earlier, the best way to have controlled 
baseline would have been to titrate plasma glucose with administered glucose for 
several hours prior to starch administration. 
 
Insulin 
The mean insulin profile from the first study (figure 4.5) demonstrated less insulin 
release form patients taking WMHM20 compared to UCCS. However it was difficult to 
be certain of this finding because of the difference at baseline.  
Insulin sensitivity - One very striking feature of the insulin data gathered in this study 
was the huge range of values of area under curve insulin values (above a lower 
measurable limit of 2 IU / L)  ranging from 2 IU/L hrs to 295 IU/L hrs. This range of 
values clearly reflects insulin sensitivity with small amounts of insulin having a great 
effect on plasma glucose in young children, whilst large amounts of insulin have 
relatively little effect in some adults. This range of insulin release demonstrates that it 
is difficult to be confident of differences between the starches over such an age range. 
There is a greater difference in insulin release related to the age of the patient rather 
than the starch. It was considered, whether adjustment of data for each starch to 
  114incorporate individual insulin sensitivity, was a possibility and these enquiries are 
detailed below: 
 
The difficulty in defining insulin sensitivity by simple ratios is indicated in figure 4.13. 
The baseline “fasting” glucose / insulin ratio has been used by some as an index of 
insulin resistance.
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Figure 4.13 – Apparent Insulin sensitivity determined by baseline glucose / 
insulin ratio before each starch load from subjects recruited in study of chapter 
4.2. A) Insulin sensitivity from each starch load with insulin resistance defined 
as <4.5 mg / 10
-4IU indicated by dotted line.
76 B) Baseline glucose /insulin ratios 
correlated with age for each starch load (best fit lines indicated). 
 
The variation in baseline characteristics is exemplified by figure 4.13. An insulin 
sensitive subject releases small amounts of insulin to effect change in glucose 
compared to an insulin resistant subject. Consequently fasting glucose – insulin ratios 
have been used to indicate insulin resistance with lower values indicating greater 
resistance to insulin action.
76;145 These patients with glycogen storage disease have 
fasted for as long as they can prior to a starch load and have had baseline “fasting 
glucose and insulin” concentrations measured. If this was a reliable measure for them, 
all lines on 4.13 A would be horizontal, and all crosses and noughts, for individual 
patients, on 4.13 B would be super-imposed upon another. This is clearly not the case; 
  115indeed the best-fit lines indicate a positive correlation for the baseline values with age 
for the UCCS starch load and a negative correlation for the WMHM20 baselines. 
Patients with GSD have a different physiology to the normal population – for most a 
fasting glucose concentration is well below the lower reference range and a true fasting 
glucose to insulin ratio would not indicate the degree of insulin sensitivity – both are 
likely to be very low. For this study, most patients did not have a true fasting glucose 
because of the clinical risk this kind of assessment would pose. It seems that the 
compromise position of baseline glucose and insulin was not sufficient to help define 
insulin sensitivity either. Some patients did have much greater insulin excursions than 
others, as discussed earlier. An alternative model such as the area under the insulin 
curve from a glucose tolerance test cannot be applied to define sensitivity from these 
data either. This is because the starch given in this test was not glucose and this would 
have a different pattern of response as a consequence. There are models that 
incorporate mixed meals but these also rely on rebound hypoglycaemia and correction 
to steady state as part of their mathematical modelling
146. Correction of rebound 
hypoglycaemia is not a feature of GSD.  Finally, as mentioned in the next section, 
there is not enough resolution of the rise and fall of either glucose or insulin in the first 
3 hours of each study, to be confident of capturing the full humoral response to the 
starch. The best methods of defining insulin sensitivity would be either an oral glucose 
tolerance test or a euglycaemic clamp study. 
Improvements made to Vitastarch study (chapter 4.3) - Most of the studies 
investigating insulin release after carbohydrate ingestion detect the insulin and glucose 
response frequently after ingestion, because there are rapid changes in both. Most 
studies sample at intervals of between 5 and 15 minutes for 120 minutes after 
ingestion and many looking at glycaemic load, rather than index, would follow the 
profile for as much as 6 hours
94;119;147. These studies give a clear idea of the nature of 
the rise and fall of glucose and insulin after carbohydrate ingestion. The first cross-over 
study sampled glucose and insulin at 60 minute intervals. It was possible to define a 
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with confidence. The difference between this study and glycaemic index studies is that 
our primary endpoint was duration of action rather than early responses. However, 
there was some evidence from this study, that the early response to glycaemic load 
had a bearing on duration of starch action. For this reason, study 2 measured glucose 
and insulin at 30 minute intervals for the first 2 hours to provide better resolution of the 
rise and fall of these parameters.  This, coupled with the fact that the patients were a 
more homogenous adult population, led to more consistent results: with increased 
duration of action, slower glucose decline and lesser insulin release being 
demonstrated. . The glucose profile for Vitastarch was significantly lower for the first 
fours than the UCCS glucose response.  
 
Conclusion These studies in chapter 4.2 were performed in 21 heterogenous subjects 
with inconclusive results whereas the study in chapter 4.3 demonstrated more striking 
results in a much small number of more homogenous adults with GSD I. Compared to 
equivalent amounts of UCCS, 50g of Vitastarch had a longer median duration of action 
(6.5 hours versus 5 hours; p= 0.059 – figure 4.6), a slower decrease in the glucose 
(0.357 mmol/hr versus 0.632 mmol/hr  p = 0.028,) a lower glucose curve in the first 4 
hours (figure 4.8, p<0.02) and lower insulin and area under insulin curves (figure 4.11, 
p<0.02 and figure 4.12, p=0.03 respectively.) All these findings are compatible with one 
another and provide compelling evidence that Vitastarch does last longer than UCCS 
for the patients investigated with a lesser insulin profile and glucose excursion. 
 
  117Chapter 5 Gastrointestinal processing   
of Uncooked Cornstarch and Heat Modified Waxy Maize Starch 
– Evidence from Breath Tests 
 
5.1 Introduction 
As discussed in chapter I, there are a number of gastrointestinal processes involved in 
the successful extraction and utilisation of glucose from dietary starch. One method of 
assessing the entire process from ingestion to complete oxidation of dietary starch 
involves the assay of enriched carbon dioxide in the breath after ingestion of tracer 
(chaper 2). In this regard, uncooked cornstarch can act as a naturally enriched 
tracer.
114;148 This form of assessment attempts to quantify the proportion of dietary 
carbohydrate actually utilised. By contrast, the quantification of breath hydrogen 
assesses the amount of carbohydrate that remains undigested, fermented by colonic 
flora and so, not being utilised to synthesize glucose.
17;116;117 The two investigations 
can often be complimentary in assessing starch digestion and utilisation. 
 
This chapter examines the short-term effect on breath enrichment with 
13CO2, after 
ingestion of uncooked cornstarch compared to the new dietary starch WMHM20 in 
children and adults with GSD I and III. Similar to cornstarch, waxy maize starch is also 
derived from North America and has similar enrichment of 
13CO2. The precise amount 
was quantified by complete combustion as discussed in the method below. Breath 
hydrogen was also measured to assess the degree of fermentation of each starch. 
This study was performed at the same time as other biochemical measurements for 
the studies discussed in chapter 4. There are 2 studies described in this chapter: the 
first examines both hydrogen and 
13CO2 excretion in children and adults with GSD I 
and III after ingestion of 2g/kg (max 120g) of each starch. In the second study only 
hydrogen excretion is measured in adults with GSD I after ingestion of 50g of 
  118emulsified WMHM20 (Vitastarch.) Heat modified waxy maize starch has a longer 
duration of action than uncooked cornstarch and it may be anticipated that this would 
be reflected in data from utilisation and fermentation studies. 
 
Hypothesis Because WMHM20 has a longer duration of action, there would be 
evidence of increased utilisation and decreased fermentation when similar quantities of 
UCCS are taken.  
 
5.2 Short-term study of the utilisation and fermentation of 2g/kg (maximum 120g) 
of uncooked cornstarch compared to WMHM20 in children and adults with GSD I 
and III. 
 
Introduction A pilot study (chapter 4.1) demonstrated that WMHM20 had a longer 
duration of action than uncooked cornstarch in 1 individual. A study protocol was 
designed to see if this benefit was observed in a larger sample of patients with GSD. 
Breath tests were collected as part of these studies to assess utilisation and 
fermentation.  
 
Method  The study protocol was approved by the Joint Ethics Committee of The 
National Hospital for Neurology & Neurosurgery and Institute of Neurology, London 
U.K., and the Institute of Child Health / Great Ormond Street Hospital Ethics 
committee, London, U.K. GSD I and III patients were recruited from adult and 
paediatric tertiary referral metabolic units in London.  Written informed consent was 
taken from all adults above 16 years and a legal guardian of children under 16 years. 
The diagnosis of GSD I and III was based on a liver biopsy showing reduced activity of 
the appropriate enzyme, a mutation in the appropriate gene or white blood cell 
glycogen debrancher enzyme activity indicative of GSD III. All had evidence from their 
medical history of fasting hypoglycaemia and were taking UCCS.  
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The study had a randomised double-blind cross over design. Patients anonymised by 
reference number were randomly allocated to receive either UCCS or WMHM20. Each 
starch was manufactured using food-grade techniques and packaged in identical 
containers bearing a reference number. The patient reference numbers and container 
reference numbers were paired by Glycologic Ltd and the supervising physician was 
blinded to this pairing. Research participants were asked to re-attend for the second 
starch load, using the alternative starch 3 days to 28 days afterwards. The supervising 
physician devised a safe personalised fasting period for each patient based on previous 
cornstarch loads and medical history. Instructions were given to the research subject, or 
their carer, for the participant to have the same diet the day before and fast interval 
immediately before each starch load. They were instructed to abstain from taking certain 
foods such as pulses that were likely to ferment for the day prior to the starch load. 
 
Starch Load Test An intravenous cannula was placed in the patient’s arm and baseline 
blood and breath samples were collected. Then, 2g of the nominated starch per kg 
body weight (maximum 120g) was mixed in cold water and ingested. Breath and blood 
samples were performed hourly after the starch administration. No further intake, apart 
from water, was allowed. The starch load test ended when the patient had fasted for 10 
hours, the blood glucose was ≤3.0 mmol/L on the bedside glucose monitor or the 
patient wished to end the test.  
 
Breath data Breath hydrogen was measured immediately at the bedside using an 
appropriately calibrated portable hydrogen measuring device (Micro H2, Micro Medical, 
Rochester, UK) while
 13CO2 breath samples were collected into a gas sampling system 
(Micro Medical, Rochester UK) and gas transferred using a gas-tight syringe to a gas-
tight 10ml vacuum tube (Labco Ltd., High Wycombe, UK). Breath CO2 was analysed 
for 
13CO2/
12CO2 enrichment by gas chromatography on a CP-Poraplot-Q column 
  120(Varian Inc., Oxford, UK) followed by isotope ratio mass spectrometry on a Thermo 
Finnigan Delta-XP (Thermo Finnigan, Bremen, Germany). Sample 
13CO2/
12CO2 
enrichment was standardised against a CO2 cylinder (5.0 grade, BOC Special Gases, 
Guildford, UK,) calibrated against the international standard Pee Dee Belemnite [PDB] 
(Iso-Analytical, Sandbach, Cheshire UK). The WMHM20 and UCCS 
13C/
12C ratios were 
analysed by elemental analyser isotope ratio mass spectrometry (Iso-Analytical, 
Sandbach, UK). The enrichment of UCCS, WMHM20 and Maxijul glucose polymer 
(SHS Ltd, Liverpool, UK)  after complete combustion were δ ‰ = -11.13, -10.75 and – 
11.32 respectively. UCCS and WMHM20 utilisation were calculated from the 
13CO2/
12CO2 ratios as described in chapter 2. 
The same study protocol was performed using the alternative starch between 5 and 28 
days later.  
 
Statistics 
Mean glucose oxidation breath values for each starch load, were compared at 60 
minute intervals using a two-tailed paired t-test. However it was noted, using an 
unpaired two tailed t-test that there was a statistical difference (p=0.0035) in the 
baseline values of 
13CO2 breath enrichment of those participants who had overnight 
Maxijul glucose polymer pump feeds prior to the starch loads, with the mean +/- 1 
standard deviation being (-18.4 +/- 2.70 ‰ vs. PDB) compared to those just taking 
UCCS (-21.6 +/- 2.97.) The 
13C content of Maxijul by complete combustion was 
ascertained due to this difference in baseline and is indicated in chapter 2. Subsequent 
analyses excluded patients taking Maxijul, and were therefore performed on those 
patients that were not managed with continuous nocturnal pump feeds and that were 
fasted for 2 hours or greater, before the starch load as indicated. The results of these 
analyses are shown in Figure 5.1, in which hourly and cumulative starch oxidation is 
indicated.  
  121 The mean hourly hydrogen excretion for each starch was compared using a two tailed 
paired t-test as indicated in figure 5.2. The area under the graph for each profile was 
also calculated; the mean area for each cohort and comparison by paired t-tests is 
indicated in table 5.2. However, the area under the curve may not be entirely 
representative of hydrogen excretion as shorter trials have less area than longer trials 
with similar excretion. Consequently the mean hydrogen excretion per starch load is 
also indicated in table 5.2. 
Results – patients 
Patient characteristics are indicated on table 5.1 
  Test Duration (hours) 
ID  Age 
(Yrs) 
SEX 
(M/F) 
Type  Pre-load 
fast (hrs) 
Nocturnal 
regimen 
WMHM20  UCCS       .     
B  4 F IA  <0.5  CNPF  4  4 
C  5  M  IA  <0.5  CNPF  3  4 
D  5 M IA  <0.5  CNPF  7  4 
E  7  M  IA  <0.5  CNPF  9  6 
G  21 M  IA  2  CNPF  10  10 
H  22  F  IA  4  UCCS  10  9 
I  22 M  IA  1  CNPF  6  5 
J  23  F  IA  2  UCCS  6  8 
K  33 M  IA  2  UCCS  10  6 
L  34  M  IA  10  UCCS  10  10 
M   47 M  IA  12  UCCS  7  10 
O  14  F  IB  5.5  UCCS  10  8 
P  15 F  IB  3  UCCS  9  10 
Q  24  M  IB  4  UCCS  10  7 
R  35 M  IB  2  UCCS  8  10 
S  38  F  IB  12  UCCS  10  5 
U  12 M  III  0.5  CNPF  7  8 
  
Table 5.1 – Characteristics of recruited participants and starch load duration. 
Nocturnal treatment regimen prior to starch load is indicated. (Further details of 
participants by subject ID in chapter 2) 
CNPF – Continuous nocturnal pump feeds  UCCS – Uncooked Cornstarch 
  122All ten adults and 7 of the 11 children were able to perform the breath tests. However, 
as discussed above, there was a statistical difference in baseline oxidation between 
those subjects that had been given glucose polymer prior to the starch load, and those 
that had fasted having taken uncooked cornstarch. Therefore, further analyses were 
confined to patients that had had uncooked cornstarch as part of their dietetic regimen. 
Results 
When compared on an hourly basis, there was no statistically significant increase in 
utilisation of UCCS compared to WMHM20, (figure 5.1A), due to the wide confidence 
intervals. However the hourly mean oxidation of UCCS appeared greater than 
WMHM20 from 3 to 10 hours. 
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Figure 5.1 – A) Mean Starch oxidation (+/- 95% confidence interval) derived 
enrichment of breath 
13CO2 for 10 subjects that were able to perform breath tests 
(and not taking glucose polymer) B) Cumulative oxidation  
 
The cumulative oxidation of uncooked cornstarch was greater than WMHM20 over the 
full time period of 10 hours (p < 0.02 – figure 5.1B) 
 
The mean hydrogen breath data are shown in Figure 5.2 There was a statistically 
significant difference at 6 hours indicating that at this peak point there is greater 
fermentation of uncooked cornstarch. In addition the mean profiles were also different 
when compared by non parametric methods. (p=0.001). 
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Figure 5.2 –Mean Hydrogen excretion (+/-  SD) for 18 patients able to perform 
breath tests 
 
 
 
 
  UCCS  WMHM20 
Age  TYPE   Area  Area/ 
time 
Area  Area/ 
time 
4 1a  540  1.80  600  2.50 
5  1a  1530  4.25  690  2.88 
5 1a  540  2.25  660  1.57 
9  1a  1230  3.42  2460  4.56 
21 1a  5880  9.80  5850  9.75 
21  1a  11610 19.35  4650  7.75 
22  1a  5250 12.50 1830  3.81 
23  1a  9630  17.83  4050  8.44 
34 1a  4140  9.86  11760 19.60 
35  1a  4800  8.00  8130  13.55 
49  1a  6990 11.65 2610  6.21 
14  1b  2430  4.50  1410  2.35 
15 1b  11250 18.75  2550  4.72 
24  1b  6900  19.17  4530  7.55 
33 1b  3990  6.65  9300  15.50 
38  1b  6750  11.25  1740  2.90 
12 3  1470  3.06  3030  7.21 
  Mean  5216 10.06 3926  7.10 
 
Table 5.2 – Area under the hydrogen curve – (ppm minutes) and mean area for 
subjects taking starch loads with UCCS and WMHM20 
 
Table 5.2 shows the calculated area under the hydrogen curve. There were no 
statistical differences between the areas under the hydrogen curve when these were 
compared for the 2 starches by paired t-test (p=0.26.) Because starch load duration 
  124differed between starch loads, this total figure was unrepresentative of the data; 
therefore, the mean hydrogen excretion was calculated from area /time. Comparing the 
2 starches, this mean hydrogen excretion showed more difference (p= 0.14). It may be 
anticipated that hydrogen excretion is greater in GSD Ib than Ia; therefore, mean 
hydrogen excretion was compared by unpaired t-tests between the two populations for 
cornstarch (p = 0.44) and for WMHM20 (p=0.81.) 
 
 
Relationship between Age and Hydrogen Excretion 
For the 6 children in our study that were 14 years and under that were able to perform 
breath tests adequately, the mean hydrogen excretion (+/- 1 SD) for the duration of the 
studies were 3.8 ppm ( +/- 2.6) for WMHM20 and 3.5 ppm (+/- 2.1) for UCCS. For the 
12 patients 15 years and over, these values were 9.8 ppm (+/- 6.1) for WHMH20 and 
13.4 ppm (+/- 6.8) for UCCS. In addition, there was statistical significance (p <0.00001) 
using a two tailed unpaired t-test comparing the mean hourly excretion between the 2 
age ranges for each starch (figure 5.3).  
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Figure 5.3 – The effect of age on hydrogen excretion in the breath  
 
The relationship between the age and mean hydrogen excretion for an individual was 
investigated by curve fitting. There was a positive linear correlation (r=0.498; p= 0.042) 
  125between the mean hydrogen excretion throughout the profile for cornstarch loads and 
the research subjects age. (figure 5.4A), as well as an exponential correlation (r=0.624; 
p= 0.0074). 
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Figure 5.4 – Sample curves fitting describing the effect of age on mean hydrogen 
excretion throughout profile of a cornstarch load (Best fit lines and 95% 
confidence intervals indicated)  – A) Linear association B) non-linear association 
 
 
5.3 Short-term study of the fermentation 50g of uncooked cornstarch compared 
to Vitastarch adults with GSD I. 
 
Introduction Data from the study performed in chapter 5.1 appeared to show greater 
fermentation of uncooked cornstarch compared to WMHM20. Since fermentation of 
starch is correlated with malabsorption, further studies were indicated. However, the 
enrichment of 
13CO2 in the breath was confounded by the 
13C content of the glucose 
polymer, independent of the starch ingested. Therefore, the measurement of hydrogen 
excretion alone was performed in this study. These measurements were made during 
the study described in chapter 4.3 and were part of the longer term study of the 
treatment using Vitastarch described in chapter 6. 
 
  126Aim To assess the degree of malabsorption of uncooked cornstarch compared with 
Vitastarch using the hydrogen breath test. 
 
Method The study protocol was approved by the Joint Ethics Committee of The National 
Hospital for Neurology & Neurosurgery and Institute of Neurology, London U.K. The 
study had a randomised double-blind cross over design. Patients anonymised by 
reference number were randomly allocated to receive either UCCS or Vitastarch. Each 
starch was manufactured using food-grade techniques and packaged in identical sachets 
bearing a reference number. The patient reference numbers and sachet reference 
numbers were paired by Vitaflo Ltd and the supervising physician was blinded to this 
pairing. The supervising physician devised a safe personalised fasting period prior to 
each starch load for each patient based on previous cornstarch loads and medical 
history. 
 
Starch Load Test An intravenous cannula was placed in the patient’s arm and baseline 
blood and breath samples were collected. When the participant’s blood glucose was 
under 4.5 mmol/L, they mixed 50g of the nominated starch in cold water and drank the 
fluid. Breath and blood samples were performed at 30 minute intervals for the next 2 
hours and hourly thereafter. No further intake, apart from drinking water, was allowed. 
The starch load test ended when the patient had fasted for 10 hours, the plasma glucose 
was ≤3.0 mmol/L on the bedside glucose analyser (YSI 2300) or the patient wished to 
end the test. When the blood glucose was ≤ 3.5 mmol/L, blood tests were performed at 
30 minutes intervals, until the test end, but breath continued to be sampled hourly. 
Breath Tests Breath hydrogen was measured immediately at the bedside using an 
appropriately calibrated portable hydrogen measuring device (Micro H2, Micro Medical, 
Rochester, UK). Breath measurements were taken at hourly intervals until the test end. 
  127Repeat Starch Load Data from the first starch load was used to guide management 
using the particular starch for the subsequent 16 weeks. After a further washout period 
of 2 – 4 weeks on normal treatment, participants re-attended for a further starch load 
with the alternative starch. 
 
 
 
Results 
Patients 
 
  Test Duration (hours) 
ID  Age 
(Yrs) 
SEX 
(M/F) 
Type  Pre-load 
fast (hrs) 
Nocturnal 
regimen 
UCCS  WMHM20    
G  23 M IA  2 UCCS*  7 7.5 
H  24  F  IA  4.5  UCCS  6  6.5 
V  25 F IA  1.5 UCCS*  4.5 6 
K  38  M  IA  8  UCCS  5  10 
O  16 M IB  1.5 CNPF  7 7.5 
Y  17  M  IB  4.5  UCCS*  4.5  X 
P  17 F IB  8 UCCS  5 7.5 
Z  19  F  IB  4.5  UCCS*  X  5.5 
Q  26 M IB  4.5 UCCS  4  5.5 
R  35  M  IB  3  UCCS  X  8 
 
Table 5.3 – Participants recruited to study 4.2. Test terminated when patient felt 
symptomatic hypoglycaemia or a measurement of plasma glucose was < 3.0 
mmol/L. 
* Participant normally managed with CNPF but took UCCS for this study.  
X – Failed to attend for second part of study. 
(Further participant details in appendix under ID code.) 
CNPF – Continuous nocturnal polymer feed.  UCCS – uncooked cornstarch 
  128 
Patients that failed to complete the trial 
Three participants failed to complete the trial, all of whom had GSD type Ib. One of 
these patients had protracted hospital admissions in the first phase of the 16 week 
long-term trial for medical problems unrelated to the trial. One of the remaining cited 
academic commitments as a reason for not re-attending for the second starch load and 
the final participant had work commitments preventing them from re-attending.  
The study described in chapter 5.1 demonstrated that there is significant variation in 
excretion of hydrogen between individuals, and that this is partly age-dependent. For 
this reason data from the 3 individuals that failed to complete both starch loads is not 
included in the subsequent analyses but are in the appendix. Data from 7 paired starch 
loads were consequently analysed: 
The median hydrogen excretion is indicated in figure 5.6. There was no significant 
difference between the median profiles (p = 0.137).  
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Figure 5.6 – Median and quartile range of hydrogen excretion from 7 subjects 
after ingesting 50g of starch. 
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  UCCS  Vitastarch 
Age  Type 
Table 5.4 Area under the hydrogen graph (ppm minutes) and mean area (over 
time) for 7 subjects that took 50g of Vitastarch. 
 
Table 5.4 shows the calculated area under the hydrogen curve. There was no 
statistical difference between the areas under the hydrogen curve when these were 
compared for the 2 starches by non-parametric methods (p=0.30.) Because starch 
load duration differed between starch loads, the mean hydrogen excretion was 
calculated from area /time (p= 0.22).  
 
Discussion 
Combined Results 
The first study performed on both adult and children appears to demonstrate reduced 
13CO2 enrichment in the breath of the novel starch compared to uncooked cornstarch 
consistent with decreased utilisation, whereas the hydrogen data demonstrates greater 
fermentation of uncooked cornstarch consistent with greater malabsorption of 
uncooked cornstarch. These findings would appear to be contradictory because it 
would be expected that the least absorbed starch would exhibit greater fermentation. 
However, there were many problems with research methodology that meant that the 
circumstances of study were far from ideal due to the intensive nature of the patients’ 
treatment. 
Area Area/ 
time 
Area  Area/ 
time 
21 1a  2550  10.63  2235  7.45 
25  1a  893  3.72  1298  7.20 
25 1a  2520  6.00  1320  3.15 
38  1a  5400  18.00  4575  7.63 
16 1b  1215  2.90  2003  4.70 
17  1b  2798  9.33  953  2.64 
24 1b  1995  8.31  1793  5.98 
  Median 2520  8.31  1793  5.98 
  130Ideally, starch load tests and hydrogen / 
13CO2 breath tests should be performed after a 
substantial fast in order to discriminate interference from other ingested substances, 
but this is rarely possible in patients with GSD. In addition there should also ideally be 
a pre-test “washout” of 
13C containing food. This again is not possible in this study 
population who are dependent on regular cornstarch with high 
13C content leading to a 
statistically different baseline breath 
13CO2 when compared to the normal population 
(Bodamer et al 2002.)
62 The best compromise was to recommend that patient’s pre-
test management was identical for each load, with patients acting as their own control. 
It is likely that the previous cornstarch use also contributed to background and baseline 
fermentation as discussed later. We assumed that day to day variation was minimal on 
the two test days, yet this was not always the case, despite similar pre-test 
management.  
 
Enrichment of 
13CO2 in the breath 
The central premise for stable isotope studies is that an ingested tracer is metabolised 
and that any increase in breath of the specific isotope reflects the extent of this 
metabolic process. The workings and constraints of this metabolic process cannot be 
gauged by these tests; the method has been likened to a “black box,” where only the 
beginning and end results are known and little is known about mechanism.
149 The 
review by Rating et al gives the example of children studied by stable isotope studies 
suffering from diabetic coma or Crohn’s disease.  It is presumed the former subjects 
would have lower breath 
13CO2 enrichment because of decreased exogenous glucose 
metabolism due to an increased endogenous glucose pool, whereas the latter would 
have decreased enrichment due to decreased absorption. The end result is the same 
but the mechanism is completely different. 
In the glycogen storage diseases both processes may be affected – both impaired 
absorption and disordered glucose metabolism are features of type I GSD. By using a 
  131cross-over study, it was hoped to ameliorate some of the disease specific differences 
but each variable can fluctuate in the same individual.
19;150 
 
The enrichment data appears to show greater enrichment of cornstarch compared to 
heat modified waxy maize starch. However, it important to assess some of the detail of 
the enrichment curve. It has been reported that  the first 180 minutes of breath 
enrichment reflects gastric emptying, and subsequent enrichment reflects post-
absorptive metabolism.
62;151 Figure 5.1 indicates that the first 60 minutes of the studies 
are similar; at 120 minutes there is greater enrichment of WMHM20 but at 180 minutes 
and beyond, there is greater enrichment of uncooked cornstarch. The diminished 
WMHM20 curve could therefore represent delayed gastric emptying. Further evidence 
of this type of effect has been demonstrated by Hiele and colleagues (1990). This team 
investigated breath enrichment after ingestion of several different 
13C rich corn 
substrates. The four starches differed in their physical properties and were described 
as “normal crystalline starch, waxy starch, starch treated by extrusion cooking and high 
amylose starch.” The characteristics of the starches differed such that the waxy starch 
had the highest amylopectin content (98%) followed by the crystalline starch with the 
high amylose starch being 30% amylopectin. The extruded starch had a high 
amylopectin content (74%) but was the only starch to be highly gelatinised (79%.) Five 
subjects had paired starch loads with 50g of carbohydrate comparing high amylose 
starch to waxy maize starch (5.5b). Six subjects had breath enrichment studied after 
ingesting 50g carbohydrate of waxy maize, crystalline, extruded starch and extruded 
starch with bran. Result are indicated in figure 5.5a. 
 
  132     * P = 0.05 comparing extruded starch with crystalline starch 
+ P = 0.05 comparing waxy starch with extruded starch 
Figure 5.5 – Breath 
13CO2 enrichment after ingestion of 50g of starch by healthy 
adult volunteers. (pre-test management identical with natural enrichment 
quantified by combustion – ratios of excretion to natural 
13C abundance)  
By kind permission of BMJ publishing group Ltd – From Hiele et al GUT 1990.
152 
 
The data indicated that the extruded starch had peak enrichment at 2.5 hours and 
rapidly decreased whereas the waxy starch peaked at 4 hours and had sustained 
elevations above the other preparations 8 hours after ingestion of the starch. It is 
probable that the WMHM20 ie heat modified waxy maize starch with a high 
amylopectin content (99.5%) is more likely to behave similar to its native starch than 
any of the other corn derivatives. Delayed peak enrichment would represent delayed 
gastric emptying with sustained elevation compatible with slower total gastrointestinal 
transit time. 
 From a methodological perspective, it should be noted that the study by Hiele et al 
collected breath at 30 minute intervals for 8 hours in healthy individuals. The study 
presented in chapter 5.1 assayed breath at hourly intervals. Therefore much of the 
resolution of the peak breath enrichment is lost. There are several other differences 
between the Hiele study and the one described in this chapter:  
  133- There are a broad age range of subjects studied in this thesis and there may 
well be a difference in enrichment due to age – because the numbers are small, this 
cannot be tested. (n= 10 after those taking glucose polymer are excluded.) 
- The dose of carbohydrate ingestion is larger in this study than most other 
studies (2g/ kg of starch to a maximum of 120g = 1.84g/kg to a maximum 110g of 
carbohydrate.) The study of glycaemic index by Jenkins et al found greater differences 
when 50g of carbohydrate was ingested compared to 100g.
94 
- The duration of the starch loads are variable. Studies on healthy volunteers in 
general have fixed duration of study but studies in patients with glycogen storage 
disease are terminated when the subject becomes hypoglycaemic. Some of these 
subjects terminated this study as early as 6 hours due to hypoglycaemia. Peak 
enrichment was demonstrated with the waxy starch of Hiele et al at 4 hours.
152 
- Conversely, 13 of the 20 starch loads lasted for 10 hours without 
hypoglycaemia. This implies that glucose oxidation from dietary carbohydrate is still 
occurring at the time the tests are terminated and that glucose oxidation has not been 
fully quantified. 
 
The method is confounded further in patients with GSD by the assumption that breath 
enrichment exclusively represents ingested substrate metabolism. The 
13C pool within 
patients with GSD is likely to be high given that subjects have ingested enriched 
cornstarch for much of their lives. The difference to the normal population was 
observed by Bodamer et al.
62 Within the context of a fasting study, however 
metabolism and oxidation of endogenous 
13C within fat, protein or glycogen to 
13CO2 
may occur and prejudice results. 
 
Excretion of Hydrogen in Breath 
Hydrogen is produced in the human gastrointestinal tract by the action of bacteria on 
carbohydrate. Symbiotic bacteria are usually present within the colon and use 
  134undigested or unabsorbed carbohydrate as their own source of energy. Hydrogen 
produced as a by-product of this process is absorbed into the blood and excreted from 
the lungs. Increased breath hydrogen production has been shown to correlate with the 
increased delivery of non-absorbed substrate to the colon in the case of lactose 
intolerance, and pancreatic insufficiency as well as the increases in the population of 
bacteria in the case of bacterial overgrowth syndrome.
153-155 To differentiate these 
processes and increase specificity, studies have selected appropriate carbohydrate 
substrates to test the appropriate disease such as lactose for lactose intolerance and 
glucose for bacterial overgrowth. Fermentation of complex carbohydrates reflect the 
culmination of several physiological processes namely digestion, absorption of glucose 
and bacterial fermentation, each of which may be altered resulting in increased breath 
hydrogen.
116 
 
The study performed in section 5.1 demonstrated increased fermentation of uncooked 
cornstarch compared to WMHM20. By paired t-tests, this difference was statistically 
significant at 5 hours. This increased hydrogen excretion is compatible with increased 
colonic delivery and fermentation of UCCS compared to WMHM20, suggesting greater 
malabsorption of UCCS. If the criterion for malabsorption of peak hydrogen excretion > 
20 ppm were used, eight UCCS subjects and four WMHM20 met this criterion.
156 The 
area under the hydrogen curves were also assessed with both the mean area and the 
mean area over time being increased in the uncooked cornstarch group, but these 
findings were not statistically significant (table 5.2.). The results from the study 
presented in chapter 5.2 are similar with the median profile for Vitastarch being lower 
than the profile for uncooked cornstarch – this finding is not statistically significant p= 
0.137.) The median area and area over time are also lower during the Vitastarch trial 
but these too are not statistically significant. The mean baseline hydrogen excretion 
was approximately 8 ppm for each starch, which is much higher than the general 
population. This reflects the fact that these subjects have high carbohydrate intake 
  135throughout the day and night, which is being fermented at the start of the study. Ideally 
all patients would be fasting for 12 hours prior to starting the study to eliminate 
background fermentation, but this is not possible in this disorder.  
 
All of the results, therefore, appear to demonstrate greater fermentation of uncooked 
cornstarch compared to WMHM20 / Vitastarch. These findings could indicate there is 
greater malabsorption of UCCS compared to Vitastarch. 
 
 However, as discussed increased fermentation does not necessarily mean that there 
is more mal-digestion or mal-absorption of cornstarch. One possibility is that colonic 
flora has positively been selected by chronic use of uncooked cornstarch resulting in 
greater fermentation. This hypothesis is actively being tested by a research group 
elsewhere by characterising colonic flora in subjects with GSD compared to controls.
157 
Another possibility continues from the hypothesis generated from the breath 
enrichment data. If there is increased gastrointestinal transit time, fermentation of 
WMHM20 starch may be delayed rather than prevented. Both figure 5.2 and figure 5.6 
demonstrate that fermentation of WMHM20 increases in the latter 3 hours of both 
studies. This supports, but does not prove, the hypothesis that there is an increased 
transit time of WMHM20 compared to UCCS. 
From a methodological perspective the problems with breath enrichment apply to 
hydrogen breath tests too: 
  - Peak fermentation of complex carbohydrates occurred after 5 hours of study. 
Several patients had terminated the test prior to or soon after this time and 
consequently data were not collected when fermentation was greatest. The fact that 7 
of the 17 patients used uncooked cornstarch in the 6 hours prior to the study, and all 
had UCCS within the preceding 12 hours, meant that some fermentation of non-
studied starch would have occurred during the study. 
  136  - Several subjects did not have hypoglycaemia even after 10 hours of fasting 
and these subjects would continue to be utilising dietary carbohydrate, consequently 
colonic fermentation would continue for some period of time after absorption of glucose 
was completed. 
  - The dose in this study was greater than most other studies. 
  - The age range studied was very varied in this study and we were able to 
demonstrate a statistically significant difference in hydrogen excretion between 
children and adults as well as positively correlating age with hydrogen excretion. This 
means that age is likely to have an effect on hydrogen excretion in this group of 
patients as discussed below. 
- In addition, only seven participants contributed data to the study presented in 
chapter 5.2. From 4 hours into the study some of these seven failed to contribute 
further data as they became hypoglycaemic and needed to eat. After 7 hours, no 
patient taking UCCS and only 3 subjects taking Vitastarch contribute data on hydrogen 
excretion. Since fermentation is a function of colonic delivery of starch, typically taking 
5 hours or longer, there are not sufficient data at the latter stages of study 5.2 to be 
confident of its findings.
116;154 
 
Significantly increased breath  hydrogen excretion was not demonstrated in 2 previous 
studies of patients under the age of 22 with glycogen storage disease type I,
19;101 but 
was demonstrated in another study in which older adults were studied.
62 The first of 
these studies by Smit et al published in 1984 by a group based in Groningen was one 
of the first publications of the use of uncooked cornstarch in the treatment of glycogen 
storage disease. They report an increase in breath hydrogen excretion in the 9 
subjects tested, but this was not in the diagnostic range for carbohydrate 
malabsorption.
101 No further data are presented in this study than this statement. The 
subsequent study published by the same Dutch group performed specific 
investigations of the gastrointestinal manifestations of glycogen storage disease in a 
  137study published in 2002.
19 This publication reports studies performed on18 subjects 
with GSD Ia and 4 with GSD Ib, aged between 3 and 22 years with a median age of 
16.3. Six of the GSD Ia patients and all the GSD Ib patients had a history of diarrhoea. 
In addition to other investigations, hydrogen excretion was measured at baseline and 
hourly for 14-16 hours after ingestion of 1.5g/ kg of uncooked cornstarch in some of 
these research subjects. Patients were allowed normal diet after 6 hours investigation 
without further starch intake.  The publication reports that breath tests were performed 
on 9 of the 18 patients with GSD Ia and none of the subjects with GSD Ib. It is not clear 
what the ages, of those that were investigated, are. For these 9 subjects with GSD Ia, 
breath hydrogen never increased above 20 ppm.  
Bodamer et al studied 8 subjects with GSD Ia aged between 16 and 42 years, mean 
age 28.3, after ingestion of 1g/kg of uncooked cornstarch and compared them to age 
matched control healthy volunteer subjects.
62 Breath enrichment and hydrogen 
excretion was measured at 30 minute intervals for the subsequent 6 hours as 
tolerated. Five of the eight subjects with GSD Ia maintained normoglycaemia for 6 
hours with 2 studies lasting 5 hours and one being terminated after one hour – the data 
for the studies that lasted greater than 5 hours are presented on table 5.4. From 3 
hours into the study, the subjects with GSD Ia excreted significantly greater hydrogen 
than controls (table 5.5) 
Time  Control  GSD Ia  p value 
(hours)  Mean  SD  Mean  SD  unpaired t-test 
3 3  3.87  17.3  20  <  0.04 
4  2.6  2.7  18  12.2  < 0.001 
5 2.09  1.87  13  9.14  <  0.002 
6  1.82  2.09  16.33  13.65  < 0.03 
 
Table 5.5 –  Mean hydrogen excretion (ppm +/- SD) after ingestion of 1g/Kg of 
UCCS in subjects with GSD and controls.  
Adapted from Bodamer et al  Eur J Gastro Hepat 2002
62 
The authors conclude that 2 of the 7 subjects fulfilled the criteria for malabsorption 
from published evidence. 
  138 
The studies presented in chapter 5.1 and 5.2 indicate a statistical difference in mean 
hydrogen excretion for the duration of the cornstarch load for those patients aged 14 
and under compared to those 15 and over (figure 5.4). Furthermore figure 5.5 
correlates mean hydrogen excretion positively with age, implying that there is acquired 
increased fermentation in this patient group. The author of this thesis has not been 
able to find any studies documenting an increase in hydrogen excretion with age. The 
control population from the above study by Bodamer et al were age matched with 
much lower hydrogen excretion. The acquired increased fermentation could be due to 
gastrointestinal mucosal factors such as inflammation resulting in decreased 
absorption of glucose, impaired digestion of complex carbohydrate or bacterial 
overgrowth. We cannot, however, exclude that the difference between this study and 
those published previously are due to differences in dose or regional variations in 
management; both studies showing no increased hydrogen excretion were Dutch and 
both positive studies were from London. The centres also used different definitions of 
starch malabsorption, without raw data being presented; consequently it is difficult to 
ascertain whether there are differences between the populations.  
 
 
Conclusion 
  Breath data demonstrated non-statistically significant increase in utilisation of 
uncooked cornstarch compared to WMHM20, whilst there was significant increase in 
fermentation of uncooked cornstarch too. These results appear inconsistent. However, 
there is weak evidence to suggest that WMHM20 has an increased gastrointestinal 
transit time on the basis of reduced early breath enrichment of 
13CO2 and increased 
fermentation in the last 3 hours of each 10 hour study. The validity of the results were 
compromised by some of the study methodology, which is well validated in healthy 
  139controls but difficult to implement in patients with glycogen storage disease due to their 
tendency to develop hypoglycaemia. Further work would need to address: 
    - The baseline characteristics that are influenced by treatment with both 
glucose polymer and uncooked cornstarch.  
- Early enrichment of 
13CO2 in the breath to reflect gastric emptying. 
- Longer assessments of both starch oxidation and fermentation to fully assess 
these variables independently of hypoglycaemia occurring.  
Such further studies are considered in chapter 7. 
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CHAPTER 6 – THE LONGTERM USE OF VITASTARCH IN GSD 
Introduction 
The intensive dietary regimens of patients with hepatic glycogen storage diseases, have 
a major impact on the lives of the patients and their families. Chapter 2 examined this 
intensive regimen and showed that carbohydrate intake could be large and that 
deficiencies of micronutrients were possible. The effect of the introduction of a novel 
starch on short-term biochemical parameters was assessed in chapter 3, with 
preliminary evidence of benefit. Some of the mechanisms of how these benefits may 
occur were examined in chapter 4.  
Vitaflo Ltd created a new starch called Vitastarch by the addition of emulsifying fats to 
the raw starch WMHM20 (heat-modified waxy maize starch). In addition to this starch, 
there was an alternative preparation enriched with vitamins and minerals, to supplement 
dietary treatment called Vitastarch plus. In the UK, both Vitastarch and Vitastarch plus 
have been classified as “borderline” foods and not medicines by the UK regulatory body: 
“The Medicines and Healthcare products Regulatory Agency” (MHRA). They are 
consequently exempt from regulation by the UK Medicines for Humans Act (2000). This 
chapter describes a long-term study of the introduction of Vitastarch and Vitastarch plus 
into the dietary regimen of patients with glycogen storage disease type I, by comparing 
their use with uncooked cornstarch. The starch loads performed as part of this trial have 
been presented in chapter 4.3 and the breath tests in chapter 5.2.  
Hypothesis Because WMHM20 has a longer duration of action, over a long-term period, 
patients with glycogen storage disease take less Vitastarch and Vitastarch plus than 
uncooked cornstarch. 
 
Method 
The study protocol was approved by the Joint Ethics Committee of The National Hospital 
for Neurology & Neurosurgery and Institute of Neurology, London U.K. The study had a 
  141randomised double-blind cross over design. Patients anonymised by reference number 
were randomly allocated to receive either UCCS or Vitastarch. Each starch was 
manufactured using food-grade techniques and packaged in identical sachets bearing a 
reference number. The patient reference numbers and sachet reference numbers were 
paired by Vitaflo Ltd and the supervising physician was blinded to this pairing. The 
supervising physician devised a safe personalised fasting period for each patient based 
on previous cornstarch loads and medical history. 
Assessments performed at each hospital visit (starch load admission & outpatient):  
Weight and blood pressure. 
The following blood tests:  
 - Fasting triglycerides and cholesterol,  
- Uric acid 
 - Iron 
  - Vitamin B12 
  - Red cell Folate 
- Thiamin 
  - Vitamin D 
 -  Zinc    
 -  Copper 
 -  Selenium 
 -  Calcium 
 -  Albumin 
          
 
Starch Load Test An intravenous cannula was placed in the patient’s arm and baseline 
blood and breath samples were collected. When the participant’s blood glucose was 
under 4.5 mmol/L, 50g of the nominated starch was mixed in cold water and the 
participant drank the fluid. Breath and blood samples were performed at 30 minute 
  142intervals for the next 2 hours and hourly thereafter. No further intake, apart from drinking 
water, was allowed. The starch load test ended when the patient had fasted for 10 hours, 
the plasma glucose was ≤3.0 mmol/L on the bedside glucose analyser (YSI 2300) or the 
patient wished to end the test. When the blood glucose was ≤ 3.5 mmol/L, blood tests 
were performed at 30 minutes intervals, until the test end.  
 
Biochemical data Whole blood was centrifuged at the bedside and plasma glucose and 
lactate were analysed immediately (YSI 2300 - Yellow Springs, Ohio, USA).  
Prescription of starch The glucose and lactate data from the load test were interpreted by 
two investigators who have experience in interpreting these results. They were blinded to 
the identity of both the participant and the starch. They were given some background 
information of normal starch dosing and the last available cornstarch load data for that 
participant (for examples see appendix) On the basis of this information a safe frequency 
of daytime dosing for the given starch was discussed, agreed and prescribed. The 
participants were asked to take the nominated starch for 16 weeks. 
 
Delivery of Starch With prior consent, the investigators arranged a projected 2 month 
supply of allocated starch to the participants’ home, based on the blind prescription. The 
starch was delivered in boxes with individual sachets bearing a reference code 
identifying the type of starch only to representatives from Vitaflo Ltd. The participants 
were asked to take the nominated starch as recommended by the blinded prescribers. 
However, it is recognised that some patients take less or more starch doses in the home 
environment – the participant was asked to note what they actually took. Any subject that 
had been advised in their clinical management to take a vitamin or mineral supplement 
was also supplied with Vitastarch plus. Vitastarch was delivered in sachets of 25g and 
Vitastarch plus was delivered in sachets of 57g with 50g of starch and 7g of minerals and 
Vitamins. If patients were taking Vitastarch plus, this replaced an equivalent dose of 
  143Vitastarch. Prescriptions were all given in multiples of 25g to conveniently accommodate 
the size of sachets. 
 
Monitoring of starch use and symptoms. For the 16 week study period, participants were 
asked to keep a record of subjective episodes of hypoglycaemia. Whilst measurement of 
blood glucose was not recommended, participants were also asked to keep a record of 
any blood glucose measurement that was taken. One member of the research team 
contacted the participant to note these data as well as general information about 
symptoms and appetite over the preceding week (example of record in appendix) The 
participant was asked to complete a diet diary after they had taken the nominated starch 
for at least 6 weeks. They were asked to write down everything they ate for a 3 day 
period and the nutritional content of the diet including the starch taken were analysed by 
an experienced state registered dietician using specialised software (Dietplan 6, 
Forestfield Software, Ltd. Horsham, UK.) 
End of study period. At the end of the 16 week study period, the research volunteer was 
asked to attend an outpatient clinic. At this visit, in addition to the tests mentioned at 
each visit, a patient acceptability questionnaire was completed asking the patient’s 
opinion of the product that they had been taking. This was followed by a washout period 
of  2 – 4 weeks and the patient re-attended for a starch load with the alternative starch 
with identical assessments.  
Table 6.1 below summarises the trial protocol: 
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Table 6.1 – Trial timeline for the use of Vitastarch in Adults with GSD I 
 
Baseline  Week 1 - 16  Between
Week 
 6- 16 
Week16 washout  Baseline 2  Week 1b – 16b  Between Week16b 
Week  
6b- 16b 
Starch 1 Load 
Test 
 Breath Test 
Acceptability 
questionnaire 
Starch 2 Load 
Test 
 Breath Test 
Acceptability 
questionnaire 
Biochemistry   Biochemistry  Biochemistry   Biochemistry 
Anthropometry 
Start starch 1 
 in diet 
Monitor Use of 
starch and 
symptoms 
3 Day  
Diet 
 Diary 
 
 
Anthropometry
Normal 
Regimen for 
2 – 4 weeks 
Start starch 2 
 in diet 
Monitor Use of 
starch and 
symptoms 
 
 
3 Day  
Diet 
 Diary 
 
Anthropometry  Anthropometry 
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Patients that failed to complete the trial – all four participants that failed to complete the 
trial completed most if not all of one 16 week phase of the trial. Two participants were 
randomised first to Vitastarch. Neither of these noted greater symptoms or problems with 
Vitastarch. One of these failed to attend the termination of phase assessment, but opted 
to continue Vitastarch supply after the trial was completed, citing fewer episodes of 
diarrhoea for his reason to opt for Vitastarch. The other patient attended the end of 
phase assessment with equivalent clinical and biochemical monitoring parameters but 
failed to attend the UCCS load. This participant cited study commitments as the reason 
for not re-attending. This participant had also been admitted into hospital during the first 
phase of the trial with significant renal impairment due to post-streptococcal 
glomerulonephritis. This complication was unrelated to therapy. 
 
Two patients were randomised to take UCCS first – one patient reported that he felt 
clinically worse than normal but the end of phase assessment was equivalent to 
baseline. This patient failed to attend for the second phase and consequently took no 
Vitastarch. This participant repeatedly cancelled scheduled repeat attendances for the 
second phase, citing academic commitments as the reason for not to re-attending. After 
four months in the wash-out phase, it was felt that this subject had significantly breached 
the trial protocol and was withdrawn from the trial. The fourth patient felt similar to normal 
during the first phase, apart from during a hospitalisation for an unrelated problem. This 
participant attended for the starch load with Vitastarch but did not like the taste when this 
starch was used in the home environment. Because this patient failed to establish a 
routine of taking Vitastarch without UCCS, they were withdrawn from the trial.  
Results from 6 patients that completed both 16 week phases of trial 
Starch use over trial period 
The amount of starch used per week by individual patients is indicated in table 6.2. If a 
patient was unwell leading to alteration of treatment, the entire week’s data were omitted.  
  146   V  K  G  M  Q  H 
VS  uccs  VS  uccs  VS  uccs VS  uccs VS  uccs  VS  uccs Week 
1  1475  1450  1050  1950  1050       725    2100  1225  850
1400  1500  1050  2500  1050 1050 700 700 875 2  2100  1225  700
3  1500     1050  2600  1050 700 700 675 2100  1225  1050   
4  1500  1400  975  2500  1050 950 700 700 625 2100  1225  700
5  1525  1450  1000  2750  1000 1050 700 700 1050 2100  1225  700
6  1525  875  2675  1050 1050 700 700 1050 2100  1225  1450  675
7  1475  1475  875  1050 1050 750 700 1050 2100  1225  875 2800 
1400  1425  875  2850  1050    700 700 1050 8  2100  1225  700
1525  1525  875  2480  1050    700 9  700 1050 2100  1075  525
10  1400  1525  875  2550  1050 1050 700 700 1050 2100  875  550
11  1500  1525  875  2850  1050 1050 700 700 1050 2100  875  875
12  1400  1425  875  2550  1050 1050 700 700 1050    775  700
13  1575  1550  850  2700  1050 1050 700 700 1025    700  700
14  1625  1450  875  2925  1050 975 700 700 1050 2100  700  700
15  1400  1525  875  3000  1050 1000 700 700 1050 2100  700   860
16  1425  1525  875  2700  1050 1050 700 700 1050 2100  790  675
Mean  1478  1480  920  2648  1047 1033 703 702 983 2100  1018  688
                                      
T 
Test  0.559  1.49851E-11  0.378  0.337  5.0527E-10  0.00023 
 
Table 6.2 – Amount of each starch used by each patient weekly (grams per week.) 
 
There was little difference in the amount of starch used by participants V, G and M. 
There was a very significant reduction in the amount of starch used by K and Q. Both 
patients have short fasting intervals (5 and 4 hours respectively) with UCCS, meaning 
that the reduction in use of starch had a large impact on their dependence on regular 
dosing. Participant H took significantly more Vitastarch. This patient was randomised to 
taking UCCS first and had to be informed of significant deterioration in long-term renal 
function at the end of the first 16 week period. This was unrelated to the trial. 
Subsequently, there was a dramatic improvement in adherence to prescribed medical 
therapy including the use of starch. This is substantiated by an increase in weight over 
the washout period as indicated in table 6.3. The adherence to prescribed treatment 
persisted through the 2
nd phase of the trial on Vitastarch. This patient returned to their 
normal starch use between weeks 9 and 16 of the Vitastarch phase as indicated in table 
6.2. 
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The change in weight of patients is shown on table 6.3. The product that the participant 
was randomised to take first is indicated in the first column. Patient Q was randomised to 
take Vitastarch first and took substantially less starch than they normally do, and lost 2.8 
Kg weight. Q took more UCCS than Vitastarch in the second phase and regained 2 Kg 
weight. Patient H was randomised to take UCCS first and lost 2.4 kg. As mentioned 
above, information was given at the end of this phase that lead to strict adherence to 
therapy leading to a 4.3 Kg increase in weight in the washout phase. A further 7.1 kg 
was gained in the second phase on Vitastarch. Patient M had little weight change on 
UCCS but increased 6.9 kg on Vitastarch. This participant did not like the taste of 
Vitastarch plus and added chocolate powder to the product which added a further 10% to 
energy intake. This, combined with a reduction in exercise during school summer 
holidays, led to an increase in weight. 
There was no significant weight change for G and V. K was randomised to UCCS first 
and increased 4.6 kg of weight concomitant with a change in employment. They took 
substantially less starch on the Vitastarch phase and finished the trial at baseline weight. 
Pre   ID First 
starch 
Pre  
UCCS 
Post 
 UCCS 
Post 
- pre  VS 
Post 
VS 
Post 
- pre 
Q V   50.3 52.3 2.0 53.2 50.4 -2.8 
H   U  63.2 60.8 -2.4 65.1  72.2  7.1 
M U  73.1 72.8 -0.3 73.6  80.5  6.9 
G V  57.8 58.0 0.2 56.7 57.7 1.0 
V   U  77.6 76.4 -1.2 76.5  76.0  -0.5 
K U  55.0 59.6 4.6 59.5 55.0 -4.5 
 
Table 6.3 – Weight change during trial (kg) – First column indicates participant identity and 
second column the product which they were randomised to take first. V = Vitastarch; U = 
Uncooked cornstarch. 
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The biochemical parameters, triglyceride, cholesterol and uric acid reflect metabolic 
control over days and weeks for patients with GSD I. The data are shown below in table 
6.4. Elevations in all parameters are common. Hyperuricaemia can lead to gout or renal 
stones and is effectively treated with Allopurinol. Patient Q was randomized to Vitastarch 
first and had gross elevation of the plasma uric acid concentration at baseline. The 
participant was urged to comply with therapy in the first instance and had an increased 
dose of Allopurinol at the end of the first phase through to the end of trial. There was also 
some increase in the plasma triglyceride concentration over the Vitastarch phase. There 
was no significant alteration in metabolic control for all other participants. In summary, 
metabolic control as measured by these three parameters appears equivalent. 
                   
   Trial  Biochemical  Pre  Post Pre  Post Reference 
   ID  Test  VS  VS  UCCS UCCS Range 
     Triglyceride  3.62  5.1  4.52  5.92  0.42 - 2.00mmol/L 
  H  Cholesterol  5.4  6.2  6.2  6  3.35 - 6.2mmol/L 
     Uric acid  267  238  435  244  149 - 369umol/L 
     Triglyceride  1.92  2.14  5.12  2.76  0.42 - 2.00mmol/L 
  K  Cholesterol  2.6 2.8 4.8 3.4  3.35  -  6.2mmol/L 
     Uric acid  235  194  304  237  149 - 369umol/L 
     Triglyceride  10.7   7.71  9.0  5.5  0.42 - 2.00mmol/L 
  G  Cholesterol    8.1 6.9 6.5 6.4  3.35 - 6.2mmol/L 
     Uric acid   326  325  393  335  149 - 369umol/L 
     Triglyceride  8.99  5.64  7.4  5.83  0.42 - 2.00mmol/L 
  V  Cholesterol  6.8  5.6  6.9  5.7  3.35 - 6.2mmol/L 
     Uric acid  406  269  309  264  149 - 369umol/L 
     Triglyceride  2.91  5.44  5.03  2.24  0.42 - 2.00mmol/L 
  Q  Cholesterol  4.1 4.5 4.1 3.2  3.35  -  6.2mmol/L 
     Uric acid  872  753  364  345  149 - 369umol/L 
     Triglyceride  3.6  3.95  1.46  3.45  0.42 - 2.00mmol/L 
  M  Cholesterol  1.48  4.2 3.6 4.3  3.35  -  6.2mmol/L 
     Uric acid  402  458  379  389  149 - 369umol/L 
 
 
Table 6.4 –Biochemical indices of metabolic control during trial.  
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Comparing the diet diaries between the two phases, the relative contribution of starch to 
the total calorie intake of the diet was reduced by 50% with Vitastarch in 2 individuals, 
increased in one individual and remained the same for the others (table 6.5) 
Trial 
 ID 
% 
energy 
from 
UCCS 
Starch 
Glucose 
Delivery 
mg/kg/min 
Total 
Glucose 
Delivery 
mg/kg/min 
% 
energy 
from 
Vitastarch 
Starch 
Glucose 
Delivery 
mg/kg/min 
Total 
Glucose 
Delivery 
mg/kg/min 
17  1.7  5.9  14  1.7  7.0  G 
H  19  0.8  3.6  30  1.3*  2.6* 
V  26  1.8  5  23  1.7  4.4 
K  54  4.3  6.1  24  1.6  3.3 
M  16  0.9  3.7  13  0.8  3.2 
Q  35  3.8  6.6  17  1.8  3.5 
 
Table 6.5 – Energy contribution of treatment starch as percentage of total energy 
intake and absolute glucose delivery rate from treatment starch and diet 
calculated from diet diaries.  
* This subject had a 15% increase in weight between assessments. If the baseline 
weight from the UCCS assessment were used as reference, the treatment starch 
delivery would have been 1.5 mg/kg/min and total carbohydrate intake 3.0 mg/kg/min.  
 
Calculation of glucose intakes, derived from total daily carbohydrate intake were also 
made from the diet diary. The glucose delivery from the treatment starch was also 
calculated. Mean glucose delivery from UCCS was 2.21 mg/kg/min, being 1.38 from 
Vitastarch. There was a trend to reduction of treatment starch glucose delivery, p = 
0.0625 (by Wilcoxon signed rank test.) The reduction is indicated on figure 6.1. There 
are 2 subjects who appear to take more starch than others, reducing intake when taking 
Vitastarch such that they are taking similar quantities of starch to the rest of the group. 
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Figure 6.1 – Glucose intakes rates calculated from dietary intake of UCCS and 
Vitastarch from diet diaries (p = 0.0625.) 
  UCCS  Vitastarch 
Percentage  
Contribution  
to total Energy by 
 
Percentage  
Contribution 
to total Energy by 
  
ID 
  
Total 
Energy 
Intake 
 
 
Table 6.6 – Total energy intake relative to estimated average requirements and 
energy contribution by macronutrients whilst taking UCCS compared to 
Vitastarch. 
 
UCCS  Vitastarch 
ID  CHO  Prot  Fat  CHO  Prot  Fat 
G  108  130  92  133  141  126 
H  80  72  71  97  66  53 
V  153  287  47  150  240  50 
K  128  83  40  87  71  44 
M  91  123  52  92  153  53 
Q  124  195  91  81  189  85 
 
Table 6.7 – Percentage intake of macronutrients relative to age and sex matched 
estimated average requirements. 
CHO – Carbohydrate   Prot – Protein   UCCS – Uncooked Cornstarch 
Percent 
Intake 
relative 
to EAR 
  CHO  Prot  Fat 
Total  
Energy
Intake 
 
Percent 
Intake  
Relative 
to EAR 
  CHO  Prot  Fat 
G  3032  104  59.5  9.5  31  3711  128  58.2  8.2  33.6 
H  1570  76  59.2  8.2  32.5  1645  79  69.1  7.3  23.6 
V  2946  128  69.2  17.8  13  2943  128  70.1  15.4  14.5 
K  2415  93  77.4  7.6  15  1876  72  69.3  8.6  22.1 
M  2238  81  65  12.3  22.8  2343  85  63.2  14.8  22 
Q  3044  119  59  14.2  26.8  2454  96  49.7  17.9  32.4 
  151Tables 6.5 – 6.7 and figure 6.1 show different aspects of dietary treatment. 
Carbohydrate intake, both from treatment and diet are indicated in table 6.5. Absolute 
energy intake and percentage contribution by constituent macro nutrients are shown in 
table 6.6, and the intake of these relative to requirements are shown on table 6.7. 
A summary of each subject’s intake follows for each limb of the study: 
Subject G – G took the same amount of treatment starch on both limbs of the study. 
However, the participant had increased total energy intake compatible with increased 
appetite when taking Vitastarch (from 104% EAR to 128% - table 6.6). The participant 
increased dietary fat and carbohydrate intake in particular but the proportions of each 
remained broadly similar in both dietary assessments. 
Subject H – This person took more Vitastarch than UCCS in this trial. Although 
treatment starch intake increased, dietary carbohydrate intake reduced when taking 
Vitastarch leading to only a slight increase in absolute energy intake. There was an 
absolute reduction of fat intake whilst taking Vitastarch, leading to a proportionate 
increase in contribution from carbohydrate. 
Subject V - There was little difference between the 2 limbs of the study. 
Subject K – This person took a substantial amount of treatment starch when taking 
uncooked cornstarch, which reduced from 54% of total energy intake to 24% when 
taking Vitastarch. The substantial reduction in treatment carbohydrate intake did not 
lead to a change in the diet with absolute fat and protein intake remaining similar but 
becoming proportionally greater within a lower total energy and carbohydrate diet. 
Subject M - Apart from a 10% increase in energy intake due to the use of chocolate 
powder with Vitastarch plus, there was little difference in the dietary analyses. 
Subject Q – This person reduced total treatment starch intake when taking Vitastarch 
Substantially from 34% of total energy intake to 17%. Similar to subject K, there was 
no dietary compensation for this reduction. Consequently there was a reduction in total 
energy intake with concomitant proportionate increase of fat and protein. 
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VS + NOT 
TAKEN  Pre  Post 
Micronutrients – Vitastarch plus and biochemical monitoring during trial 
Bold and underlined below reference range. 
Pre  Post Reference 
ID: G  Vitastarch  Vitastarch Cornstarch Cornstarch Range 
Iron     18.5 18.6   
5.0 -  
25.0umol/L 
Vitamin B12  160    180 141 150 - 900ng/L 
Redcell Folate  244     226 297 150 - 650ug/L 
Thiamine     194 184    66 - 200nmol/L 
Vitamin D     24 28    15 - 100nmol/L 
Zinc     16.8 14.6    11 - 18umol/L 
Copper     18.5 20.8    11 - 22umol/l 
Selenium     0.87 0.88    0.89 - 1.65 
Calcium     2.42 2.55 2.51 2.10 - 2.55 
Albumin        53 52 35 -50 
 
 
VS + taken  Pre  Post  Pre  Post Reference 
ID: H  Vitastarch  Vitastarch Cornstarch Cornstarch Range 
Iron     11.1 6.5 24.3
5.0 -  
25.0umol/L 
Vitamin B12  152  130 163 186 150 - 900ng/L 
Redcell Folate 
(serum) 
4.6  332 (serun) 5.8  (serum) 5.7  3.0 - 20ug/L 
Thiamine  180     112 148 66 - 200nmol/L 
Vitamin D  23     20 21 15 - 100nmol/L 
Zinc  11.1  17.2 13.9 11 11 - 18umol/L 
Copper  16.88  12.73 17.7 18 11 - 22umol/l 
Selenium  1.1     1.16 0.18 0.89 - 1.65 
Calcium  2.24  2.22 2.18    2.10 - 2.55 
Albumin  41  39 41 41 35 - 50 
 
 
VS + taken  Pre  Post  Pre  Post Reference 
ID: V  Vitastarch  Vitastarch Cornstarch Cornstarch Range 
Iron  13.1  10.5 15.6 10.2
5.0 -  
25.0umol/L 
Vitamin B12  477  493 387 602 150 - 900ng/L 
Redcell Folate  1226  779 937 1057 150 - 650ug/L 
Thiamine  164  142 149 153 66 - 200nmol/L 
Vitamin D  96  46 67 55 15 - 100nmol/L 
Zinc  13  14.6 17.4 13.9 11 - 18umol/L 
Copper  19.9  17.85 15.9 17.2 11 - 22umol/l 
Selenium  1.66  1.69 1.28 1.49 0.89 - 1.65 
Calcium  2.4  2.36 2.39    2.10 - 2.55 
Albumin  49  48 48 48 35 - 50 
 
  153 
VS + taken  Pre  Post  Pre  Post Reference 
ID: K  Vitastarch  Vitastarch Cornstarch Cornstarch Range 
Iron  8.8  12.6 7.6 7.3
5.0 -  
25.0umol/L 
Vitamin B12  288  214 163 224 150 - 900ng/L 
Redcell Folate  361  673 414 368 150 - 650ug/L 
Thiamine  148  172 156 153 66 - 200nmol/L 
Vitamin D  35  63 74 37 15 - 100nmol/L 
Zinc  11.2  11.8 14.7 12 11 - 18umol/L 
Copper  14  14.96 11.3 16.1 11 - 22umol/l 
Selenium  0.58  1.07 0.9 0.68 0.89 - 1.65 
Calcium  2.12  2.21 2.37 2.29 2.10 - 2.55 
Albumin  38  41 43 43 35 - 50 
 
 
VS + taken  Pre  Post  Pre  Post Reference 
ID: M  Vitastarch  Vitastarch Cornstarch Cornstarch Range 
Iron  7.8  6.9 8.4 2
5.0 -  
25.0umol/L 
Vitamin B12  1500  1500 1185 1372 150 - 900ng/L 
Redcell Folate  13  738 849 750 150 - 650ug/L 
Thiamine  188  153 175 144 66 - 200nmol/L 
Vitamin D  41  48 45 43 15 - 100nmol/L 
Zinc  14  13.7 15.2 15 11 - 18umol/L 
Copper  16  18.1 20.3 18 11 - 22umol/l 
Selenium  0.71  1.05 0.99 0.88 0.89 - 1.65 
Calcium  2.27  2.41 2.37 2.34 2.10 - 2.55 
Albumin  42  46 42 46 35 - 50 
 
 
VS + taken  Pre  Post  Pre  Post Reference 
ID: Q  Vitastarch  Vitastarch Cornstarch Cornstarch Range 
Iron  10  1.9 5 5.2
5.0 -  
25.0umol/L 
Vitamin B12  886  >1500  500 758 150 - 900ng/L 
Redcell Folate  253  489 (serum) 6.7  619
150 - 650ug/L 
(3 - 20.0ug/L) 
Thiamine  78  93 63    66 - 200nmol/L 
Vitamin D  23  17 23    15 - 100nmol/L 
Zinc  16.9  16 15.5 17.4 11 - 18umol/L 
14.5  22 24.43 14.47 Copper  11 - 22umol/l 
Selenium  0.76  1.41 0.84    0.89 - 1.65 
Calcium  2.48  2.54 2.54 2.41 2.10 - 2.55 
Albumin  48  48 44 43 35 - 50 
 
Table 6.8 – Biochemical tests monitoring nutrition in individual subjects 
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   UCCS  Vitastarch    
  
 
 
Table 6.9 – Micronutrient intake estimated from diet diaries for subjects taking UCCS and Vitastarch  
 
^ inclusive of selective mineral supplement; * inclusive of multivitamin preparation, ~ Not taking Vitastarch plus;   # taking Vitastarch plus 
Bold and underlined below RNI
G  H^  V*  K^  M*  Q^  G ~  H #  V #  K #  M #  Q #  RNI 
 
Calcium 
 
1783  589  2023  618  1931  446  2001  816  1942  955  982  1655  700 - 1000 mg 
 
Copper 
 
0.85  1.39  1.46  1.2  2.47  1.74  1.39  1.31  1.79  1.37  1.5  2.06 1.2  mg 
 
Zinc 
 
8.6  4.83  16.6  6.23  19.8  12.6  9.76  9.71  19.11  10.08  15.6  17.03  7 - 9.5 mg 
 
Selenium 
 
24.7  25  97.4  19.3  105.8  44.1  42.6  35.7  65.5  39.2  52.2  68.5  60 - 75 μg 
 
Thiamin 
 
1.35  1.06  2.42  1.05  2.68  1.01  1.69  1.32  1.64  1.59  1.72  1.45  0.83 -1.02 mg 
 
Riboflavin 
 
3.36  0.82  3.62  0.96  3.51  1.3  2.92  0.98  3.66  1.41  1.97  3.34  1.10 - 1.30 mg 
 
Niacin 
 
9.16  10.03  38.6  15.8  38.9  21.54  12.79  6.53  16.8  12.48  28.3  19.2  13.7 - 18.9 mg 
 
B12 
 
10.7  0.7  13.9  1.56  9.1  9.7  9.4  1.7  11.7  2.2  5.9  16.1 1.5  μg 
 
Folate 
 
202  194  459  243  883  154  179  234  316  260  286  272 200  μg 
 
Vitamin C 
 
63  197  54  109  73  48  69  61  66  136  42  58 40  mg 
 
  155 Table 6.8 and 6.9 show individual participant’s nutritional biochemistry investigations, 
at each phase of the trial, and nutritional assessments from diet diaries respectively. 
Biochemical selenium deficiency is noted in four of the subjects which resolved in all 3 
that used Vitastarch plus. Dietary assessment also noted intake below the reference 
nutrient intake (RNI) in four patients taking UCCS and Vitastarch, with the median 
value being higher in those taking Vitastarch plus (24.9 and 39.2 μg / day respectively.) 
2 vegetarian subjects were noted to have biochemical evidence of B12 deficiency, 
although functional assessments were not made; only one of these was evident from 
the dietary assessment. The only other nutritional deficiency measured by biochemical 
assessment was subject Q who had a borderline low plasma thiamine. Thiamine has 
an essential role in the production of energy being a co-factor in the pyruvate 
dehydrogenase complex. Excessive flux in the glycolytic pathway with decreased co-
factor leads to clinical and biochemical sequelae. Cases of Beri-Beri are well 
recognised in populations with high carbohydrate and low thiamine intake.
158 Both Q 
and M had low serum Iron, but these were the only subjects from this cohort that have 
GSD Ib and this is a well recognised feature of GSD Ib.  
 
Niacin intake was below the reference nutrient intake in 3 dietary assessments, when 
the subjects were taking both UCCS and Vitastarch plus. Three subjects had an 
estimated low Zinc intake from dietary assessment taking UCCS that improved taking 
Vitastarch plus.  
 
All subjects had a normal plasma calcium. However, there was substantial variation in 
dietary intake with 2 subjects having intakes below the RNI taking UCCS and 2 
subjects having more than twice the RNI intake of calcium.  
 
As discussed in chapter 3, subject H had multiple projected deficiencies by dietary 
assessment including calcium, zinc, selenium, riboflavin, niacin, vitamin B12 and 
  156folate. This subject also had a low total energy intake with macronutrient 
insufficiencies.  
 
 
 
Patient Preference Questionnaire 
At the end of each phase of the trial, the participant was asked to complete a structured 
questionnaire asking them their opinion of the taste, texture convenience and ease of 
use of the product they had been taking over the preceding 16 weeks. The scores are 
indicated in table 5.10. The questionnaire and scoring system is shown in appendix 3. 
The higher scores indicate greater preference. M showed a clear preference for UCCS, 
whilst Q favoured Vitastarch. The remaining patients expressed similar preferences on 
the basis of these questionnaires. However when patients were formally unblinded, all 6 
opted for use of Vitastarch. Two of these objectively took less Vitastarch than UCCS, 
one cited fewer gastrointestinal disturbances and another that they had increased 
appetite. The remaining 2 patients gave no reason for opting for the new starch apart 
from the fact that it is “new”. 
 
 
  K M G V  H  Q 
   UCCS  VS  UCCS  VS  UCCS VS  UCCS VS  UCCS VS  UCCS VS 
1  2 3 3  2 3 3 1 3 3 2 2 3
2  2 2 3  1 2 3 3 3 2 2 2 3
3  2 2 3  1 3 2 3 3 2 2 2 2
4  2 2 3  1 3 2 3 3 2 2 2 2
5  2 2 1  1 1 2 2 2 1 2 2 2
6  2 2 3  2 3 3 3 3 3 2 2 2
7  1 3 3  3 2 3 3 3 2 3 1 3
8  1 1 3  2 3 3 3 3 3 3 2 3
9  2 2 3  3 3 3 3 3 2 2 2 3
16  19  25  16  23 24 24 26 20 20  17 23 Total  
 
Table 5.10 – patient preference scores – (refer to appendix) 
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Symptom monitoring during trial 
The participants were telephoned on a weekly basis and asked about various symptoms 
that were entered onto a case report form.  Tables 6a – 6f (appendix) indicate reported 
symptoms that were noted by patients on a weekly basis during the trial. The scoring 
system is indicated for each table. The lower the score, the less troublesome the 
symptom  being assessed. 
 
 
 
Summary of symptom monitoring: 
•  There was no difference in either subjective episodes or measurement of 
hypoglycaemia. 
•  One patient was more bloated with UCCS but there was no difference with other 
patients. 
•  Several patients reported marginally improved appetites on Vitastarch, whilst one 
patient reported an improved appetite. 
 
 
Discussion 
Two individuals appeared to use significantly less Vitastarch than uncooked cornstarch 
over the course of the trial – subject K’s mean intake of Vitastarch was 35% that of 
UCCS whilst on average subject Q’s Vitastarch intake was 47% that of UCCS. The 
change of intake of these two participants was reflected in the diet diary assessment of 
macronutrient intakes with the K and Q reducing their starch intake nearer to the mean 
value for the group. In contrast, subject H’s mean UCCS intake was 68% of the 
Vitastarch intake. As mentioned earlier, however, subject H was given some bad 
prognostic data at the end of the first period of the trial, when she had UCCS and this led 
  158to adherence to prescribed therapy. This resulted in a gain of 4.3 Kg weight, in the 
washout period and subsequent continued increase starch intake. This increased 
adherence to therapy diminished in the last 4 weeks of the second trial period, when the 
participant was taking Vitastarch 
 
The absolute macronutrient intake of the diet did not alter dramatically indicating that 
those that did alter carbohydrate intake did not alter their diet to accommodate the 
change. This aspect of the trial was observational with data being noted. Consequently, 
patients were not instructed to alter their diets and there was no observed change in the 
diet assessments. If however, there is a substantial decrease in starch intake with 
concomitant increased appetite; appropriate dietetic advice could lead to a more 
nutritionally complete diet. 
 
There were several micronutrient deficiencies observed with selenium deficiency being 
noted by diet assessment and biochemical monitoring. In all cases that it was used, 
Vitastarch plus corrected this deficiency. Calcium intake varied greatly, partly because 
some individuals regularly take their treatment starch in milk. As a consequence some 
take more than twice the RNI of calcium and may risk bowel disturbance or 
nephrocalcinosis as a consequence. This practice would be in contrast to many 
international centres that restrict lactose intake. However, there has hitherto been no 
clinical observation indicating that this level of intake results in harm in this cohort of 
patients. By contrast, 2 subjects taking UCCS alone had low calcium intakes. Given that 
these subjects are at greater risk of osteopenia, this also is a concern.
62  In both 
instances, Vitastarch plus restored the assessment intake to above the RNI. Several 
other micronutrient deficiencies were noted particularly in those that had sub-optimal 
total energy intake. The impact the high carbohydrate diet has on both appetite and 
actual dietary intake could have an impact on micronutrient deficiencies. Biochemical 
assessment of fat-soluble- vitamin and essential fatty acid status were not made in this 
  159study. Given the low fat diet that these patients have, this would have been desirable 
and is something that should be considered in further studies. Detailed discussion on the 
potential of the GSD diet to result in clinical problems is in chapter 3. This study showed 
that carbohydrate intake could be reduced in some individuals leaving the potential for a 
more complete diet. 
 
There are few precedents for the valid introduction of a new dietary treatment in GSD. 
The major interventions that have had an impact were the introduction of continuous 
nocturnal pump feeds and the introduction of uncooked cornstarch into the dietary 
regimen of patients with GSD. The introduction of nocturnal nasogastric feeds was 
preceded in 1972 by a publication by Folkman et al noting that intravenous hyper-
alimentation improved the biochemical parameters of a patient undergoing porta-caval 
shunt surgery for the treatment of GSD I.
159 This patient was not fit for surgery and 
improved substantially with intravenous feeding. This led to the publication of a case 
series of 3 patients having nocturnal feeds continuously via nasogastric feeds by Greene 
et al.
43 This group had noted improvement in biochemistry within 4 weeks but had 
beneficial clinical outcome of increased growth velocity observed over a period of 13 
months. These studies set the precedent, but more robust evidence of beneficial effect 
could only be made after therapy had been given for several years.
117 – 119 
Likewise the early publication of Chen et al in 1984 was an “open label,” clinical study of 
successive patients that were managed with uncooked cornstarch.
7 Complete data 
obtained from starch loads and clinical follow up were not published.  Eleven patients 
were recruited and starch load data from two of these are presented. The authors 
comment that they used several doses and “the optimal dose was generally found to be 
between 1.75 and 2.5g/kg of ideal body weight.” The details of the dosing studies were 
not presented. This publication was vital but much of the detail of efficacy, dose and 
metabolic control were much more apparent from subsequent studies.
20,37 
 
  160The trial presented in this thesis was a randomized double-blind cross-over study with 
each treatment phase lasting four months. The short-term effects described in chapter 4 
appeared beneficial and consequently a longer-term study was indicated. The primary 
end-point of this long-term trial was reduction of overall starch use and with this 
endpoint, results were variable. Of the 10 patients recruited, 4 failed to establish therapy 
on the cross-over limb of the study. 2 of these never established therapy with Vitastarch. 
One of the remaining 2 did not show any dramatic improvement with Vitastarch and the 
other defaulted the end of Vitastarch phase assessment for several months rendering 
the assessment inadequate.  This participant did, however, opt to continue therapy with 
Vitastarch. Of the remaining 6 patients 2 patients responded well by significantly 
reducing treatment starch whilst one apparently required more starch – this could be 
explained by increased compliance. Metabolic control did not deteriorate and the starch 
was well tolerated. No increase in side-effects were noted and in one subject appetite 
improved. 
 
Despite these findings, this was a study of a small number of adults from one centre. 
Individual variability and perception of disease and treatment played a large part in 
adherence to therapy. Those that reduced their starch intake were more likely to take 
risks than those that didn’t. The three subjects that demonstrated no change of treatment 
did not take less than the prescribed dose of starch on any occasion. They did however 
sometimes take extra doses. It is notable that the three subjects that did not reduce their 
starch doses were the ones that took overnight naso-gastric pump feeds, whereas those 
that altered therapy took nocturnal corn-starch. In adult life, the former population 
probably self-selects itself to take fewer risks. It is also true that they have a more limited 
period of time in the day to alter therapy as they are obliged to take pump feeds for 
several hours overnight. In this context and with such small study numbers, it can be 
difficult to make a universal comment about benefit, but Vitastarch could lead to a 
reduction in starch intake in some individuals. 
  161Nutritional deficiencies were discovered in several of these patients. The GSD diet may 
have an impact on the overall quality and completeness of nutritional intake. Without age 
and sex matched control populations, these findings cannot confidently be attributed to 
GSD, but it seems likely.  
 
Conclusion 
The hypothesis that introduction of a new starch into the dietary regimen of patients 
with GSD would lead to less starch use remains unproven. However, this study 
demonstrated that Vitastarch was well tolerated in the dietetic regimen of patients with 
GSD type I. In some subjects, it led to a dramatic decrease in overall starch 
consumption. However, it did not, spontaneously lead to an improvement in the quality 
of the diet. Multiple dietary insufficiencies were noted and rigorous dietetic 
management is needed to prevent clinical problems. In four individuals, Vitastarch plus 
did show benefit in improving some but not all of the abnormal biochemistry and 
projected insufficiencies from dietary assessment. Similar to the introduction of 
nocturnal glucose polymer and uncooked cornstarch, it is likely that firm evidence of 
long-term benefit will not be available until Vitastarch has been incorporated into the 
diet for several years. 
 
 
  162CHAPTER 7 - DISCUSSION AND FURTHER STUDIES 
Chapter 7.1 - Summary of studies performed 
This thesis has attempted to characterize the diet of patients with hepatic glycogen 
storage diseases, implement a change and study the short-term and long-term effects 
of this change.  
 
The dietary analyses performed in chapter 3 confirmed that the dietary management of 
such patients is indeed intensive with some individuals taking greater than expected 
amounts of carbohydrate, leading to nutritional deficiencies. On the whole, these 
patients and their carers need to be constantly vigilant about their diet; if they are not, 
patients can rapidly become unwell. This can lead to large amounts of carbohydrates 
being ingested at the expense of other macro- and micronutrients. Details about the 
pattern of eating, the nature of the foods consumed and the impact the different eating 
patterns have on psychological wellbeing have not been examined in detail but is 
something that should be studied in greater depth. 
 
In a series of studies, chapter 4 examined the impact the use of equivalent amounts of 
uncooked cornstarch and heat modified waxy maize starch had on short-term 
concentrations of plasma glucose, plasma lactate and serum insulin. The study 
presented in chapter 4.2 using native WMHM20 in adults and children appeared to 
demonstrate benefit on the glucose profile in some but not all  individuals  , but there 
was no difference in the lactate and insulin profile. By contrast, the more homogenous 
group of adults with GSD I studied in chapter 4.3 showed both a significant difference 
in the glucose and insulin profile as well as in the area under the curves analyzed. If 
translated into long-term management, this difference could well reduce long-term 
morbidities. 
 
  163Chapter 5 attempted to quantify utilization of ingested starch by examining the 
enrichment of 
13CO2 in the breath as well as mal-digestion of non-utilized starch by 
assessing fermentation by measuring hydrogen in the breath. The study presented in 
chapter 5.1 did demonstrate greater fermentation of uncooked cornstarch but also 
greater utilisation. This finding appeared inconsistent but there were a number of 
methodological difficulties that made the findings uncertain. The greatest problem was 
the duration of assessment of the studies; the durations of studies were very variable, 
being determined by when hypoglycaemia occurred rather than when utilisation or 
fermentation of ingested starch had been fully completed. One surprising finding of this 
study was the positive correlation between mean hydrogen excretion and ages, 
implying that greater fermentation is acquired as patients grow older. 
 
Chapter 6 examined the introduction of nutritional products Vitastarch and Vitastarch 
plus into the dietary regimen of adults with GSD I. A small number of patients were 
recruited of which several failed to complete the trial. It is difficult therefore, to be 
confident on the outcomes of this trial. However, 2 of the 10 subjects demonstrate 
dramatic reduction in the amount of starch they took without an impact on monitoring 
biochemistry. Three subjects showed little change and one increased their starch use 
during the trial. All 3 adults that did not alter their carbohydrate intake during the trial 
continue to take nocturnal glucose polymer feeds and consequently have a more 
conservative approach to treatment than the other 3 subjects that were managed 
exclusively with dietary starch. However, after completion of the trial all opted to take 
Vitastarch and one has subsequently discontinued nocturnal glucose polymer after a 
further clinical starch load with Vitastarch. This subject has consequently decreased 
the amount of intake of treatment carbohydrate. Vitastarch plus rectified biochemical 
evidence of Selenium deficiency in 3 subjects and improved nutritional assessments of 
other micronutrients. 
 
  1647.2 Limitations of Studies 
Limited sites: The patients recruited for the studies performed in this thesis were all 
managed in 3 centres in London. The 3 centres work closely with each other and have 
similar management protocols and draw patients from similar ethnic backgrounds. 
There are widespread ethnic and genetic differences in the hepatic glycogen storage 
diseases and regional differences in treatment that may mean that the findings from 
this study will not be applicable to other patient populations. This can only be tested 
further by other centres replicating these data. To some extent, this has occurred as 
discussed in chapter 7.5. 
 
Recruitment and retention: Recruitment to studies is rightly by informed consent of 
adult participants and parents of child participants. For the short-term studies in 
chapter 4, recruitment of children and adults from the cohort of patients managed at 
our centre was successful. However, recruiting and retaining patients for the long-term 
study of chapter 6 was more problematic. Several were not prepared to make frequent 
trips to the research centre; others found it difficult to integrate the trial protocol into 
their daily regimen. People with certain personalities may be more likely to recruit to a 
clinical trial than others. Several of the older patients that had not been managed by 
our centre since childhood did not participate. This may have been because they were 
not familiar with researchers. Conversely, those managed at our centre since 
childhood may have felt obliged to participate, as their treating doctors were also the 
researchers. Research in rare diseases is well recognised to be problematic as 
individuals can exert a large effect on outcomes
160 
 
Most of the patients with GSD Ib did recruit to this study, possibly because they have a 
higher burden of disease than those with GSD Ia – mostly unrelated to hypoglycaemia. 
Recruitment to this study was therefore subject to a selection bias, which was 
dependent on several complex variables.  
  165When dealing with patients with a high burden of disease, it is not surprising that 
several have disease related complications over the course of an eight month clinical 
trial. Four of the 10 patients recruited to this study had hospital admissions unrelated to 
the study. 2 of these patients had simple gastroenteritis and completed the study. The 
other 2 patients had more complex problems – one is likely to have had a renal stone 
associated with dysuria, abdominal pain and haematuria and the other had 2 
admissions – the first with post streptococcal glomerulonephritis and the second with 
pneumonia. These complications in these 2 individuals were severe but not trial 
related. They may have played a part in both subsequently not completing the full trial 
protocol. Given the significant morbidities of this patient group, it would have been 
desirable for many more recruits to this study.  
Breath data – The studies looking at breath enrichment of 
13CO2 and hydrogen 
excretion were designed to help understand some of the mechanism of starch 
digestion and glucose absorption. However, the studies were confounded by 
interference with collected data by the use of glucose polymer and treatment 
cornstarch. Furthermore, data collection was curtailed prematurely in several instances 
when patients became hypoglycaemic. This, therefore, meant that data was very 
incomplete. 
 
Chapter 7.3 FURTHER STUDIES 
Dietary therapy 
Assessment of current dietary therapy.  Any modification of current therapy relies on 
accurate assessment of current therapeutic goals and actual therapy.  
 
A much cited therapeutic target is that 65% of dietary energy should be in the form of 
carbohydrate. It is not entirely clear where this figure originated from. In 1969 
Fernandes and Pikaar, indicated a desirable range of carbohydrate intake of between 
50 – 70% for GSD I and 40 – 50% for the other hepatic glycogenoses.
161 This 
  166recommendation was mainly based on dietary manipulations, mainly of fat intake, 
performed over a 15 week period on 7 children aged between 1 and 4 years of age, 
two of whom had GSD type I. The main biochemical outcomes of this study were the 
serum concentrations of cholesterol, phospholipids and total fatty acids. In this short 
study of 2 children with GSD I, the researchers were unable to demonstrate significant 
difference in outcome with an iso-caloric diet of 47% carbohydrate compared to 67%. 
However, in one subject aged one year, the researchers were able to demonstrate 
significant elevation of the fatty acids, cholesterol and phospholipids in a low 
carbohydrate (42%) high fat diet specifically when the fat was medium-chain 
triglycerides (MCT.) For the 5 other patients with GSD type III and IX, high 
carbohydrate diets (70%) were associated with higher serum concentrations of fatty 
acids than a low carbohydrate diet (39%) but became more elevated when MCT was 
used. Other oils such as corn oil, olive oil and milk fat were better tolerated than MCT. 
This study, similar to several others performed by Fernandes in the 1960s is an 
important assessment of the physiological milieu of patients with glycogen storage 
disease. They have broadened the understanding of biochemical consequences of 
disease and therapy; they have an important role to play for targeting research, even 
today. They should not however be used to guide therapy in every individual with 
glycogen storage disease as they are case studies performed in young children looking 
at specific biochemical outcomes. Clinical correlates are not indicated and other 
important biochemical variables such as glucose and lactate are not examined in this 
particular study, although reference is made to the preceding hexose study that does 
measure these.
162 This study is a short-term physiological intervention study rather 
than long-term dietary one. The dose of administration of glucose in the hexose study 
was 2g/kg as a bolus or 1.5g/kg/hour (25mg/kg/min.) Because this dose is so large, it 
would be also be difficult to gauge what glucose requirements are. 
 
 
  167In the 1970s and 1980s a series of studies looking at endogenous glucose production 
rates were performed. These are discussed in detail in chapter 3. The method involved 
the infusion of dideuteroglucose followed by subsequent quantification of the 
proportion of labelled and unlabelled glucose. By making serial measurements of this 
proportion after infusion is discontinued, the endogenous rate of appearance of 
glucose can be calculated.  Bier calculated, in healthy controls,  that endogenous 
production was 7.1 mg/kg/min for children under the age of six, 5.4 mg/kg/min for older 
children and 2.3 mg/kg/min for adults.
84 Schwenk and Hammond used a different 
approach by administering glucose via a nasogastric tube in children under the age of 
7, noting changes in insulin, glucose and lactate profiles of patients with GSD type I.
1 
They concluded that elevations in lactate were suppressed at infusion rates of 8.6 
mg/kg/min. Collins et al studied endogenous glucose production rates in adults and 
children with GSD I, finding that in adults endogenous production was variable both 
between individuals and within an individual.
150In some instances, glucose production 
was the same as healthy volunteers. One limitation of all these studies is that all are 
performed at rest. Mundy et al showed that failure of glucose production in patients 
with GSD led to decrease in glucose within 6 minutes of starting exercise, compared to 
controls.
163 The dietary analyses performed in chapter 3 also show that total energy 
intake can be very variable in this group of patients with some taking 150% the energy 
intake recommended. In adults, burden of disease is very variable and consequently 
relative carbohydrate proportion should be adjusted according to total dietary energy 
and needs rather than being based on theoretical glucose production rates. Further 
evidence of a more pragmatic approach than a theoretical approach is provided by a 
more recent Japanese study using MCT treatment.
164 In contrast to the Fernandes and 
Pikaar study there was a slight adjustment to carbohydrate proportion of total energy 
from 70% to 65% with the balance contributed by MCT in an iso-caloric diet. This was 
an open intervention for a period of time between 1 and 3 months that could be 
criticised for bias; the MCT intervention being second in each case without a return to 
  168original treatment, in growing children. Despite these shortcomings, they report an 
improvement in mean glucose, lactate and triglycerides with an increase in ketone 
body production. Several previous reports have shown decreased ketogenesis in GSD 
I; the postulated mechanism being that malonyl-CoA produced from acetyl CoA 
generated by both glycolysis and β-oxidation inhibits carnitine palmitoyl transferase-I. 
This inhibits further β-oxidation and consequent ketogenesis. Therefore, the finding 
that ketosis and presumably gluconeogenesis could be increased is encouraging. 
However, it has been previously reported that the mutation that these 3 Japanese 
patients have namely G747T, is associated with a milder than classic phenotype.
165 It 
is possible therefore in milder cases that carbohydrate intake need not be as great as 
estimated from previous studies if gluconeogenesis can be enhanced and ketones can 
be synthesised effectively as an alternative fuel. 
  
 
For patients with GSD I, it has been proposed that dietary treatment should provide 
65% of calories from carbohydrate in children with classic disease taking the reference 
energy intake. However, increased requirements will be necessary during exercise and 
decreased requirements are likely in adults and those with milder disease. The range 
of glucose requirements, in adults with GSD I and patients with “non-classical” disease, 
have not been sufficiently defined, to make reliable recommendations of intake. Further 
studies of these are indicated. 
 
Glycogen storage disease type III Dietary treatment of patients with GSD III is subject 
to more debate and controversy. Because gluconeogenesis remains intact in GSD III 
compared to GSD I, there are several advocates of diets including gluconeogenic pre-
cursors. A high protein diet has been advocated for the musculoskeletal forms of 
glycogen storage disease, GSD II,III and V by Slonim in several publications.
51;166-169 
The rationale for this form of therapy is that the myopathy is caused in part by skeletal 
  169muscle catabolism, which fuels gluconeogenesis. Exogenous protein would, in theory, 
reduce this catabolic tendency and provide a source of a gluconeogenic substrate. 
Again there is some evidence of this effect from physiological studies of protein 
turnover in patients with GSD II and III.
170-172 In the short-term, the amino acid alanine 
has been shown to reverse these physiological effects. However, a systematic clinical 
trial has yet to be performed to categorically prove benefit on clinical parameters of 
either a high protein diet or specific amino acids in the treatment of the musculo-
skeletal glycogenoses. Despite this, either or both could play a role in therapy. Clearly 
determining the role of protein in gluconeogenesis and in the reduction of myopathy is 
an important factor that needs to be clarified in clinical studies before 
recommendations can be made on the macronutrient composition of the diet of 
patients with GSD III. 
 
Patient’s understanding of dietary treatment - Reliable determination of carbohydrate 
requirements from clinical studies can guide clinicians in making dietary 
recommendations for individual patients. However, what the patient actually takes can 
be quite different to what is recommended. The carbohydrate intakes demonstrated in 
chapter 3 showed considerable variation. Patients and carers have been educated and 
have experience of managing hypoglycaemia and incorporate a recommended 
treatment into their dietary regimen.  
Most clearly understand that simple sugars and complex carbohydrates relieve and 
prevent hypoglycaemia respectively. With this knowledge, each makes individual 
dietary choices. However, the consequences of excess carbohydrate in the diet, both 
in terms of complications related to excess and compromises in macronutrient and 
micronutrient dietary composition are less well understood because they are not 
immediate risks for the individual. It is in this area of education that treatment can be 
improved. Patients should be aware that burden of disease can change and nutritional 
advice is consequently a dynamic process that should accommodate change. 
  170For the clinician, it therefore becomes imperative not only to be able to assess 
requirements and monitor changes in these, but respond to the patient’s complete 
dietary management. From the literature, the only detailed assessments of 
requirements of adults with GSD I is the study by Collins et al
150, but this demonstrates 
a dramatic variation in endogenous glucose production in a small numbers of adults. 
The European Study of Glycogen Storage Disease type I recommend serial profiling of 
patients as an in-patient on an annual basis.
173 This method has short-comings 
because patients are sedentary and eat differently in a hospital environment compared 
to a home or work environment. The practice of performing cornstarch loads alone is 
even less adequate as it does not incorporate dietary intake into the management of 
patients. Both have an effect on glucose homeostasis. Monitoring glucose and lactate 
within the home environment would seem the best means of gauging dynamic 
metabolic control. Saunders et al evaluated a portable finger-prick lactate monitor 
which appeared to be reliable.
174 Our research group is evaluating sub-cutaneous 
continuous glucose monitors in patients with GSD I. The unpublished data shows that 
glucose concentrations measured by one of these devices are unreliable in the 
hypoglycaemia range. 
 
Essential Fat and Micronutrient Intake – There is great potential for significant dietary 
imbalance in this patient group. Micronutrient deficiencies have been noted in this 
study. Essential fatty acid intake may be sub-optimal to enhance health and it would be 
prudent to measure their biochemical concentrations.  Quite apart from deficient 
intakes, surplus micronutrients – in particular calcium may be problematic in some. In a 
group of patients that have renal tubular disease, that are at risk of end stage renal 
failure and nephrocalcinosis, calcium intakes of more than twice the recommended 
nutrient intake (set 2 standard deviations above the estimated average requirement) is 
of great concern. This amount of intake occurs as many patients in the UK mix their 
  171cornstarch in milk, and this can be taken several times a day. It is therefore important 
to perform routine surveillance of intake and complications in these patients.  
Outcome data should be gathered in the form of a disease registry. This is already 
being done by the International Study of Glycogen Storage Disease Type I (ISGSD 1), 
to which our centres contribute. However regional differences in patient disease 
burden, accurately recording treatments and dietary management, investigation of 
complications and outcomes of these, make meaningful analyses very difficult. The 
findings of the ISGSD I study first series of analyses have been presented, and was 
confounded by these regional variations of study population, treatment variations and 
data collection. 
 
Efficacy Of Vitastarch 
The Kaplan Meier curves in chapter 4.2 and 4.3 appear to show a longer duration of 
action of Vitastarch compared to uncooked cornstarch. As previously mentioned, the 
population that was studied may well be different than other populations world wide. 
Our research group have encouraged other groups to perform similar starch load data 
and to this end, the GSD research group based in Florida have recently performed 
starch loads of 100g of each starch on 12 patients with GSD I aged between 15 and 34 
years, demonstrating similar findings in terms of increased duration of action.
175 
Median test duration was 7 hours using traditional uncooked cornstarch (Argo
TM), and 
9 hours with Vitastarch. The difference between test durations for individual subjects 
by paired non-parametric analyses were statistically significant – p= 0.013.  The 
findings in our studies have therefore now been replicated in a different population.  
 
There have been several assumptions in the design of our studies. Whilst Vitastarch is 
an uncooked waxy maize cornstarch that may have similar chemical properties to 
standard cornstarch, it is physically different. From a research perspective, it should be 
considered to be a new substance and simple trials such as dosing studies need to be 
  172performed. Chen et al reported that 2g/kg was the optimum dose for uncooked 
cornstarch but this may not apply for Vitastarch.
7 The optimum dose from our studies 
has not been elucidated – we have used a dose of 50g and 120g in adults and a 
maximum of 2g/kg in children. Higher doses may result in longer durations of action 
but this is unknown.  
 
As mentioned earlier, it is envisaged that this carbohydrate therapy will result in less 
release of insulin and that this may confer health benefits over several years. In 
particular complications related to chronic hyperinsulinism such as polycystic ovarian 
syndrome and features of insulin resistance as part of the “metabolic syndrome” may 
improve.
176 However, such changes cannot be demonstrated in small-scale studies 
and may only be seen in children treated with this carbohydrate through to adult life. 
The pathogenesis of both complications is presumed to take several years. Disease 
registries of large series of patients may detect such differences. 
 
Having demonstrated efficacy in glycogen storage disease, consideration should be 
made of other diseases and other situations where they may be benefit of the new 
starch. From a metabolic perspective, uncooked cornstarch is used in some disorders 
of beta-oxidation such as long-chain acyl-CoA dehydrogenase deficiency (LCHAD). 
One group has apparently used the native WMHM20 in some children with this 
disorder but the data have only been presented as a poster without full publication. The 
data is not presented on the related abstract.
177;178 They report that glucose control 
was adequate, but that the children still became unwell. It is difficult to comment on this 
finding without detailed analysis of the data. However, It is possible that in fat oxidation 
defects, the relatively high level of insulin conferred by cornstarch use, inhibits lipolysis. 
Glucose homeostasis is maintained but toxic long-chain fatty acid accumulation may 
not be suppressed by a carbohydrate that releases little insulin. In this sense, insulin 
exerts a protective effect in beta-oxidation defects. If studies are performed in beta-
  173oxidation defects, long chain fatty acid metabolites should be measured in addition to 
glucose in order to gauge whether they are exerting a toxic effect. 
 
For diseases where insulin release does need to be restricted, this carbohydrate may 
be of use. Clearly patients at risk of diabetes mellitus and older children with congenital 
hyperinsulinism may benefit from this product. Carefully controlled studies should be 
considered for such conditions.  
 
Mechanism of action of heat modified waxy maize starch 
As discussed in chapter 5, there were several methodological difficulties using breath 
enrichment of 
13CO2 and hydrogen breath tests in patients with glycogen storage 
disease. Critically these were not the principal endpoints of each study so were not 
evaluated fully. Despite these shortcomings, one hypothesis was suggested, namely 
that Vitastarch confers delayed gastric emptying compared to uncooked cornstarch. 
This hypothesis should be tested on its own in healthy volunteers first that are not 
prone to complicating hypoglycaemia. If research subjects are given a labelled sodium 
1-
13C-acetate tracer and a lactose 
13C-ureide tracer, these are metabolised when food 
enters the duodenum and the large bowel respectively. If they are administered with 
food, they therefore measure gastric transit time and coecal transit time repectively.
179 
A study comparing this carbohydrate with other reference starches including uncooked 
cornstarch would clarify whether delayed transit time is the mechanism of action of 
Vitastarch. The advantage of using healthy volunteers is that the same study could 
also examine the time to complete oxidation of the naturally enriched 
13C carbohydrate. 
These participants could exclude 
13C products for several weeks prior to the study, 
substantially reducing background release unlike patients with GSD who are 
dependent on enriched cornstarch and glucose polymer. If patients with GSD are 
studied, one way of reducing this background 
13CO2 excretion is by using a 
12C source 
of glucose polymer, essentially derived from potato starch.
180 
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Mundy, Lee and Tester performed several unpublished studies using different 
starches. Of the starch loads performed, WMHM20 conferred the best profile, having 
the longest duration of normoglycaemia. This starch performed better than native waxy 
maize starch.
181 The observation that heat and chemically modified waxy maize starch 
confers greater in vitro slowly digested starch content and lower in vivo glycaemic 
index has subsequently been independently noted by a Chinese research group.
182 
They propose as others have before that there is greater cross-linking between starch 
molecules rendering the starch less digestible.
183 However, He et al go further stating 
that their esterified and heat-modified waxy maize starch promotes cross-linking and a 
relative hydrophobic environment, being less accessible to digestive enzymes. They 
also suggest from in-vitro kinetic studies that there is non-competitive inhibition of the 
digestive enzymes by the esterified heat modified waxy maize starch fragments. This 
hypothesis is therefore one of reduced digestion of starch rather than delay in transit 
time leading to a lower glycaemic response. It would be anticipated that less digestion 
of starch would lead to greater fermentation and this was not observed in our limited 
studies. This hypothesis does need to be studied further in the context of the starch 
that was used in this thesis. Again, healthy volunteers should be studied first to gauge 
hydrogen and short-chain fatty acid products of fermentation for longer than we were 
able to do in our studies.
184 
 
 
 
 
 
 
 
 
  175Conclusion 
This thesis has identified nutritional deficits in patients with hepatic glycogen storage 
diseases. Some take excessive carbohydrate and have micronutrient deficiencies. A 
new physically modified waxy maize starch confers a better metabolic profile in terms 
of lesser glucose excursions and decreased insulin release. In a few individuals it has 
a longer duration of action. This could offer the prospect of less therapeutic 
carbohydrate intake, allowing patients to integrate their diet with their peers. As a 
consequence, it is hoped that some long-term complications related to insulin 
resistance will be diminished and that patients can experience a better quality of life. 
Various aspects of the implementation of such a dietary strategy require monitoring to 
ensure long-term benefit. Further studies are required to better understand the 
mechanism of action and optimal treatment strategy of the new heat modified waxy 
maize starch. 
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  189Appendix 1 Control Data for chapter 3 
 
The following tables are data from UK national diet and nutrition surveys performed in 
children aged 4 – 18 years in 1997 and adults in 2000/01.
66;67 These population dietary 
intakes form the control group with which data collected from this thesis are compared. 
  MALES  
  4 – 6  yrs 
(n=184) 
7-10 yrs 
(n=256) 
11-14 yrs 
(n=237) 
15-18 yrs 
(n=179) 
TOTAL 
(n=856) 
Total calories 
 
1520 
(303) 
1777 
(354) 
1968 
(435) 
2285 
(561) 
 
% of EAR  89 
 
91  89  93   
Total Protein (g) 
 
49 
(13.5) 
54.8 
(12.4) 
64 
(15.4) 
76.5 
(13.9) 
 
Protein as % of 
food energy 
12.9 
(1.76) 
12.4 
(1.85) 
13.1 
(2.2) 
13.9 
(2.5) 
13.1 
(2.18) 
Total 
Carbohydrate (g) 
209 
(42) 
248 
(51) 
271 
(64) 
301 
(84) 
 
Carbohydrate as 
% of food energy 
51.6 
(4.33) 
52.4  51.7 
(4.1)  (4.6) 
50.5 
(5.41) 
51.6 
(4.68) 
Total Fat (g) 
 
60.1 
(14.5) 
69.8 
(17.0) 
77.2 
(20.9) 
89 
(24.2) 
 
Fat as % of food 
energy 
35.5 
(3.9) 
35.2 
(3.7) 
35.2 
(4.27) 
35.9 
(4.68) 
35.4 
(4.17) 
FEMALES 
  4 – 6 yrs 
(n = 171) 
7-10 yrs 
(n = 226) 
11-14 yrs 
(n = 238) 
15-18 yrs 
(n = 210) 
TOTAL 
 (n = 845) 
Total calories 
 
1397 
(275) 
1598 
(281) 
1672 
(371) 
1622 
(417) 
 
% of EAR  91 
 
92  89  77   
Total Protein (g) 
 
44.5 
(11.1) 
51.2 
(11.1) 
52.9 
(13.2) 
54.8 
(15.2) 
 
Protein as % of 
food energy 
12.7 
(1.99) 
12.8 
(1.9) 
12.7 
(2.17) 
13.9 
(2.48) 
13.1 
(2.2) 
Total 
Carbohydrate(g) 
191 
(40) 
218 
(42) 
228 
(56) 
214 
(58) 
 
Carbohydrate as 
% of food energy 
51.4 
(5.01) 
51.3 
(4.32) 
51.2 
(5.24) 
50.6  51.1 
(5.62)  (5.07) 
Total Fat(g) 
 
55.9 
(13.8) 
63.8 
(13.8) 
67.2 
(17.6) 
64 
(20.1) 
 
Fat as % of food 
energy 
35.9 
(4.4) 
35.9 
(4.1) 
36.1 
(4.98) 
35.9 
(5.37) 
35.9 
(4.76) 
 
Table A1a – Mean macronutrient intake of control children (and 1 standard 
deviation), stratified into 4 age groups and gender.
66 
National Diet and Nutrition Surveys are Crown Copyright. The authors and owners of copyright are not responsible for 
analyses and interpretations of survey data made in this thesis. 
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  19 - 24 yrs 
(n=108) 
25-34yrs 
(n=219) 
35-49yrs 
(n=237) 
Total 
(833) 
Total calories 
 
2247 
(525) 
2337 
(587) 
2361 
(614) 
 
% of EAR  89 
 
93  94  92 
Total Protein (g) 
 
77.8 
(18.8) 
90.6 
(51.0) 
90.1 
(23.3) 
88.2 
Protein as % of 
food energy 
14.9 
(2.6) 
16.5 
(4.7) 
16.7 
(2.9) 
16.5 
(3.63) 
Total 
Carbohydrate (g) 
273 
(62) 
277 
(75) 
279 
(86) 
275 
(79) 
Carbohydrate as % 
of food energy 
49.0 
(6.3) 
47.7 
(5.8) 
47.5 
(5.9) 
47.7 
(6.0) 
Total Fat (g) 
 
85.8 
(29.2) 
87.1 
(28.0) 
88.3 
(28.9) 
86.5 
(28.2) 
Fat as % of food 
energy 
36.0 
(6.0) 
35.8 
(5.4) 
35.9 
(5.6) 
35.8 
(5.63) 
FEMALES 
 
  19 - 24 yrs 
(n=104) 
25-34yrs 
(n=210) 
35-49yrs 
(n=318) 
Total 
(891) 
Total calories 
 
1665 
(459) 
1570 
(390) 
1654 
(424) 
 
% of EAR  86 
 
82  86  85 
Total Protein (g) 
 
59.9 
(16.3) 
58.7 
(15.7) 
65.1 
(15.9) 
63.7 
(16.6) 
Protein as % of 
food energy 
15.4 
(3.55) 
15.9 
(3.6) 
16.7 
(3.49) 
16.6 
(3.5) 
Total 
Carbohydrate(g) 
206 
(61) 
196 
(53) 
206 
(61) 
203 
(59) 
Carbohydrate as % 
of food energy 
49.1 
(8.3) 
48.7  48.6 
(5.8)  (6.8) 
48.5 
(6.7) 
Total Fat(g) 
 
63.9 
(26.4) 
59.8 
(19.7) 
61.9 
(21.5) 
61.4 
(21.7) 
Fat as % of food 
energy 
35.5 
(7.58) 
35.4 
(5.9) 
34.7 
(6.3) 
34.9 
(6.5) 
 
Table A1b – Mean macronutrient intake of control adults (and standard 
deviation), stratified into 3 age groups and gender (No trial patients were in the age 
group 50 – 64  and hence these reference data are not shown but they are included in 
the total.)
66;67 
National Diet and Nutrition Surveys are Crown Copyright. The authors and owners of copyright are not responsible for 
analyses and interpretations of survey data made in this thesis. 
 
  191  MALES  
  4 – 6  yrs 
(n=184) 
7-10 yrs 
(n=256) 
11-14 yrs 
(n=237) 
15-18 yrs 
(n=179) 
TOTAL 
(n=856) 
Cis 
monounsaturated 
19.4 
(4.87) 
22.8 
(6.08) 
25.6 
(7.21) 
29.6 
(8.35) 
24.6 
(7.72) 
Total cis- 
polyunsaturated 
9.3 
(2.91) 
11.3  13.3 
(3.64)  (4.31) 
15.5 
(5.21) 
12.5 
(4.72) 
Total cis n-3 
polyunsaturated 
1.29 
(0.570) 
1.58 
(0.692) 
1.95 
(1.239) 
2.19 
(0.862) 
1.77 
(0.949) 
Total n-6 cis 
polyunsaturated 
4.8 
(1.20) 
4.9 
(1.370 
5.2 
(1.23) 
5.3 
(1.40) 
5.1 
(1.33) 
FEMALES 
  4 – 6 yrs 
(n = 171) 
7-10 yrs 
(n = 226) 
11-14 yrs 
(n = 238) 
15-18 yrs 
(n = 210) 
TOTAL 
 (n = 845) 
Cis 
monounsaturated 
17.8 
(4.38) 
20.9 
(4.89) 
22.4 
(6.1) 
20.9 
(7.5) 
20.6 
(5.9) 
Total cis- 
polyunsaturated 
8.4 
(3.01) 
10.5 
(3.31) 
11.8  11.8 
(3.85)  (4.40) 
10.7 
(3.94) 
Total n-3 cis 
polyunsaturated 
1.15 
(0.499) 
1.44 
(0.548) 
1.65 
(0.716) 
1.61 
(0.640) 
1.48 
(0.639) 
Total n-6 cis 
polyunsaturated 
4.6 
(1.24) 
5.1  5.5 
(1.46) 
5.7 
(1.68) 
5.3 
(1.41)  (1.52) 
 
 
MALES 
  19 - 24 yrs 
(n=108) 
25-34yrs 
(n=219) 
35-49yrs 
(n=237) 
Total 
(833) 
Cis 
monounsaturated 
29.6 
(10.46) 
29.9  27.9 
(9.50)  (9.23) 
29.1 
(9.76) 
Total cis- 
polyunsaturated 
       
2.1 
(0.750) 
2.30 
(1.100) 
2.31 
(0.920) 
2.27 
(0.960) 
Total n-3 cis 
polyunsaturated 
Total n-6 cis 
polyunsaturated 
12.6 
(5.35) 
13.1 
(4.59) 
13.1 
(4.91) 
12.9 
(5.27) 
FEMALES 
  19 - 24 yrs 
(n=108) 
25-34yrs 
(n=219) 
35-49yrs 
(n=237) 
Total 
(833) 
Cis 
monounsaturated 
21.8 
(8.77) 
19.9  20.2  20.2 
(6.88)  (7.30)  (7.39) 
Total cis- 
polyunsaturated 
       
Total n-3 cis 
polyunsaturated 
1.69 
(0.750) 
1.60 
(0.630) 
1.68 
(0.760) 
1.71 
(0.770) 
Total n-6 cis 
polyunsaturated 
10.1 
(4.95) 
9.4 
(3.95) 
9.5 
(3.91) 
9.4 
(3.33) 
 
Table A1C – Mean unsaturated fat intake of control adults (and standard 
deviation), stratified into 3 age groups and gender. 
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Y3 
W8  Y2 
Appendix 2 – Symptom monitoring scores – chapter 6 
X7 X2 Y7 
Week  VS uccs VS uccs  VS uccs VS uccs VS uccs  VS uccs
1 0  0 0  1 0 0 0 0  0
2 0  3 1  1 0 0 0 0 0 0 0  0
3 0      2  0 0 0 0 0 0 0 0 
4 0      1  1 0 0 0 0 0 0 0  0
5 0  0 0  3 0 0 0 0 0 0 0  0
6 0  0 2  1 0 0 0 0 0 0 0  0
7 0  0 1  0 0 0 0 0 0 0 0  0
8 0  0 0  0 0     0 0 0 0 0  0
9 0  0 0  1 0 0 0 0 0 0  0
10 0  0 0  0 0 0 0 0 0 0 0  1
11 0  0 0  0 0 0 0 0 0 0 0  0
12 0  0 0  0 0 0 0 0 0  0  0
13 0  0 0  0 0 0 0 0 0  0  0
14 0  0 0  0 0 0 0 0 0 0 0  0
15 0  0 0  0 0 0 0 0 0 0 0 
16 0  0 0  2 0 0 0 0 0 0 0  0
0  3 7 10 0 0 0 0 0 0 0  1 Total 
 
Table A2a – Number of subjective episodes of hypoglycaemia per week 
 
 
      Y3     W8     Y2     X7     X2     Y7 
Week  VS uccs VS uccs VS uccs VS uccs VS uccs  VS uccs
1  0 0 0 0 0 0 0  0 0
2  0 0 0 0 0 0 0 0 0 0  0 0
3 0      0  0 0 0 0 0 0 0 0 
4 0      0  0 0 0 0 0 0 0 0  0
5  0 0 0 1 0 0 0 0 0 0  0 0
6  0 0 1 0 0 0 0 0 0 0  0 0
7  0 0 0 0 0 0 0 0 0 0  0 0
8  0 0 0 0 0 0 0 0 0  0 0
9  0 0 0 0 0 0 0 0 0  0 0
10  0 0 0 0 0 0 0 0 0 0  0 1
11  0 0 0 0 0 0 0 0 0 0  0 0
12  0 0 0 0 0 0 0 0 0   0 0
13  0 0 0 0 0 0 0 0 0   0 0
14  0 0 0 0 0 0 0 0 0 0  0 0
15  0 0 0 0 0 0 0 0 0 0  0 
16  0 0 0 1 0 0 0 0 0 0  0 0
Total  0  01  20 00 00 0   0  1
 
Table A2b – Number of measured episodes of hypoglycaemia (<3.0 mmol/L) per 
week 
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     Y3     W8     Y2     X7     X2     Y7 
Week  VS uccs VS uccs VS uccs VS uccs VS Uccs  VS Uccs
1  0 0 0 2 0 0 0  0 0
2  0 0 0 2 0 0 1 0 0 0  0 0
3 0      1  2 0 0 1 0 0 0 0 
4 0      2  2 0 0 0 0 0 0 1  0
5  0 0 2 2 0 0 0 0 0 0  1 0
6  0 0 3 2 0 0 0 0 0 0  2 0
7  0 0 2 2 0 0 0 0 0 0  0 0
8  0 0 2 2 0     0 0 0 0  1 0
9  0 0 1 2 0 0 0 0 0  1 1
10  0 0 2 2 0 0 0 0 0 0  1 0
11  0 0 1 2 0 0 0 0 0 0  1 2
12  0 0 2 2 0 0 0 0 0   1 0
13  0 0 0 2 0 0 1 0 0     1 0
14  0 0 1 2 0 0 1 0 0 0  0 2
15  0 0 1 2 0 0 1 0 0 0  0   
16  0 0 2 2 0 0 1 0 0 0  0 2
0 0 22  32 0 0 6 0 0 0  10 7 Total 
 
Table A2c– Score for abdominal bloating (0 =None, 1 =mild, 2=moderate, 3=severe) 
 
 
      Y3     W8     Y2     X7     X2     Y7 
Week  VS uccs VS uccs VS uccs VS uccs VS Uccs  VS Uccs
1  2 0 0 0 0 0 0  0 0
2  0 0 0 0 0 0 0 0 0 0  0 0
3 0      0  0 0 0 0 0 0 0 1 
4 0      0  0 0 0 0 0 0 0 1  1
5  0 0 0 0 0 0 0 1 0 0  1 0
6  0 0 1 0 0 0 0 1 0 0  0 0
7  0 0 0 0 0 0 0 1 0 0  0 0
8  0 0 0 0 0 0 0 0 0  1 0
9  0 0 0 0 0 0 0 0 0  1 0
10  0 0 0 0 0 0 0 0 0 0  1 0
11  0 0 0 0 0 0 0 0 0 0  1 0
12  0 0 0 0 0 0 0 0 0   1 0
13  0 0 0 0 0 0 0 0 0     1 0
14  0 0 0 0 0 0 0 0 0 0  0 1
15 0    0 0  1 0 0 0 1 0 0 0 
16  0 0 0 0 0 0 0 0 0 0  0 2
Total  2  01  10 00 40 0   9  4
 
Table A2d– Score for diarrhoea (0 =None, 1 =mild, 2=moderate, 3=severe) 
 
 
 
 
  194      Y3     W8     Y2     X7     X2     Y7 
Week  VS uccs VS uccs VS uccs VS uccs VS Uccs  VS Uccs
1  0 0 1 1 0 0 2  1 2
2  0 0 1 1 0 0 1 1 0 2  1 2
3 0      1  1 2 0 1 0 0 2 1 
4 0      1  1 0 0 1 0 0 2 1  1
5  0 0 0 1 1 2 0 1 0 2  1 1
6  0 0 1 1 2 1 0 0 0 2  1 1
7  0 0 1 1 1 2 0 0 0 2  1 1
8  0 0 1 1 0     0 0 0 2  1 1
9  0 0 1 1 0     0 0 0 2  1 1
10  0 0 1 1 0 1 0 0 0 2  1 1
11  0 0 1 1 0 1 0 0 0 2  1 1
12  0 0 0 1 0 1 0 0 0     1 1
13  0 0 0 1 0 1 0 0 0     1 2
14  0 0 0 1 0 1 0 0 0 0  1 2
15  0 0 0 1 0 0 0 0 0 0  1 
16  0 0 0 1 0 0 0 0 0 0  1 2
0 0 10  16 6 10 3 2 0 22  16  19 Total 
 
Table A2e– Score for appetite (0 = Good, 1 =Same as normal, 2=Poor) 
 
 
      Y3     W8     Y2     X7     X2     Y7 
Week  VS uccs VS uccs VS uccs VS uccs VS uccs  VS uccs
1  2 0 0 0 0 0 0  0 2
2  0 2 0 0 0 0 0 0 0 0  1 0
3 0      0  0 0 0 0 0 0 0 0 
4 0      0  0 0 0 0 0 0 0 0  0
5  0 0 0 0 0 0 0 0 0 0  0 0
6  0 0 0 0 0 0 0 0 0 0  0 0
7  0 0 0 0 0 0 0 0 0 0  0 0
8  0 0 0 0 0     0 0 0 2  0 0
9  0 0 0 0 0     0 0 0 2  0 0
10  0 0 0 0 0 0 0 0 0 0  0 0
11  0 0 0 0 0 0 0 0 0 0  0 0
12  0 0 0 0 0 0 0 0 0     0 0
13  0 0 0 0 0 0 0 0 0     0 0
14  0 0 0 0 0 0 0 0 0 0  0 0
15  0 0 0 0 0 0 0 0 0 0  0 
16  0 0 0 0 0 0 0 0 0 0  0 0
2  20  00 00 00 4   1  2 Total 
 
 
Table A2f– Score for general health  (0 =same, -2 = better, 2 = worse) 
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